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FIBRINOLYSIS BY BILE 
ABSTRACT 
A protease has been found in the bile of 11 mammalian species 
investigated. The protease~ given the tentative name of 
cholelysin, has been studied intensively in Abattoir ox bile. 
It makes up less than 10% of the ox bile protein, and is a 
potent fibrinolysin, as well as being active against the sub-
strates a-casein, and the synthetic esters of tyrosin (ATEE) 
and arginine (BAEE). It is inactive against _trypsinogen, 
chymotrypsinogen and plasminogen. 
Isolation ana purification of this protease from ox bile pro-
ved complex, and was finally achieved by an 8 step procedure 
which yielded a dry white powder, stable for 45 months (to 
date) at 4°c. Quality control of this procedure was ef fe c -
ted by means o f a fibrin · plate assay, using chymotrypsin as 
.,,.. 
a reference .standard: the dose response curves of cholely-
sin and chymotrypsin were closely similar on the fibrin plate, 
enabling cholelysin (units/!) to be ~ubstituted for chymo-
trypsin (mg/l) , in equivalent diameters o f fibrinolysis. 
Gradient.elution by tri~/~aCl from Whatman _DE 32 ~reduced 
four areas, or Peaks, of fibrinolytic activity of ~holelysin, 
each with some differing characteristics against the various 
substrates. The se complexities were _not studied in detail, 
and a simplification of the procedure was discovered, ~sing 
batchwise elution with tris buffer. Thereafter, only the 
first peak was studied (Peak I). 
Studies on the inhibition of cholelysin were done using many 
known inhibitors, including serum of man , and 4 laboratory 
animals ; serum of two patients with homozygous deficiency 
o f _a1-antitrypsin; · a2 - macroglobulin, say bean trypsin inhibi -
tor, and aprotonin. The serum studies were done with heated 
and unheated material; platelet-rich and platelet-poor plasma 
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were also studied. Serum was fractionated by paper electro-
phoresis in an attempt to discover the globulin fraction con-
taining the inhibitor. No inhibition was found in the a-
globulin fractions, and inhibition was maximal in the inter--
a-globulin and a-globulin fractions. ATEE-este~ase activi-
ty of cholelysin wa~ inh~bited by serum a~ ·stongly as fibri-
nolytic activity~ 
' A limited series of studies of coagulation was done; chole-
lysin was only found to influence fibrinogen, being quite 
strongly fibrinogenolytic in vitro. A s light effect on 
ADP - induced aggregation of platelets was found at a low 
ADP concentration. Using a rat ~odel originally de-
vjsed for the study of the anticoag~l~nt effe~t ~f ancrod, 
cholelysin was found to be weakly anticoagulant. The dose 
was low by comparison with ancrod, and the result approached, 
but did not r each , statistical significance. 
The split products o f plasmin ~ nd cholelysin digestion of sta-
b ilised fibrin were .studied by po lyacrylamide gel e lectropho-
resis (PAGE), and . these were found t~. be entirely different. 
. ·. 
The kinetic~ of the reaction betweeti c~olelysin and fibrin 
~ere studied by means o ~ a new techni~1e (the composite cuvet-
te method) and . by this method it was shown t~at cholelysin made 
a two-phase attack on the fibrin molecule. The attack was stu-
died at 2, 10 , and 30 minutes following commencement of fibri-
nolysis , and the biphqsic nature of the attack was proved by 
a sharp increase in the number of reaction products present 
between the 2 and r.o .minute samples. The molecular- weight of 
fibrin split products by plasmin were shown to agree with those 
·found in published work. 
Finally, the molecular . weight of cholelysin was estimated by 
PAGE and by column chromatography with and without SDS . It 
seems probable that . the basic molecular weight is· __ 7 · O 00, 
with a dimer of - 13 000 and a tetramer of - 28 000. 
-------- --~ 
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CHAPTER ONE 
INTRODUCTION 
Through the millennia of evolution, the mammalian body has 
evolved a complex system for immediate defense and repair 
of the tissues. The humoral elements of this are made up 
of four systems of zymogens - coagulation, £ibrinolysis, 
complement, kallikrein-kinin which form an interlinking web 
to seal off injuries and then make a scaffold on which re-
pair can take place. 
In this web, the fibrinolytic system plays many roles, one 
of the more important of which is to maintain the integrity 
of small tube systems througho~t the body. Thus, activators 
of fibrinolysis are found to be secreted from the lining c ells 
o f , or present in : 
renal tract (Macfarlane and Pil l ing, 1942) 
capillaries and v eins (Fearnley, Revill and Tweed, 1952) 
milk (Astrup and Ster ndorf , 1953 ) 
semen (von Kaulla, 1953) 
tears (Storm, 1955) 
saliva (Albrechtsen and Thaysen , 1955) 
cerebro~pinal fluid (Albrechtsen, Storm and Classen, 1958) 
aqueous humour (Pandolfi, Nilsson, Robertson and Isaacson, 
1967) 
bile (Oshiba, Hata and Okamoto , 1969). 
Intracellular activators of fibrinolysis have also been des-
cribed, one of which is water soluble (Albrechtsen, 1957), 
the other extractable with potassium thiocyanate (As t rup and 
Stage, 1952) . 
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All these activators activate the zymogen, plasminogen, pre-
sent in the plasma, to plasmirt. They are not themselves directly fibrinolytic. 
The fibrinolysin described in the monograph differs from all 
enzymes described above, in being fibrinolytic in its own 
right. In this it differs from the activator of fibrinoly-
sis described in bile by Oshiba, and listed· above (Oshiba, Hata and Okamoto, 1969). 
· This substance was first observed during experiments in li-
ver transplantation done by Dr Rosemary Hickman in the Sur-gical Research Laboratories of the University of Cape Town, 
·.vhich we.ce desig·ned to study the viability of . the pig liver 
after a period of 'warm ischemia'. In these experiments, the pig liver was isolated from its circulation by clamps on the hepatic artery, portal vein, and hepatic veins . Be-
cause the pig does not readily survive occlusion of the por-,j.: tal vein, a bypass was led between the portal vein and the 
superior vena c ava . 
Ischernia of the liver obtained in this way was allowed to 
ccntinue for up to 60'. During this time, various coa gu-lation studie s were carried out (fibrinogen, one stage pro-thrombin time, partial thromboplastin time, euglobulin lysis. tiem). Of these, only the euglobulin lysis time _showed a 
major change; there was a marked and rapid increase in fi -brinolysis as measured by this test. At the end of the pro-
cedure, restoration of the normal circulation was followed by 
an equally rapid fall of the euglobulin lysis time to normal levels (Figure 1- 1) . 
This lead naturally to a query as to the fate of the increa-
sed lytic activity: was it perhaps excreted into bile? A drop of bile was placed on a fibrin plate (Astrup and Mlil-lertz, 1952) and a large zone of lysis developed. The stu-
- 7 -
dies described in this monograph grew out of this observa-
tion. They failed to confirm the presence of an activator 
of fibrinolysis, but instead, and serendipitously (Walpole, 
1937), they revealed ~n unexpected new fibrinolysin, which 
has been given the tentative name of cholelysin (Figure 1-2). 
Studies of cholelysin extended over some seven years, depen-
ding on the availability of staff, space and funding. These 
studies form the basis of this thesis. 
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Figure 1- 1: Fibrinolytic activity in the pig· during the period 
of 'warm ischaemia'. 
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"7 8 
Figure 1-2: Fibrinolysis by three ·different preparations 
of bile fibrinolysin (in duplicate) -on the 
standard fibrin plate . 
I 
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CHAPTER TWO 
THE PHYSIOLOGY OF FIBRINOLYSIS 
! 
2.1 At this stage, the process of fibrinolysis will be des-
cribed, as it is understood to occur in man. · This will 
form the. background for some of the work described in la-
ter chapters. 
Introdnctio:1 
John Hunter (18t2) first described the incoagulability 
of the blood folowing sudden death. The natu re of this 
process remain ed ~bscure until Morawit i showed in 1906 
that in such cases the blqod lacked fibrinog en. He 
suggested that the fibrinoge n had been digested by an en-
zyme. 
The last 50 years have seen a steady expansion of our un-
derstanding o f fibrinolysis , commencing with Tillet and 
Garner (1 933) who showed that c ert ain haemolytic strep -
tococci produced a . fibrinolytic agent, and followed up 
by Milstone (1941) who showed that this agent had a sub-
st.rate (plasminogen) in plasma. ·Investigators t oo nu-
merous to name have carried on this work. This account 
is based on reviews by Davidson (1977), Kaplan · (1980) 
and Heimark, Kuiachi, Fujikawa and Davie (1980). 
2.2 Functions of the fibrinolytic system 
-~ ·· 
These will be listed here without prolonged discu s sion. 
This study concerns a fibrinolytic agent that has only 
been shown to have local activity within the biliary 
- ., o. -
tree; thus it ha s no known relevance to fibrinolysis 
in the body as a whole. 
(a) Dissolution of intravascular clot. This applies 
to s e ssile clot in veins or arteries, and to micro-
clots occurring during disseminated intravascular 
coagulation (DIC ). When fibrinolysis is le~s ef-
fective (eg pregnancy) or overwhelmed (eg meningo-
coccal septicaemia), microclots may cause major oc-
clus ion of the microva scular circula tion. Organ 
failure may follow (acute renal failure, gangrene}. 
(b) Fibrinolysis in small tube systems throughout the 
body: this wa s touche d upon in Chapter One. The 
fibrinolytic system aids in maintaining p a tency in 
these small , tubes. In the particular case of the 
capillaries, fib r i nolytic ac t ivity is at all t imes 
higher than in gener al cir culation, and is readily 
a ugmen ted by such sti_rnuli as ischemia, anoxia t exer-
c i s e, a n d pharmacologica l age nts such as e pinephrine , 
histami ne, n i cotinic ac id an~ pyrogens. During any 
.. 
acute episode of defibrin~~idn / plasminogen a ctiv~tor 
act i vity increa s es sharply ~t ·-capillary l e vel (Ash-
f ord , Weinst ein and Freiman, 1968). I t is highly 
probabl~ that similar con sideration s apply to oth e r 
small tube systems; however, dynamic studies on 
these systems have not b e en reported ye~. 
(c) Woun d repair. The stimulated macrophage may be a 
· very active producer of plasminogen activat o r . Con-
ceivably this plays a role in the remodell i ng of t i s-
sues during wound healing (Lind and Gordon, 1979J. 
(d) Metastasis. There is some evidence that i mplantation 
o f a mal ignan t met astasis in a blood v essel is more 
successful if fibrinolysis is increased (Salzbury, 
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White, Tsolakidis, McKinna and Griffith s, 1973). 
(e) Cross-linking between enzym~ cascades. There is 
suggestive evidence that plasmin may initiate com-
plement sequence through C1q (Ruddy, Gigli and Au-
sten, 1972) (Atkinson and Frank, 1977). 
2.3 Activation of fibrinolysis 
It has long been known that activation of the first fac~ 
tor of the intrinsic chain of coagulation (Factor XII) 
would lead to activation of 
(1) coagulation 
(2) fibrinoly s is 
(3) kallikrein-kinin system. 
The activation o f p laiminogen was thought t o proceed 
v ia activat i on o f a plasmi~ogen proactivator p r esent in 
. _.,.. 
plasma , which was converted by activated Factor XI I 
(XI Ia) t o pla s minogen activato r (Figure 2-1) (Fearnley , 
' 1 9 5 2 ) • \ ' ·, ' , 
Factor XI I a 
Plasminoge n proactivator ac t i v a t o r 
plasminogen plasmin 
Figure 2-1: Early concept of . the activation of plas-
minogen i n plasma. 
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Later work has shown a more complex picture. One 
plasminogen activato; present in .circulating plasma -
probably the major one - has been identified as pre-
kallikrein (Mandle and Kaplan, 1977a) though other ac-
tivators ~xist (Mandle and Kaplan 1977b). Initiation 
of the enzyme cascade leading to fibrinolysis _can be 
attributed to Factor XIIa alone in the presence of kao-
lin (Heimark, Kurachi, Fujikawa and Davie op cit, 1980). 
The enzyme cascade proposed by these authors is as fol-
lows {Figure 2-2). 
Factor XI.I 
(Factor XIIa) 
Kaolin 
HMW kininogen 
Prekallikrein Kallikrein 
( 1 ) 
(2) 
/ 
( 1) 
Kallikrein 
(Factor XIa) 
Kaolin 
HMW kininogen 
(2) (3) 
.- , 
' -. 
Factor XII Factor XIIa 
Kallikrein 
Plasminogen Plasm.in 
(3) Kallikrein 
Kininogen Bradykinin 
Figure 2-2: Generation of plasmin · following interac-
tion b etween kallikrein and Factor XII 
(from Heimark , Kurachi, Fujikawa and Davie, 
and Davie op cit, 1980) .. 
HMW kininogen = high molecular weight kini-
noge n, a catalyst in this reaction. 
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Other known activators are: 
Factor XIa (weak) · 
Streptokinase derived from beta-haemolytic streptococci 
(Tillett and Garner, 1933; Milstone, 1941). This ac-
tivates plasminogen to form a streptokina~e-plasmin com-
plex which itself acts as a powerful activator of plas-
minogen (Derenzo, Barg, Boggiano, and Buck 
1967). 
Urokinase secreted by the kidney into the renal tubules* 
where it activates plasrninogen to plasmin (Sgouris, Inman 
and McCall, 1960) · (Lesuk, Terminiello and Traver, 1965). 
Endcpe;t~dases sg trypsin, thronbin and pl~smin. These 
probably have little phy~iological effect,being strong-
ly inhibited by .circulating inhibitors. They may play 
a part in inflammation, but not otherwise (Sherry, 1977). 
Tissue activators , referre._d to in Chapter One. 
-· 
These enzymes all activate plasminogen to plasmin . I t 
appears that physiologically thi~ acti~ation should be 
' . 
regarded as two phase (Sherry op c~t, 1977 p 1297) ~ 
(i)· sol phase: In circulating plasma, activator and 
free plasmin are rapidly inhibited by alpha 2-
plasmin inhibitor and alpha-2-macroglobulin . A 
portion of the plasmin bound to alpha~2-macroglo-
bulin is slowly released, ~nd can exert a lytic. 
effect on formed fibrin. 
(ii) gel phase: Plasminogen is preferentia lly bound 
to fibrin formed. Activcitor diffuses in, and 
activates it to plasmin, which lyses the clot . 
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2.4 Inhibition of fibrinolysis 
The major circulating plasmin inactivator is a2-plasmin 
inhibitor (Collen, 1976) (Moroi and Aoki, 1976). A 
specific antibody directed against this inhibitor neu-
tralises virtually all inhibitory activity of plasma to 
activator-induced clot lysis (Moroi and Aoki op cit, 1976). 
The inhibitor complexes with plasmin, urokinase and tryp-
sin on a 1:1 molar basis. 
When a2-plasmin inhibitor is spe cifically removed from 
plasma, a slower reacting plasmin-neutralising ability 
remains, which is due to a2-macroglobulin. This inhi-
bitor bind~to plasmin, trypsin, chymotrypsin, thrombin, 
kallikrein, and elastase. These enzymes continue to 
show activity against small mol ecular weight substrates 
while so bound, but none against large proteins, and it 
has been suggested that they are sequestrated by the in-
hibitor, and are then protected against other inhibitors; 
while smaller substrate molecule s still have access to 
the endopeptidase within the macroglobulin-enzyme com-
plex (Barrett, Starkey and Munn, 1974). 
Other circulating inhibitors have been found to have ac-
tivity against plasmin, but it is doubtful if they play 
any major part in its inhibition. These are: 
a1-antitrypsin, which reacts irreversibly with plasmin 
in a time-dependent and non-stoichiometric fashion. 
cI inhibitor which inhibits Factor XIIa and active frag-
ments of XIIa. It also inhibits plasmin; variable 
amounts of this inhibitor may b e precipitated along with 
plasmin during preparation of the euglobulin lysis 
time test, producing unreliable results unless strict 
attention is paid to methodology (Kluft and Brakman, 1975) 
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but little is known of the importance of antithrombin 
III as a plasmin inhibitor. 
Inter-alpha-~ntitrypsin inhibits plasmin, but provides 
only a small contribution to the total antiplasmic ac-
tivity of the blood. 
Platelet inhi.bitor This is a rapidly acting inhibi-
tor of uncertain significance. 
Other inhibitors are undoubtedly present; they inhibit 
the activation of plasminogen but are not yet well cha-
racterised. 
2.5 Fibrinolysis and fibrinogenolysis 
Plasmin splits fibrinogen .in .a .seEies .of reattions .1:; 
that h as been exhaustively studied (Marder and Budzyn-
ski, 197 4). The molecul~r weight of fibrinogen is 
j40 000 . The successive products of i ts digestion by 
plasmin are: 
fragmen t molecular weight 
X 240 00 0 
y 155 000 
D 83 000 
E 50 000 
The sequence of these reactions is shown in Figure 2-3. 
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Fibrinogen 
fragment X 
Fragment y + Fragment D 
Fragment E + Fragment D 
Figure 2-3: Sequence cif digestion of fibrirrogen 
by plasmin 
Fibrinogenolysis and fibrinolysis 
Plasmin spl its both fibrinogen and fibrin. The struc-
ture of fibrinogen, and *the degradation p r oducts of fi -
brinogen and fibrin, have been studied in detail . The 
following account i s based on papers by Pizzo, Taylor, 
Schwartz, Hill and McKee (197 3) , Pizzo, Schwartz, Hill 
and McKee (1972), Budzynski, Marder and Sheinoff (1974) , 
Marder and Budzynski (1974), and Gaffney (1~77) . 
2.5.1 Fibrinogen - structure 
Fibrinogen is a soluble protein with a molecular weight 
of about 340 000.' Its shape is _uncertain, as bioche-
mical data from fibrinogen conversion to fibrin are at 
odds with physical data from X-ray diffraction studies. 
It is produced by the liver, and has a biological half-
life of~ 48 hours, the mechanism of physiological 
breakdown being uncertain . . The plasma concentration 
is 2-4 mg/ml. 
Fibrinogen is a dimeric molecule, each unit of the dimer 
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containing three individual polypeptide chains which 
are named Aa, BS, ~nd y. 
is shown in Table 2-1. 
Their gross constitution 
Table 2-1: Gross constitution, and c ross-linking 
of derived fibrin 'monomer', of human 
fibrinogen. 
Polypeptide Molecular Fibrino- Polymerisation -
cha.in weight peptide 
A 67 000 A polymer 
B 58 000 B 
47 00 0 dimer 
,;;. 
These chains have a complex interconnection at their 
N-terminal ends, forming the s6-called 'dis~lphide 
knot'. This structure is shown _in Figure :2-4 taken 
from Saffney (1977 op cit , with permission). The 'Y 
chains form stable and s ymmetrical disulphide brid-
ges, as shown; 11 of the 28 disulphide bridges of 
fibrinogen are contained in the disulphide knot. 
•N 
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~i«J st<1~e disulph.d~ bood 
'ZZlZlZ .unstable d ;suJp•,;ci., b<>nd 
+ site of cJea....-d9e by thrombin 
N 
Shown are the two y chains formi ng a stable cavalent:IJ bonded . 
structure onto which the other c.hains seem to be tied. The bonds between the two y chains in positions 8 and 9, and those between the 
two Aa. chains in position 28, are symmetrical and stable. disulphide bridges. An additional stable disulphide bond is shown between the Aa. position 36 and the Bi3 position 65 in each of the fibrinogen sub-
units. (fhe remaining disulphide bridges arc thought ta be unstable 
and can und:rgo disulphide exchange (Blomback et al. 1974)) . 
This figure 1s adequate also to relate the two un-its of t.he whole fibrinogen d imer, since knowl e<;f,ge of t he chemistry of the dimeric 
structure of fib r inogen is limited to the N-DSK domain 
In this figu re, _a lso in ~g. 4 and 5, the lengths of the lines rel,)resenting 
the polypeptide chains are not proportional to their moleculu 
weights 
Figure 2-4 : Schematic model of the N- terminal di-
sulphide knot portion o f the dimetric 
fibrinogen molecule. 
The sulphur-containing amino acids cysteine and 
methionine have been of value in determining the pri-
mary and secondary structures of fibrinogen. The a.re 
56-58 cysteine residues and about the same number of 
methionine residues. Cyanogen bromide fragmentation 
of the molecule yields a large numDer of peptides, 
which have been related to the dissim.ilar fragments 
produced by plasmin dige s tion, to build up a gross 
structure of the three chains. Th i s structure is 
' } 
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shown in Figure 2-5 (from Gaffney op cit, 197~ with 
permission). 
A:·cx. CPNl Br I N-DSK i . CNBr-3 I ! Hol-.DSK 1?,---,__....:.H;.:.ciZ:::..-....:D:..::Sc.,:K~......,, 
• E 1 I O 
_ I..__P.,...:l....c· l __ .,c..Pl'----2-~ll 
B~ CNBr l N - DSK lf11:s,-2l I Ho1-os·K I Ho2-DSK Pl I E Ii . D II 
CHO 
y CNBr I N - DSK 11 Hol - OSK 
- Pl . :E II D II 
CHO 
Abbreviation: 
Hi2-DSK: a hydrophilic disulphide knot· 
: Where applicable, the fragment to which each chain subunit belongs j is indicated, e.g. the major hydrophobic disulphide knot (Ho1-DSK) is· composed of three polypeptide chai~s that occupy the sa~e 
regions of fibrinogen as the three subunits of fragment D. Peptide S".quences in the CNBr- and Pl-media:ed. fragment~ account f?r 
near;y the total sequence of ·the three ch,.ins of fibrinogen, while 
those subunits with inter-chain disulphide bridges will help to 
establish the relative pos.itions of the chains (see fig. 2). The approxi-
m ,.te locations of th e carbo'1ydrcte (CHO) side chains on the B~ and 
Figure 2-5 
y i:hains are indicated ' 
Schematic representation of the locations 
of the major cyanogen bromide (CNBr) - and 
the plasmin (P1)-mediated fragments in the 
thre e chains of fibrinogen - Aa; BB , a nd 
y : and of the major end products of plas-
min digestion - fragments D and E. 
2.5.2 Fibrinogen-:- coagulation 
In the physiological situation, thrombin is the only en-
zyme capable of initiating coagulation through polymeri-
sation. of fibrinogen. Thrombin does this through two 
distinct mechanisms: 
(1) conversion of fibrinogen to fib r in 'monomer ' 
(2) activation of Factor XIII (fibrin stabilising fac-
tor) in the presence of ca++. 
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(1) Thrombin cleaves fibrinopeptides A and B from 
the A and B chains of fibrinogen re~pective-
ly. The original dimer (AaB8y) 2 then poly-
merises spontaneously to non-stabilised fibrin 
polymers (a8y) 2p. The resultant clot is rea-
dily lysed by plasmin. 
(2) Thrornbin activates Factor XIII to form stabili-
sed fibrin in the presence of 1Ca++~ · Activated 
Factor XIII 'stabilises' the fibrin clot by the 
formation of covalent isopeptide bonds between 
different fibrin molecules, crosslinking occu-
ring between pairs of glutamine and lysyl resi-
dues ~ Two of these pairs are located close to 
the carboxy terminal ends of they chains, re-
gions that are containe_d in the largest of the 
fragment D molecules. Four other pairs of -- -
crosslink sites are 16cated at the c arbox y ter-
minal ends of the; Aa chains. 
not poly:me:tise . 
The BB chain does 
Fibrin crosslinking involves rapid pa iring of 
two y chains from different fibrin molecules , 
and slower polymerisation of multiple a c hains . 
A comp lex superstructure o f covalent linkage s 
results, which renders the clot insoluble in weak 
acid or 5 M urea (Marder and Budzynski , 1974) . 
2.5.3 Fibrinogen and fibrin - degradation by plasmin 
2.5.3.1 Fibrinogen and non-stabilised fibrin 
Plasmin produces virtually identical breakdown products 
from these two proteins 1 differing only in the presen-
ce or absence of fibrinopeptides A and B from the frag -
ments. The complex breakdown sequence is shown in 
Figure 2-6 (from Marder and Budzynski, 1974 1 with per-
mission). 
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I l 
IWlZI 
17lffJll/lllffm7lllil 
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FRAGMENT D 
cf!J e , "VI/Ill/A 
D I =: Y!ll/l/!il/JJJil(J//j/JJ 
EI) j:::: :=:::VIII///Pmj//J/(hl, 
.FRAGMENT Y 
dj [2J 
0 D 
III CJ 
FRAGMENT ·E 
YI II 1//l/lli)!l!U/(!IA 
Wll/)/}l}!)/J 
F~AGMENl 0 
Act 
B/3 
t 
Figure 2-6 : The asymmetric pathway of pJ:a smic degra-
dation of fibrinogen. Fibrinopeptides 
A and Bare noted in black; the portions 
that are first cleaved by plasmin are 
shown in white. The longitudinal posi-
tion of the polypeptide chains indicates 
the junctional centre occupied by the 
NH2-terminal portion (from Marder and 
Budzynski, 1974 , with permission). 
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2.5.3.2 Stabilised fibrin 
StabiJised fibrin is resistant to attack by plasmin. 
This appears to be due to the a chain crosslinking. 
The preferential attack by plasmin on fibrinogen and 
fibrin is shown in Table 2-6. 
Table 2-6: Preferential attack by plasmin on fi-
brinogen and fibrin occurs as shown. 
{Fibrinogen 
fnon-crosslinked fibrin 
1 
2 
(Aa 
(a 
- (BB 
(8 
3 y 
,;,· 
Cross linked fibrin 
1 8 or y 
2 ,.a - a Polymers 
'The ability of crosslinking to transform highly labile 
carboxyl ends of the a chains into areas of high re-
sistance to plasmin is quite dramatic . Inde ed , the 
lysis of crosslinked a chains of fibrin seems to re-
pre~ent a rate-limiting step during digestion of fi -
b r in clots ' ( Ga.ffney , 1977) . 
As a result of the crosslink bonds~ digestion of sta-
bilised fibrin produces products that are distinctive 
from those of fibrinogen or non-crosslinked fibrin. 
The most important of these distinctive products is 
a derivative of fragment D of approximately twice its 
·size, called double- Dor n ~aimer. This D-dimer is 
linked by covalent bonds at the carboxy-terminal ends 
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of they chains. This is the major difference in 
structure betw~en degradatiori producfs of fibrino-
gen and fibrin (Marder and Budzynski, 1974). 
D-dimer is isolated as a single species, even after 
prolonged digestion of crosslinked fibrin by plas~ 
min, with a molecular weight of 81 000, or about 
twice the weight reported for fibrinogen fragment 
D. After 18 hours of digestion of highly cross-
linked fibrin by plasmin, sodium dodecyl sulphate and 
polyacrylamide gel electrophoresis .showed the follo-
wing products: D-dimer (y-dimer) MW 81 000, 
B" fragment MW 45 000 and a" fragment .MW 15 000 (Piz-
zo, Taylor, Schwartz, Hill and McKee, 1973) . 
The products of the formation of a fibrin clot have 
physiological functions . Fibrinopeptide A is chemo-
tactic for neutrophilsz fragment X clots slowly, 
crosslinks with fibrinogen and forms poor clots, 
while f r agment D acts in . a he~arin- l ike way a s an 
\ ·· .. 
anticoagulant . Fragments D and· E are commonly es-
.. -. . ' 
timated by laboratory procedure·s · that measure 'split 
products of fibrin(ogen) ' . Further proteolysis 
produces p e ptide fragments havi~g ne i the r ~hysiologi -
cal nor immunological properties. 
2.6 Fibrinolxsis: the scope of this thesis 
Studies reported in subsequent chapters deal with as-
pects of the primary fibrinolysin found in the bile 
of 11 mammalian species studied -man, baboon, dog, cat, 
mouse, _ rat, hamster, ox, pig, goat, sheep. 
~ Chapter Three deals with methods of assessment of fi-
brinolysis; and gives reasons for choosing the fibrin 
plate test as the basic research tool for this study. 
.~ .:.: __ ;--.,_; -
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This fibrin plate is then studied in detail, and the 
nature of the dose'-response curves that can be obtai-
ned on it are discussed. The nature of the dose-
response curve of bile fibrinolysin (cholelysin) on 
the fibrin plate is presented, and a comparison made 
with the dose-response curve of chymotrypsin. Chole-
lysin is then guantitated in terms of chymotrypsin, 
which makes possible a quantitative iassay in unit/l. 
This assay is used in all subsequent work on chalely-
sin. The heated fibrin plate is discussed. 
Chapter Four discusses bile - its composition, and the 
composition . of gallbladder bile. The availability 
and purity of bile from various sources is presented, 
with reasons for standardising on ox bile from the 
Municipal Abattoir, Cape Town. Procuring and qua).i-
ty control o f ox bile are discussed. 
Chapter Five deals with the methods of purification 
o f bile . Fibrinolysis by whoie bile; and column chro-
\ .... · .. 
matography. of whole bile are priefly presented, f ollo-
- •. 
wed by an account of ammonium --slilphate precipitation 
of cholelysin, and more complex combined procedures 
o f purification and concentration of choleiysin . Va-
rious fractions of bile -G 200, Peaks I, II, III and 
IV are described, and batchwise elution of Peak I. 
Molecular weights of the ammonium sulphate precipitate 
and of Peaks I, II, III and IV are estimated. 
Chapter Six discusses substrates acted.on by cholely-
sin. Those investigated are: 
(1) endopeptidases trypsinogen, chymotrypsinogen, 
plasminogen 
( 2) a-casein 
(3) ATEE 
(4) BAEE 
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In the experiment studying the esterase activity of 
cholelysin on ATEE, simultaneous estimation of fi-
brinolytic and esterase activities was made. This 
produced evidence that different fractions of .chole-
lysin might have differirig esterase and fibrinolytic 
activities. 
Chapter Severy diicusses inhibitor of cholelysin. 
The major inhibitory substance stud_ied was human se-
rum. This potent inhibitory property was assessed 
. in heated and unheated serum, and in serum from two 
patients with homozygous a-antitrypsin deficiency. 
An attempt was made, using paper electrophores~s of 
whole serum, to determine what fraction of serum was 
responsible for the inhibitory effect; this was com-
pared with the irihibitory effect o f the s ame serum o n _,__ 
chymotrypsiri. The s erum o f the rat, rabbit, guinea-
pig a n d mouse was al s o s tudied for its i nhibitory ef-
·:, . feet. Other substances s~udied·-~ere: a 2-macroglo-bulin, soy bean trypsin inhibitor and aprotonin . 
Chapter Eight discu~ses the e ff ect of chol~lysiri on 
routine coagulation and platelet furiction tests, and 
on the platelet count in the rat. An attempt is made 
to establish a biologica l half :life 1 and a LD5 ~ fo r cholelysin in the rat. An . experiment wa·s undertake n 
t6 establish if cholelysiri had in vivo anticoaguiant 
properties in the rat. 
Chapter Nine discusses polyacrylamide . gel electropho~ 
resii (PAGE) . PAGE of cholelysiri with chymotrypsin 
control is· followed by a study of the e f fee ts of mer-
captoethanol and SDS on cholelysin. PAGE' of the split 
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products of f~brin digestion by cholelysin and plas-
min at 24 hours is compared . . 
Chapter Te~ describes a new method for the study of 
enzyme kinetics at a sol/gel interface, termed the 
composite cuvette method. This method is used to 
study the kinetics of the cholelysin/fibrin reaction: 
the reaction is shown to occur in ~wo phases, and 
this is proved by analysis of FSPC in the two phases 
by PAGE. Finally, a double reciprocal relationship 
is shown to exist between concentration of cholelysin 
and V, with stabilised fibrin as the substrate. 
ChapLe = Eleve n aiscusses molecular weig~ts o f ch0le-
lysin and of fibriri split products. Cholelysin was 
analysed by column chromatography with and without 
SDS. At least three · s eparate forms exist, which are 
probably monomer (- 7 000 ), dimer (- 14 000) and te -
· tramer (_ 28 000) . Howevei, the possible dimeric 
f o rm exists in the presence of SDS 2 g / 100 ml . Fibrin 
split products of digestion by- p_lasmin are analysed -
and compared with the work of ~arlier authors ; the 
resul~s agree closely . The fibrin split products of 
digestion by cholelysin are analysed and are shown to 
be entirely different from those due to plasmin. 
Chapter Twelve summarise s this thesi s , and discusse s 
possibilities for future work on cholelysin. 
summary 
.. - ---- --
Chapter Two the physiology of fibrinolysis is discus-
sed in the light of recent advances. _ Activators and 
inhibitors are considered. The structure of fibrino-
gen and the nature of fibrinolysis and fibringenolysis 
--are considered in detail . 
3. 1 
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CHAPTER THREE 
THE ASSESSMENT OF FIBRINOLYSIS - THE FIBRIN PLATE 
The assessment of fibrinolysis methods 
Clinical situations usually regu~re methods which will give a rapid assessment of fibrinolysis, and unfortu-
nately these methods are all unsuitable for gu.antitation. The more accurate methods are either time-consuming, or both and have not found widespread acceptance in the 
clinical situation . 
Clinical testing of fib~~nolysis is usually done by: 
..r.-
(a) Dilute whole blood clot lysis time (Fearnley, 
1965) 
'>·· 
·, (b ) Euglobulin lysis time (vo"n ~aulla, 1963) (Cha-
krabarti , Bielawiec, Evans and Fearnl8y, 1968 ) (c) Fibrinogen titre test (Sharp, Howie , Bi..ggs and 
Me thuen, 1958 ) 
More accurate tests with widespread acceptance are: 
(d) Fibrin plate test (Astrup and Milllertz, 19 52). 
This is sensitive, precise, and reproducible. A large number of tests can be done in one day by one technician, and the plates are easy to prepare. 
(e) Fibrin agar plate test (Wo.lf, 1969). The pre-paration of this test involves a heat degradation 
step for fibrinogen which is not easy to stan-
dardise; otherwise, this is a convenient and 
accurate method for the measurement of fibrino-lysis . . 
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(f) Radioactive isotope labelling of fibrinogen : 
(Fletcher, 19&4). This ~s extremely accurate, 
but is expensive and requires expensive equip-
ment. 
(g) Caseinolytic test (Johnson, Kline and Alkjaer-
sig , 1969). This is the method recommended by 
the National Heart Institute of Bethesda, Md, · 
USA. It is accurate and· quick, bu.t has the 
disadvantages of being cumbersome, thus limiting 
the number of tests that can be done in one day; 
and also non-physiological, so that its relation-
ship to physiological events is unclear. 
For the above reasons, the fibrin plate test was final-
ly chosen as the basic research tool for this study. 
3.2.1 The fibrin plate test 
(a) Physiology 
The fibrinogen used in stand~rd techniques of pre-
paration of the £ibrin plat·~ always contains both 
plasrninogen and plasrninogen activator. An un-
known substance applied to the fibrin p~ate could 
t herefore cause fib r inolysis by o ne o f two methods: 
(i) by activation of plasrninogen activator 
or of plasminogen itself · 
(ii ) by direct fibrinolysis. 
These two possibilities are summarised in Figure 3-1. 
Activation of 
Factor XIIa 
Plasminogen 
activator 
Plasminogen 
Fibrin 
"" 28a 
Urokinase 
Streptokinase 
Other activators 
Plasmin 
Other fibrinolysins 
Fibrin degradation 
products 
Figure 3-1 : Pathways of fibrinolysis on ~he un-
. -
heated fibrin plate. 
' . ........ _ 
·, 
If the fibrin plate is heat;d to-·- ao 0 c for 45', all 
plasminogen and plasminogen activator activity is 
destroyed , while the fibrin of the plate suifers only 
minor heat degradation (Thomson, 1970). Thus, the 
heated fibrin plate may be used to exclud~ fibrino-
lysis requiring the intervention of either plasmino-- . 
gen or plasminogen activator. Figure 3~1 can then 
be redrawn as follows: 
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Plasmin 
Other fibrinolysins 
Fibrin Fibiin degradation products 
Figure 3-2: Pathways of fibrin6lysis on the heated 
fibrin plate. 
3.2.2 Materials and methods 
Physiol.ogical conditions werE: i:idhered to wherever pos-
sible. The fibrinogen selecte~ was> 90% clottable 
(Kabi human fibrinogen) . Because higher conc e ntrations 
of fibrinogen ori the fibrin plate decrease sensitivity, 
the low physiological concentration of 2 mg/ml was cho- . 
sen (plasma level 2-4 m~/ml). Calcium was added to 
the final concentration routinely used in laboratory 
coagulation techniques (M 0,02S) · . . After addition of 
the thrombin-calcium mixture to . the fibrinogen solution 
in the P~tri dish, careful slow rotation o f ~e plate 
for 20 rotations was essential if reliable results were 
to be obta.ined. 
The original fibrin plate technique d escrlbed by As-
trup and Mullertz (1952) was first attempted . For 
reasons that could not be est~blished, this type of 
fibrin plate proved highly unstable, commonly under~ 
going spontaneous lysis Wlthin 24 hours of preparation. 
This made it unsuitable for periods of overnight incu-
bation. Various modifications were tried; the tech-
nigue finally adopted gave excellent four day stabili-
ty at 4°c. The two methods are surnmariseq in Table 
3-1. 
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Table 3~1: Comparison of materials and methods used 
by Astrup with those used in this study. 
Fibrinogen sour-
ce 
Fibrinogen con-
centration 
Thrombin source 
Thrombin added 
Calcium concen-
tration 
Type of Petri 
dish 
Period of incu-
bation after 
formation of the 
clot 
Storage 
Tes t incub a -
tion 
Astrup 
Bovine 80-90% 
clot table 
Usually O ;·2%. 
(2 mg/ml) 
Bovine 
20 units 
Glass auto-
claved 
Not stated 
Not stated 
18-:-20
0
hou:r. s 
at 37 C \" ·-
\ ' ·. 
King 
Kabi human 90% 
. clottable 
0,2 % (2 mg/ml) 
Bovine 
0,2 units 
M 0,025 
Plastic disposable 
presterilised (except 
heated fibrin plate 
2 hours at 37°c 
4 days at 4°c 
21 h ours at 37°c 
3.2.3 Dose response curves on the fibrin plate 
Two types of dose- response curve 
on the fibrin plate (Haverkate and 
se are summarised in Table 3-2. 
··---:::-::.. 
have been described 
Tr aa s , 1 9 7 4) . The-
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Table 3~2: Dose response curves on the fibrin plate. 
Enzyme 
(a) Plasmin 
(b) Trypsin 
Chymotrypsin 
Papain 
Brinase 
Urokinase 
Bacterial-
proteases 
Zone of 
lysis (x) 
Concen-
tration (y) 
Log area Log 
Diameter Log 
Graph paper for (a): log/log 
Graph paper for (b): semilog 
Equation of curve 
Logy= Log X + k 
y = Antilog x + k 
Equal drop volumes are used, with a fixed period of 
incubation. ·rf test and reference solutions plo~_in 
the same way, the test can b e expressed in terms of the 
reference solution. Haverkate and Traas (op cit, 
. 
. 
1974) suggested that the log/log curve . generated by 
plasmin might be due to instabtlity o f plasmin under 
standard conditions of incubation: after 17 hours 
of incubation at 37°c , only 10~20% of plasmin a cti-
vity remained , whereas 100 % of chymotrypsin activity 
was retained . Trypsin and chymotryps in h a~e nearly 
identical curves, and are detectable at very low le-
vels; Haverkate and Traas (op cit, 1974) give the 
following levels for lowes t detectable conce ntrations : 
trypsin 0,06 g/ml 
chymotrypsin 0,20 g/ml 
plasmin 0,003 U/ml · 
The difference between the dose-response curves of 
urokinase and plasmin remains unexplained. 
Standardisation 
This study commenced in 1969, and American National 
I 
I 
! . 
I 
I 
I 
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Red Crosi human plasmin was used as the standard from 
the commencement. · It proved to be reliable; through 
7 years of use, the standard test dose produced a zone 
of lysis of 13 + 1 mm diameter. The later information 
from Haverkate and Traas (op cit, 1974) did not seem to 
necessitate changing to (say) a chymotrypsin standard . 
3.2.4 Stability ~nd reproducibility 
Both these parameters were studied at intervals through-
out this study. Results of stability testing on three 
separate occasions are given in Table· 3-3 below. 
Table 3-3: Doubling dilutions of human plasmin 0,1 
U/~l on the fibrin plate in three diffe-
rent years, followed through 4 days o f 
fibrin plate life. All resuJt,;; in mm 
diameter of ione of lysis. Full detaill 
in Appendix 3. 
Day 
Yea r 0 1 2 3 4 X s SE.M 
1970 14,3 13,0 12,7 14,7 . 14, 0 13,7 · 0,77 0,34 
1972 13, 3 13,7 13, 7 12,7 12,3 1 3, _1 0,62 0,25 
197 4 13,5 13 ,8 12,3 13,0 13,3 13, 2 0,57 0, 23 
X 13,7 -13, 5 12,9 13,3 13,2 
Reproducibility was also studied repeatedly. Shown 
h~re is a bile fibrinolysin preparation assayed on se-
parate fibrin plates on one day in different years ~ 
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Table 3-:4: Reproducibility of the· fibrin plate assay, 
using a -bile fibrinolysin, in three diffe-
rent years. All results in mm diameter 
of zone of lysis. 
Test 
Year 1 2 3 4 5 . 6 X s SE.M 
1974a 26 25 27 28 25 25 26 1 , 26 0,51 
1974b 12 12 1 1 14 12 1 1 12 1 , 1 0 0,45 
1975 32 30 33 32 34 30 32,5 0,84 . 0 I 34 
J.2.5 The heated fibrin plate 
The physiology of this fibrin plate is discussed in 
3.2.1 above (Figure 3-2, page 29) . Agents causing 
lysis on th is fibrin plate are primary fibrinolysins, 
and are differentiated fuh damentally from those that 
. trigger the l ytic cascade at a more r emote level . 
The results o f this test using bile fibrinolysinare 
discussed in Chapter Three sectio~ J;4 .page 41. 
3.3 The assay of bile fibrinolysin (cholelysin) 
At this point it is necessary to .anticipate some of 
the work reported in Chapter Five. All steps in the 
purification procedures required guantitat ion o f the 
fibrinolytic effect p~esent in eluates, precipitates, 
supernatants, etc. This was possible through compa-
rison with the dose-response curve of chymotrypsin, 
and this work must be reported now to give intelligi-
bility to later findings . 
The name cholelysin is propos.ed for t...rie group of f i-
' 
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brinolysins studied in this work, and it will be used 
henceforth where relevant. · 
The dose-response curve of cholelysin proved to be very 
similar to that of chymotrypsin. Studies of doubling 
dilutions with five preparations are shown in Table 3-3 
below. 
Table 3-5: Fibrinolytic effect of various preparations 
of cholelysin Peak · I (see 5.3.7) on the fi-
brin plate. Results in min diameter of zone 
of lysis. Full details given in Appendix 
III. These results arc show~ graphically 
in Figure 3-3. 
Dilution 
Test No factor 
;.. 
1 2 3 4 5 
1 37, 2 35,0 28 ,5 25;3 20,5 
2 . 33,0 31 ; 3 22,0 19,0 15,0 
4 28,8 26,3 16, 3 14,0 10,0 
8 23 ,6 . 21 , 0 9,0 9,3 5, 8 
1 6 19 ,2 16, 7 ( 3 I O) 
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Figure 3-3: Fibrinolytic effect of five different pre-
parations of cholelysin on the standard fi -
brin plate. Relative concentration plotted · 
against diameter of zone of lysis (m.~} . 
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From Figure 3-3 it can b e see n that chole lysin fell in-
to the se~ond catego~y of fibrinolytic a gents, giving a 
straight line on semi-logarithmic pape r. The slope of 
these five curves over 1 log cycle is given in Table 3-6. 
Table 3-6: Decrement of . lytic diamete r of cholelysin 
Peak I (various preparatio~s) over one log 
cycle of dilution (ex trapolated in the two 
cases where a full log cycle wa s not cove-
red). 
De crement i .n lyt..i.c d j_arne ter (mm) 
over one log cycle of dilution 
Expt 1 2 3 4 5 X s SEM 
(mm ) 15 15,5 21 17 18 17,3 2,39 1 , 07 
-1,'r· 
3 .3.1 Quantitation o f chole lys in 
I 
r 
As d isc u s sed in 3 . 2 .3 above , i f t wo _fibrino l y sins plot 
in the same way; the one can b e expresaed in ter ms o f t he 
o t h e r . Bot h t ryps 1n ~nd c hymotrypsin g a v e c losely s imi-
lar plot s, but chymotrypsin was preferred because of the 
finding by Haver kate a nd Traas (op cit, 1974) that chy-
motrypsin had 100 % stabil i ty under sta ndard condi t i on s 
of incuba tion on a fibrin plate, whereas trypsin showed 
a 40% degradation. 
In Tables 3-7 ~nd 3-8,-and in Figure 3-4, the dose -
response curve of c hymotrypsin is shown, and is ~om-
pared with the 5 dose - reponse curves of cholelysin shown 
in Figure 3-3 . 
- 37 -
Table 3-7: Fibrinolytic action of chymottyPsin on the 
fibrin plate. All results in mm diameter 
of zone of lysis. 
Chymo-
Test trypsin 
mg/i.. 1 2 3 4 5 6 ,X s SEM 
200 40 43 41 41 41,25 1,26 0,63 
100 31 34 33 31 .. 31 - 33 32,2 1,33 0,54 
50 26 27 26 25 25 26 25 -, 8 0,75 0,31 
25 20 20 19 20 21 21 20,2 0,75 0 I 31 
12,5 15 15 14 16 14 15 14,8 0,75 0,3 1 
6,25 9 9 8 8 9 9 8,7 0,52 QI 21 
3,13 4 4 4 3,5 3,5 4 3,8 0,26 0 I 11 
\'·---. 
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Figure 3-4: Dose-re.sponse curve for chymotrypsin on the 
fibrin plate. Results .in mm diameter of 
zone of lysis. Cholelysin dose-response 
curves from Figure 3-3 plotted for compari-
son. 
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Concentrations of chymotrypsin above 200 mg/l gave less 
accurate results, and the large zones o·f lysis were sel-
dom truly circular. However, when results were avera-
ged the curve held true up to 1 000 mg/l. Above that 
point, the curve was extrapolated for the occasional 
very high concentration of cholelysin. 
Table 3-8: Dose-response curve of higher concentrations 
of chymotrypsin on the fibrin plate. Re- . 
sults in mm diameter of zone of lysis. 
Chymotrypsin Zone of lysis 
concentration (two diameters measured Mean mg/£. at right angles) 
500 4·9 X 44 50 X 42 46,25 
1 000 55 X 49 52 X 46 50,5 
;;;. The decrements over one log c ycle in mm of lysis for chy-
motrypsin and cholelysin Peak I are shown in Table 3- 9 . 
Table 3-9: Decrement over one log cycle in millimeters 
of chymotryps in and the mean o f five curves 
of cholelysin Peak I. 
mm decrement 
over one log cycle 
chymotrypsin _ 
cholelysin Peak I 
19 
17,3 + 1,07 
Comment: The se curves agreed closely enough for chymo-
trypsin to be used as a reference unit for cho-
lelysin. Accordingly mg/l for chymotrypsin 
was transformed into units/l for cholelysin 
Peak I, and a table was drawn up (Table 3-JO). 
·, 
i 
f 
Table 3-10: 
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This was the standard reference table for 
this study·. 
Activity of cholelysin expressed in units/l 
of chymotrypsin equivalent. The equation 
of this curve is: 
! 
y :: antilog ( o , o 5 3 3x + o , 3 ) units 
where X :: · diameter of zone of lysis in mm 
y :: concentration in units/l, 
where 1 unit · == 1 mg chymotrypsin 
Diameter Units/ /?.. Di..:1.meter 'Jnits/l Diarr.eter Units/.Z 
of lysis of lysis of lysis (mm) (mm) (mm) 
4 3,3 21 26,3 38 212 ... 
5 3 ,7 22 29,7 39 239 
6 4,2 23 .,... 33,6 40 270 
7 4,7 24 37,9 41 306 
8 5,3 25 42,9 42 346 
·,'· 
' 
48 s' ' •. 9 6,0 26 
... I 43 391 
10 6,8 27 54,8 44 442 
1 1 7,7 28 62,0 45 500 
12 8, 7 29 70, 1 . 45 565 
13 9,8 30 79,2 · 47 6 38 
14 11 , 1 31 89,6 48 72 2 
15 12, 6 32 10 1 49 8 16 
16 14,2 33 · 115 50 923 
17 16,0 34 129 51 1 043 
18 18,2 35 146 52 1 180 
19 20,5 36 166 53 1 333 
20 23,2 37 187 54 1 507 
3.4 
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The heated fibrin plate 
Cholelysin invariably caused lysis of a heated fibrin 
plate, proving that it was directly fibrinolytic. 
Th~re . was little or no difference between results on a 
heated and an unheated fibrin plate. Results using 
various fractions of cholelysin (see Chapter Four for 
details of purification of these fractions) are shown 
in Table 3-11 and are plotted in Figure 3-5. 
Table 3-11: The effect of various preparations of cho-
lelysin on heated and unheated fibrin pla-
tes. Presterilised glass Petri dishes 
used throughout. Results in mm diameter 
of lysis. 
··· · 
Enzyme Fibrin plate 
Unheated Heated 
1 
Whole bile 1 4 O 
2 35 
Ammonium 
sulphate 
precipi-
tate 
Fractions 
1 18 
2 36 
( see Chapter IV) 
G 200 30 
Peak I 16 
Peak II 4 
Peak III 7 
Peak IV 10 
Plasmin 14 
Urokinase 14 
Streptokinase 20 
2 
44 
32 
18 
32 
32 
19 
4 
6 
1 1 
14 
14 
22 
Mean ·. ' , 1 
42 
33,5 
18 
34 
31 
17,5 
4 
6,5 
10,5 
14 
14 
21 
44 
26 
18 
37 
30 
15 
4 
5 
10 
13 
0 
0 
2 
42 
28 
16 
32 
34 
19 
4 
6 
12 
14 
0 
0 
Mean 
43 
27 
17 
34,5 
32 
17 
4 
5,5 
11 
13,5 
0 
0 
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Figure 3-5 : Fibrinolytic effect \ of __ cholelysin on 
heated and unheated ftbrin plates c om-
pared . Several ex~eriments are plot-
ted h ere that we re not listed in.Table 
3 - 11. 
Summary 
Methods of assessing fibrinolysis are briefly -discus-
sed. For scientific accuracy, one of the less rapid 
tests was preferred, and reasons are given for choosing 
the fibrin plate assay as the basic research tool for 
this study. The physiology and methodol ogy of the fi-
brin plate are then discussed , and the nature _o f the 
dose-response curves to be found on it. It shows a 
high degree of sensitivity, and has excellent stabili-
- 43 -
ty when stored at 4°c, and reproducibility. The hea-
ted fibrin plate is . a useful research tool for dis-
tinguishing fibrinolysins form activators of fibrino-
lysis. The dose-response curve of cholelysin is shown, 
and compared with that of chymotrypsin. A table of 
units/l of activity is drawn up for cholelysih, using 
chymotrypsin as the reference standard. 
' 
., 
\ ·--... 
' . 
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CHAPTER FOUR 
BILE 
-4.1 Bile is a complex mixture of substances. For the pur-poses of this study, the point of major importance was the · composition of gall -bladder bile, ·as nearly all stu-dies were done on bile derived from the ox gall-bladder. The composition of mammal:i_an bilP. does not ap::;:iear t c- va-
ry greatly from species to species, but I was unable to find data on ox bile. Figures for the composition of 
secreted bile and gall-bladder bile given here are quo-ted from 
(i) Liver and biliary disease Eds R. Wright, 
K. Alb~rti, S . Karran and G. Millward-Sadler, (1979) 
(ii) Handbook of Physiology: S~ction 6 - Alimeritary Canal (1968) Vol 5 Chapters 110 , 11 2 , and 113. 
Bile acids - cholic and chenodeoxycholic 
(ratio 2:1) 
acids 
0,5 
0,7 
0,7 
Cholesterol 
Bilirubin 
Protein 
0,03-0,3 
are secreted per day. 
However, figures for total protein/24 hours of 0,275 and o·,514 g respectively are given by Rosenthal, Kubo, Do-linski, Marino, Mersheimer and Glass (1965) for two pa-tients with presumed normal livers on T-tube drainage for extra-hepatic obstruction. Of this, about 80% was 
albumin, and the remainder was not identified. Total 
g 
g 
g 
g 
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volume of bile per day is up to 1 litre, or 0,5 mg 
protein/ml bile. However, as the gall bladder con-
centrates bile up to 100 times, there could be signi-
ficant quantities of bile proteins in it, and in this 
study we found raw bile to contain 2-6 mg protein/ml. 
Electrolytes are present in approximately isotonic 
quantities with plasma, and are almost entirely remo-
ved during concentration in the gall bladder, while 
bile acids and cholesterol concentrate up to 100 times. 
Precipitation of insoluble cholesterol and lecithin is 
prevented by the formation of micelles or aggregates of 
bile salts and lecithin, forming 'liquid crystals' into 
which cholesterol is incorporated. Lecithin greatly 
increases the ability of bile salts to incorporate cho-
lesterol, by acting as a polar lipid to swell the micel-
les into 2 molecule thick discs. It drops the number 
of bile salt molecules required to solubilise one cho-
lesterol molecule from 35 to 10. 
According to Wheeler (1968), the gall bladder exists 
because the secretion of bile is continuous, but its 
arrival at the intestine for its digestive function 
must be periodic. By concentration, it can accommo-
date about half the daily output of bile at any one 
time. 
From the point of view of this study, everything except 
the protein content was irrelevant, and much time and 
effort was devoted to removel of the strongly charged 
bile salts, as will be discussed below. Bile pigments 
served as a marker for successful purification of bile, 
and Fouchet's test for bilirubin was used for quality 
control. 
4.2 Availability and purity of bile 
The first experimental work was done using human bile. 
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This was obtained from T-tube drainage of patients in 
the Department of Surgery. · It was potently fibrino-
lytic, but was usually infected, so that many speci-
mens were unsuitable for study. The supply of patients 
on T-tube drainage was erratic as well. 
Other available species of mammal were therefore stu-
died to discover a reliable source of bile. Fibrino-
l lytic activity was found in the bile of 11 species: 
cat, dog, goat, sheep, guinea-pig, mouse, ox, pig, · rab-
bit and rat - as well as man. 
It was decided to standardise on ox bile from the Muni-
cipal Abattoir, C3.?e 'I'oKn as this \''as nvailabl 3 in 
large volumes under controlled conditions. The Direc -
tor of the Abattoir, Dr Albertyn, was most helpful at 
all times . 
Oxen are killed at the Aba.ttoir by stunning foll owed by 
exsanguination . The carcasses are immediately proces-
sed . Bile was obtained directl1 £rom the gall-
bladders within 60' of death. 
Ox bile was also proce ssed in Pretoria by Dr T Haylett 
-
of the Council for Indu s trial and Scientific Research, 
acting on behalf of the South African Inventions De -
velopment Corporation . He produced a highl y potent 
cholelysin solution for our biological exper iments 
(Chapter Eight), but experienced difficulty with the 
gelling of the bile after ammonium sulphate precipita-
tion, which he ascribed to mucoproteins present in the 
bile? from winte~ feed in the Transvaal. 
4 ~3 Quality control 
Because the Director of the Abattoir, Dr Albe·rtyn, kind-
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·,, 
ly allowed direct access to the oxen while being pro.:. 
cessed, most contamination was excluded. The Abat-
toir workers would hand us the . excised gall-bladder, 
and this would be aspirated with a sterile needle at-
tached to a 50 ml syringe, ·which was then emptied in-
to a pre-sterilised glass container~ Volumes of 5 
10 litres were readily obtained in a short space of 
time. 
All batches of bile were cultured for organisms, and 
were discarded if organisms were grown in significant 
quantity, or if any organisms found showed inherent 
fibrinolytic potential. Specimens from which 'occa-
sional' colon ies were grown were regarded as ar.cepta~ 
.ble. 
A batch would usually commence its processing in the 
laboratory on the same day, but occasionally samples 
0 . would be left for 1 - 7 days at -40 C before work com-
menced. This did not affect the lytic potentia~ of 
raw bile. \--...__ 
.\ ....... , 
4.4 SurnI_!_lary 
·, 
--
------·· 
Human bile was used in _the fi~st series of experimentsi 
but supplies :were unpredictable, and often infect_ed. 
A survey of available mammalian species wa~ made. All 
showed fibrinolytic activity, and it was decided to 
standardise on ox bile from the abattoir. ·_ The procu~ 
·ring and quality control of ox bile are described. 
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CHAPTER FIVE 
METHODS OF PURIFICATION OF CHOLELYSIN 
FROM OX BILE 
5.1 Introduction 
The complex micellar solution of bile was almost en~ 
tirely redundant from the point of view of this stu-
dy. ALl that was desired was a purified protein so-
lution, but it took some years of experimentation to 
achieve this result, and it would be futil e to retrace 
the many at tempts made towards this -goal . There were 
many blind alleys and many disappointments. Rather, J;.. . in discussing the numerous techniques listed in Table 
of Contents , the emphasis will be on the positive·re-
sult that led towards a successful solution, and the 
poorer methods will be discussed- briefly in Appendix 
5. 
5.2 Bile 
5.2 . 1 Column chromatography 
The first method studied was column chromatography of 
raw human bile on sephadex G200 (fine). This gave 
several patterns of elution, three of which are shown 
in Figures 5-1, 5-2 and 5-3. Lyt ic activity was mea-
sured on the standard fibrin plate, and reported i n 
mm
2
, as at that time the semi-logarithmic nature of 
the dose-response curve had not become apparent . 
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Figures 5-1, 5-2 and 5-3 : Profiles of elution of 
whole human bile from 
sephadex G200 (fine). 
Eluant tris/NaCl. 
Lytic activity 
Optical density 0--0-0 
( King , 1 9 7 2 ) 
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Comment on Figures 5-1, 5-2, and 5-3: the eluate was 
contaminated with bil~ pigmen€s and bile salts, and 
the optical density of fractions at 275 nm bore no re-
lation to their fibrinolytic activity. It was deci-
ded to test known constituents of bile for their lytic 
activity. Further methods of purification of the 
fibrinolysin(s) should be sought. 
In TabLe 5-1, constituents of bile that were tested 
-for their fibrinolytic potential are listed. They 
were available in pure form. 
Table 5-1: The following were tested for fibrinoly~ 
· tic potential on the standard fibri~ plate. 
No fibrinolysi s was observed with any one . 
sodium taurocholate 10 mEq/l 
sodium glycochol ate 10 mEg/ .e. 
bilirubin 5 mg/100 ml 
5 . 2 .2 Ammon i um sulphate precipitation 
Ammonium sulphate precipitated fibrinolytic activity 
from bile. The point of 100% precipitation varied 
over the whole range of trials £ram 8 to 45% . I f a 
second precipitatibn was made after reconsti~ution of 
the precipitate, a lower concentration of ammonium 
sulphate might be effective . The first precipita-
tion step gave concentrations of 2-4 X, the second 
of up to 50 times~ A typical early experiment is . 
shown in Figure 5-4. 
C 
.!!! 
"' >, 
-0 
"' .. 
C 
0 
160 
BO 
N 40 
Figure 5-4: 
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5 10 15 20 
Ammonium sulphate 
\ 
\ 
\ 
\ 
25 .,. 
Fibrinolytic activity of precipit~te 
Fibrinolytic activity of supernatant 
Pattern of precipitation of fibrinolytic 
activity by ammonium sulphate from raw 
human bile in one typical experiment. 
Com.i-nent: No sample of human or ox bile was found which 
failed to show 100% precipitation of lytic activity at 
ammonium sulphate concentration of 46% or lower. For 
this reason, an initial concentration of 50% W/V was 
decided on for later work. 
Column chromatography of a once precipitated sample, 
which was then reconstituted, is shown in Figure 5-5. 
Such samples gave a more consistent pattern of elu-
tion. 
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Figure 5-5: - Elution profile of an ammonium sulphate 
precipitated ,;oncentrate of bile applied 
to sephadex G200 (fine) 7 = 85 ml 
0 
K = + 0,9. 
av J 
Finally, a sample of reconstituted concentrate, follo-
wing one precipitation wi_th ammonium sulphate, was ap-
plied to sephadex G50 (medium), and ~he elution profile 
recorded. Neutral sugar and protein (biuret) were also 
measured, but bore no relationsh~p to fibrinolytic ac-
tivity, as is shown in Figure 5-6. 
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Figure 5-6: Elution profile of an ammonium sulphate 
precipitated sample of raw b~le on sepha-
dex G50 -(mediur,1) . Neutral sugar D-0 
and protein (biuret)ll---e were estimated 
on the same fractions. V
0 
= 95 ml 
.Kav = O, 3. 
Comment: it was apparent .that insufficien.~ purifi~a-
tion had yet been achieved, and other methods of pre-
cipitation of fibrinolytic activity from raw bile were 
sought. These were: 
5.2.3 Acetone precipitation 
5.2.4 Chloroform/methanol partition (Bligh and Dyer, 
1959) 
5.2.5 Polythylene glycol precipitation 
5.2.6 Precipitation with various agents capable of 
causing cholestatic jaundice in man: 
promazine, chlorpromazine, amitryp-
, . 
tilene.~ trifluperazine (Clarke, Maritz and 
Denborough, 1972). 
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Unfortunately, these methods proved either ineffec-
tive, or unacceptably damaging to fibrinolytic acti-
- vity. They are discussed briefly in Appendix 5. 
5.3 Precipitated fraction 
5.3.1 Redissolving of the ammonium sulphate precipitate at 
vari~us levels of pH was studied at the commencement of 
this work. Tris buffer M 0,006 was used, and the fol-
lowing result obtained. 
Table 5-2: Ammonium sulphate precipitate of bile, 
50% W/V, redissolved in tris M 0,006 
- I 
1 
pH nun 
10,5 14 
9,5 17 
. 8 I 5 22 
7~5 - 20 
6', 5 16 
5,5 13 
at various pH levels. Volume of added · 
tris kept constant, and lytic activity 
tested on the fibrin plate. Results in 
nun diameter of zone · of lysis. 
Test 
2 3 
uni"_s mm units mm units 
11 , 1 19 20,5 24 37,9 
16,0 21 26,3 25 42,9 
29,7 25 42,9 29 70,1 
23,2 24 37,9 28 62,0 
14,2 20 23,2 26 48,5 _ 
9,8 18 18,2 
Comment: following this result, the pH of tris buf-
fer was standardised at 8,5 except where otherwise 
stated. 
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5.3.2 Reprecipitation with ammonium sulphate led to consi-
derable concentration, and 25-50% loss of activity. 
This could have been acceptable, but unfortunately 
the bile salts and pigments formed a tarry deposit 
that interfered with further work. It was necessary 
to find more effective ways of removing them from so-
lution. 
5.3.3 An effective anion exchanger was sought, and found in 
sephadex ASO. This produced marked clearing of bile 
_pigments and salts, and the remainder of the -unwanted 
substances, and at the same time absorbed fibrinolytic 
activity strongly. 
J 5.3.4 · The most effe ctive method for desorbing fibrinolytic ~ 
act~vity was found to be an acidification s~ep. Used 
with sephadex, this did not produce marked loss of ac-
tivity, while at the same time bile pigment concentra-
tion, and protein, fell sharply in t~e desorbed · frac-
tion. Followjng thi3 , an ammonium sulphate precipi-
tation step was incorporated. These steps, and their 
effects on bile, are shown in Table 5-3. 
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Table 5-3: Effects of adsorbtion with sephadex A50, 
desorbtion at pH 3, and subsequent preci-
pitation with ammonium sulph2te, on fibri-
nolytic activity, and protein and biliru-
bin content, of bile. Volume of redissol-
ved solutions -held constant through. 
Fraction 
Lysis 
nun diam 
44 
Units/! 
442 
Protein 
mg/ml 
2,4 
Units/mg 
protein 
130 
Fouchet 
(bilirubin) 
++++ Raw ox bile 
sephadex ASO 
supernatant 
sephadex ASO 
desorbtion 
at pH 3 
4 3,3 • 0,6 2, a· +++ 
_aiymonium sulphate 
supernatant 
ammonium sulphate 
precipitate 
redissolved 
40 
0 
41 
5.3.5 Adsorbtion on AG1-X.8 
270 
0 
_ 306 
This is a synthetic compound. 
1 , 1 208 +++ 
+++ 
0,75 408 ++ 
It is a strongly basic 
anion exchanger having guarternary arrm1onium active groups 
,on .a polystyrene framework. 
It was tried instead of sephadex A50 because it is con-
siderably cheaper, and easier to regenerate. It pro-
ved effective, but led to a somewhat lower recovery of 
fibrinolytic activity than when sephadex A50 was used. 
5.3.6 Column chromatogra~ 
Because Fouchet's test was still positive after the 
ammonium sulphate precipitation step, molecular exclu-
I 
• 
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sion was added for further purification. Sephadex 
G200 had proved effective in earlier experiments, and 
was used again. The eluted fractions off the column 
were pooled, and referred to as 'Fraction G200'. The 
effect on fibrinolytic _activity, protein content, and 
bilirubin concentration, are shown in Table 5-4. 
Table 5-4: Effects of column chromatography (on sepha-
dex G200) of the fraction produced by the 
steps outlined in Table 5- 3 , on fibrinoly-
tic activity, and protein and bilirubin con-
tent of bile. 
/ 
Lysis Units/! Protein 
Units/mg Fouchet 
mm diam mg/ml protein 
Fraction G200 
Experiment I 32 101 0,178 567 + 
Experiment II 25,5 44 0,231 190 + 
Experiment III 24 38 0,159 239 + -
This fraction could be concentrated by ultrafiltration, 
but it was still contaminated, and the pattern of elu-
tion varied considerably, without clearcut relationship 
to optical density. One experiment is illustrated in 
Figure 5-7. 
0,3 
0,2 
0, 1 -· 
J 
en s .µ 
i::: ·r-l 
i::: 
I.(') ::1 
300 
r-- 200 
N en 
·r-l 
o en 
0 >, 
M 
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5 
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Figure 5-7: Production of Fraction G200. A sample of 
bile following redissolving ~f ammonium sul-
phate precipitate (section 5.3.4) was ap-
plied to sephadex G200. Fractions we~e tes-
ted for fibrinolytic _activity, and for op- . 
tic ~l density &t 275 nm. 
This fraction is roughly comparable to the fraction 
shown in Figures 5-5 and 5-6. 
5.3.7 NaCl gradient elution of 'fraction G200' from Whatman 
DE 32. 
This step was introduced because 'fraction G200' showed 
a poor correlation between protein content and fibrino-
lytic activity, and still contained bilirubin. It was 
thought that gradient elution might also add information 
about the physical nature of cholelysin. 
The pattern of gradient elution was variable. Four 
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peaks of fibrinolytic activity were usually seen. 
· of these, only the first peak was consistently present, 
though usually all four were seen. Peak 4 was most 
likely to be absent. These were designated Peaks I, 
II, III and IV, and were collected separately and con-
centrated by ultrafiltration for the work on substra-
tes described in Chapter Six. In Figures 5-8, 5-9, 
5-10 and 5-11 below i four typical patterns of gradi_ent 
elution are shown. 
in the Peaks. 
Fouchet's test was usually negative 
Figures 5-8, 5-9, 5-10, 5-11. 
Fraction G200 applied to a Wha~man DE 32 column, an~ 
eluted with a ·sodium chloride gradient. 
fo~ all four experiments were the same: 
Sample: 4 ml dialysed G200 
Column: Whatman 1,5 X 45 cm 
Flow rate: 28 ml/hour 
Resin: Whatman DE 32 
Buffer: Trif" M 0,006 pP. 8,5 
Fractions: 3,2 ml 
Gradient: M 0,006 0,05 40 ml 
(Nacl) M 0,05 - 0,10 40 ml 
M 0, 10 - 0,15 40 ml 
M 0,15 - 0,20 40 ml 
M 0,20 100 ml 
Conditions 
12 
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U1 Ul 
r--- -~ 
N Ul 0,2 :>-i 
!>1 r-1 
..µ 
~ ~ 80 
s:: 
Q). Ul 
'O .µ 
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Figure 5-8: Pattern of gradient elution of cholelysin 
G200 from Whatman DE 32. 
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Figure 5-9: Pattern of sodium chloride gradient 
elution of cholelysin G200 from What-
man DE 32. Peak IV is absent. 
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Figure 5-10: Profile of elution of cholelysin from 
Whatman DE 32, Method A. The four 
Peaks obtained are indicated in the 
graph. 
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Figure 5-1t: Profile of elution of cholelysin from 
Whatman DE 32, Method A. The four 
Peaks obtained are indicated on the 
graph. 
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Table 5-5: Results of the experiment shown in Figure 
5-8 expressed in tabular form: 
Total Volume· Tota). Protein Units/mg Peak Fractions (ml} activity units mg/ml protein 
units/l 
I 8-15 25,6 636 16,28 0,055 2% 
II 16-22 22,4 235 -5, 26 0,012 438 
.III 23-38 !:> 1 , 2 276 14, 13 Or032 404 
1v· 39-51 41, 6 359 14,93 0,050 299 
. / 
( 
These results showed satisfactory r"eduction in protein 
content while retaining fibrinolytic activity. Higher 
values for units per mg protein were obtained on other 
occasions. Thr ee sets of re3ults are shown in Table 
5-6. 
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Table 5-6: Results of NaCl gradient elution of cho-
lelysin from Whatman DE 32 under condi-
ti6ns identical with tho~e set out in 
Figure 5-8. Three experiments. 
Peak Lysis Activity Protein Units/mg diam mm (units/!) . . mg/ml protein 
I 26,5 51,6 0,019 2 716 
26 48,5 0,055 882 
21 26,3 0,034 774 
II 13 9 ,8 . 0,010 980 
7,5 5,0 0,016 313 
17 16,0 0,027 593 
III 9 6,0 0,015 400 
/ 
11 7,7 0,023 335 
(No Peak III in third experiment) 
IV 12. 8,7 0,020 435 
22,5 31,7 0,062 511 
6,5 4,5 0,035 . 129 
5.3.8 Full flow sheets for sephadex A50 and for AG1-X8 
are shown in Tables 5-7 and 5-8. 
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Table 5-7: Flow sheet for the purification and con- . 
centration of cholelysin from raw ox bile. 
Method A 
· Ox bile 100 ml 
! 
1 Desalting with sephadex A50: 4 gadded 
at 20°c. Stirring continuously for 30l. 
2 Centrifuge - 15 000 rpm for 30 minutes 
at 4°c. 
Supernatant 
retained at 4°c 
Pellet 
! 1 Wash with 50 ml Tris HCl pH 3,0 2 Centrifuge as abOY. '.) 
, _, ___ _ 
I 
recombine 
Supernatant Pel.let (discard) 
1 
2 
3 
Supernatant 
(discard) 
supernatants 
Make up volume to 100 ml with Tris buffer 
pH 8,5 
Add ammonium sulphate 40 g 
Centrifuge at 15 000 rpm for 15 minutes at 
40C 
Pellet 
1 Redissolve in Tris HCl pH 8,5 
r 
Dialyse against Tris HCl 
pH 8,5 overnight at 4°c 
1 litre changed once 
Column chromatography on sephadex G20G 
l 
All lytic fractions combined= .Fraction G200 
l . 
Sodium chloride gradient on Whatman DE 32 
Peaks I II III IV 
' 
0 
Dialyse overnight against Tris HCl buffer pH 8,5 at 4 C 
(dialysis fluid changed once) 
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Table 5-8: Flow sheet for the purification and concen-
tration of cholelysin from raw ox bile. 
Method B 
Ox bile 2 litres 
l 
1 
2 
Effluent 
! 1 2 3 
Effluent 
(di::--card) 
Desalting with AG 1X-8 160 g, stirring con-
tinuously by hand for 30 minutes 
Centrifuge in basket centrifuge 
Precipitate - regenerat~ (see methods) 
Add ammonium sulphate 50% W/V 
Stir slowly for 30 minutes at room temperature 
Centrifuge in basket centrifuge 
-·----, 
Precipitate 
A 
I Dissolve in minimum volume of 
Tris HCl pH 8,5 
2 Dialyse overnight against 30 litre 
Tris buffer pH 8,5, in boiled dia-
lysis tubing approximately 4,5 cm 
diameter, changing dialysis fluid 
once 
Whatman DE 32 
Elute with 6 l Tris buffer pH 8, 5 
Elute with 0,1 M NaCl in Tris 
buffer pH 8,5 
Fractions were typically 200 ml. 
and tested for lytic activity. 
All fractions retained 
3 Retain first elution (= Peak I} 
4 Dialyse in Tris buffer pH 8,5 to 
remqve NaCl 
5 Concentrate on Amicon filter 
6 Assay for lytic activity and 
protein content 
7 Flash freeze dry 
s 
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This multiplicity of Peaks, and irregular elution from 
a column, led into greater complexity than seemed justi-
fied at this stage. This thought was strengthened by 
the discovery that Peak I could be eluted from Whatman 
DE 32 by tris buffer alone. Subsequently, a pulse of 
sodium chloride could be used to clear remaining activi-
ty from the column. When the procedure was carried out 
in this way, activity was fairly evenly divided between 
the two batches, though with runs on a large column more 
activity tended to remain in the second batch. Results 
of 6 experiments are shown in Table 5-9. 
Table 5-9: Batchwise elution . of cholelysin from Fraction 
(a) 
(b) 
G200 applied to Whatman DE 32. Tris M 0,006 
pH 8,5 followed by NaCl 0,1%. 
Two sizes of column: (a). 40 x 1, 5 cm 
(b) 72 x 14 cm 
Applied to Recovery Recovery Tric; NaCl Tris/NaCl 
column (units) (units) % .elua~c eluate rat.:io 
2,3 2,46 107 1,26 1,:w 1,05 
5,4 5,28 98 .3, 17 2 .. 11 1, 50 
4,7 4,~2 94 - 3, 29 1 , 13 · 2, 91 
105,2 137,3 131 39,1 98,2 0,40 
96,1 101,6 105 44,2 57,4 0, 77· 
58,2 58,2 100 25,8 _32, 4 o·, ao 
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These results, though variable, did indicate that s~f-
ficient Peak I could be obtained for experimentation, 
and subsequently this Peak was used for all experimen- · 
tal work except some of the substi ate studies reported 
in Chapter Six. An example of batchwise elution is 
given in Figure 5-12. 
V 40 ml 
0 
Height 17,2 cm 
Fractions 3 ml 
Elution: 
( 1 ) 60 ml tris buffer pH 8 5 
, 
(2) NaCl 
to 
0, 1 M pH 8,5 
O} 
'I 
0)1. ....... E en 
~ -1,J 
.... 
~ §40 
.... 
CII 
0,1 0...C 0 <ll 
>, 
.... 
10 .to 30 40 50 70 
Fraction 
.... - --- -
iO 
l 
- - - -- --- ---- -- ,.- .. ...  _.., ._ ··-· _... ,~ --
-·- -- - - - · - · · ·- --- J 
' J 
Figure 5-12: Batchwise elution of Peak I off Whatman 
DE 32. 
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5.3.9 Dialysis 
5.3.9.1 Lowering of electrolyte and other chemical concen-
trations. Dialysis was resorted to, to remove un-
wanted chemicals from the solution eg ammonium sul-
phate, sodium chloride, potassium biphthalate; and 
for lowering of electrolyte concentration after ul-
trafiltration. The standard technique employed was 
to use double the volume of the solution to be dia-
lysed, and to change this one~ over 24 hours at 4°C. 
Usually tris buffer M 0,006 pH 8,5 was employed. 
Dialysis led to an unacceptable loss of activity (up 
5.4 
5.4.1 
· to 100%) until it was found that boiling the dialysis 
tubing first prevented this loss. 
C)ncentration 
Considerable concentration was possible using ammo-
nium s~lphate preci~itation alone. A twice preci-
pitated samp~e of bile could attain a concentration 
of lytic activity= - 20 x original sample, as the 
following table shows. 
5.4.2 
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· Table 5-10: Summarised experiment in which fibrino-
lytic activity was twice precipitated 
from raw bile by ammonium sulphate. It 
was found that low concentrations of am-
monium sulphate might be sufficient for 
complete reprecipitation. 
Stage Volume Lysis Units/.t Concentration (mm diam) 
1 20 ml 20 23,2 1 , 0 
2 10 ml 25 42,9 1 , 8 X 
3 2 ml 44 442 19,1 X 
Stages (1) Raw bile 
(2) Ammonium sulphate addec. W/V 33% ' 
(3) Ammonium sulph :>.te added W/V 4% 
I 
. However, there Wc.s heavy contamination from bile salts 
and pigments, and this procedure was unsatisfactory as 
a final method of purification. 
Ultrafiltration 
This technique was used extensively. It led to con-
centration of fibrinolytic activity of 2 - 15 times, 
with considerable loss of activity during the process. 
An Amicon ultrafilter was used, with UM 2 filler pas-
sin~ all molecules below 1 000 molecular weight. Re-
sults are shown in Tables 5-11 and 5-1~. 
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Table 5-11 : Effect of concentration by ultrafiltra-
tion on activity of cholelysin. Ami-
con with UM 2 filter. Peak I used in 
all four experiments. 
Experi- Units ml Total Concentration 
ment units Post/Pre 
ml units 
A Pre: 0,0098 1 1 1 1,088 
Post: 0,062 7,9 0,490 14,1 6,3 
LQSS 55% 
B Pre: 0,0064 172 1 , 110 
Post: 0,095 8 0,763 21,5 14 , ·9 
Loss 31% 
~· Pre: 0,0792 14.5 11,484 
Post: 0,165 ·i2 1,984 12, 1 2,1 
Loss 83% 
D Pre: 0,0862 132 11,380 
Post: 0,710 6 4,260 22,0 8,2 
Loss 63% 
Protein concentrations were estimated in experiment 
D above, and are reported in Table 5-12. 
'. 
5.5 
5.5.1 
5.5.2 
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Table 5-12: Protein concentration, and acitivity/mg 
protein during concentration of cholely~ 
sin Peak I by ultrafiltration. 
Protein 
mg/ml 
Pre-concentration 0,0071 
Post-concentration (22x) 0,1611 
Increase 22, 7 X 
units 
86,2 
-710 
Units/mg 
protein 
12 141 
4 407 
2,7 
., 
X 
Comment: These experiments showed a considerable loss, 
with much variability. They also showed that one pos-
sibility was denaturation of the protein concerned 
~Table 5-12). 
St:>0ilisation 
Stabilisation by addition of calcium or magnesium 
Earlier preparation di.th heavy contamination by other 
bile constituents showed much loss of activity with 
t . Th dd·t· f ++ ++ · h · 1 · 1 ime. ea 1 ion o Ca or Mg in p ysio ogica 
quantities led to no improvement. 
Freeze drying 
This technique was used in an attempt to cut down loss 
. 
of fibrinolytic activity during stor~ge of products 
over months at -40°c. It was found that there was 
an average loss of fibrinolytic activi ty of _50% .at 
6 months of storage at -4o 0 c. 
Freeze-drying resulted in even greater loss of acti-
vity. 
5.5.3 
5.6 
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Flash freezing - freeze-drying 
In this technique, t~e concentrated and purified spe-
cimen was frozen instantly in 2 ml aliquots in liquid 
nitrogen at -196°c, and then freeze dried in the usual 
way. Using this method, there was no loss of activi-
ty over 6 months, and this .was the procedure which was 
standardised for later work. 
Summary and flow sheet analysis 
The procedure of purification, concentration, and sta-
bilisation of cholelysin is described. The final method 
used the following procedures in succession: 
Raw ox bile 
Typical specimen 
of bile 
Redissolved after 
sephadex A50 step 
Redissolved after 
NH4 (so4 ) step 
Fraction G200 
Peak I 
Peak I after se-
cond elution off 
Whatman DE 32 
Protein 
mg/ml 
2-6 
2,4 
1 , 1 
0,750 
0,200 
O,IJ:34 
0,007 
?ibrinolytic 
activity 
(units/l) 
10-1500 
442 
270 
306 
120 
26,3 
86,2 
Units/mg 
protein 
130 
208 
408 
600 
774 
12 141 
The above figures are, of course, an average state-
ment of a highly variable process. The maximum and 
minimum figures for the various steps are given in 
Table 5-13. 'Peak I after second elution' gave the 
highest figure for ac~ivity in units/mg protein re-
corded during this stuqy. 
,. 
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....;::;;;;;;;;;;.;;;.;;~_;...-1...:...;;..3: Recovery of fibrinolytic activity during 
processing of ox bile. 
Maximum Minimum 
- ::W ,..b:j 1 C 100 100 
~. _. n1ve d after NH4 (so4 ); 
.:;p.rec±p" tate 91 69 
. . -:r:±:ior. G200 85 50 
~~iatmilll vE 3 2 ( total 
y 85-90 42· 
63-67 12 
_ -.: ,..1:1 t ice, figures fell be-=ween the two extremes, 
~nd -~rge scale recovery of cholelysin from ox bile 
was obviously possible. 
~·. 
... 
6.1 
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CHAPTER SIX 
SUBSTRATE SPECIFICITY OF CHOLELYSIN 
Endopeptidases such as trypsin and chymotrypsin are 
active against many substrates. In this chapter, 
the activity of cholelysin against some of these sub-
st:r.a·tes is described, and compared with that of chy-
mot~ypsin and trypsin. Plasminogen was added in a 
furth~r attempt to find pl~sminogen activator acti-
vity of cholelysin. Substrates studiec were: 
( 1) Trypsinogen, chymotryp,;inogen, plasminoge ~1 
(2) Casein 
(3) N-acetyl-L-tyrosine ethyl ester monohydrate (ATEE) 
(4) N-benzoyl-L-arginine ethyl ester hydrochl ori~3 (BAEE) 
6.2 (1) Trypsinogen, chymotrypsinogen, plasminogen 
These zymoger.s are ·3.Ctivate·d by their own activa-
ted forms (Guyton, 1976). Because trypsinogen 
and chymotrypsinogen derived from the pancreas 
are physically in such close contact with the 
biliary tree, it was essential to establish if 
cholelysin was related to either of them in any 
way. 
In these experiments, each active enzyme was ap-
plied to the fibrin plate in a 1/1 dilution in 
tris buffer pH 8,5, M 0,006, when tested alone. 
In experiments that involved mixing the active 
enzyme with a zymogen, the zymogen was substitu-
ted in equal volume for the tris diluent. 
Blank 
value 
0 
· o 
4 
0 
77 
Table 6-1: Attempt to activate trypsinogen, chy-
motrypsin and plasminogen with chole-
lysin. All results in mm diameter of 
zone of lysis. Full details are given 
in Appendix 6 p 220 Strength of enzyme 
solutions used in this experiment was: 
plasmingen and plasmin 
trypsiriogen and trypsin 
0, 1 CTA_ U/ml · 
1 000 U/ml 
chyrnotrypsinogen and chymotrypsin -
1 . 000 U/ml 
Fraction G200 was used throughout. 
- - - -
Enzyme Substrate 
added Cholclysin Trypsin Chyrnotrypsin Plamnin 
None 12 , 2. 14,8 14, 4. 12,2 
Trypsinogen 11,6 23;6 
Chymotrypsinogen 11 , 0 22;2 
Plasminogen 13,0 21 , 0 
The left hand column 'Blank value' - gave the 
lytic activity of each zymogen when tested separa-
tely. All available commercial samples of chymo-
trypsinogen had lytic activity, though the other 
zyrnogens were inert on a fibrin plate. 
Comment: Cholelysin failed to activate any of 
these zymogens, proving its separate identity. 
It seemed possible that chymotrypsinogen interfe-
red with the lytic activity of the cholelysin solu-
tion tested; the calculated combined lytic effect 
should have been about 14,8 mm, which is signifi-
-cantly different from the result observed. How-
ever, this observation was not followed up .. 
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6.3 (2) a-casein 
In 1968, the National H~art Institute, Bethesda, 
Md, USA, approved a caseinolytic assay for plas-
min, plasminogen and urokinase in purified sys-
tems {Johnson, Kline and Alkjaersig, 1969). 
This described a reproducible system for the as-
say of plasmin in terms of the release of tyrosine 
from a-casein. Under the described conditions 
{see Methods), one unit of plasmin was defined_as 
the amount which released 0,1 micro-equivalent of 
tyrosine/minute from a specified casein prepara-
tion. · In terms of the spectrophotometric result, 
1 unit of CTA plasmin/ml after 20 minutes of incu-
~ation with casein, caased an in~rease in optical 
density of the TCA-soluble supernatant at 275 nm 
of 0,300. This was a~proximately true o~ this 
experiment when done in Cape Town, though values 
tended to b0 slightly lower (see Table 6-2). 
This was ascribed to slight deterioratio~ ~n ~he 
a-casein and/or the plasmin durj _ng their journey 
from the United States. 
Table 6-2: Cisein~Jytic effect of plasmin in the 
standard system (Johnson, Kline and 
Alkjaersig op cit, 1969). These re-
sults were considered close enough to 
the published paper to accept the sys-
tem for study. 
Increase in OD at 275 nm 
1971 0,270 
1972 0,290 
1973 0,285 
6.3.1 
,;t 
... 
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Cholelysiri was also caseinolytic under the condi-
tions described above. Results of 3 experiments 
are shown below in Figures 6-1, 6-2, and 6-3. 
·Results of these experiments are s~mm~rised in 
Table 6-3. 
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Figure 6-3: Caseinolytic effect of cholelysiri 
Peak I. 
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. ·rP- -3 _,, ..2 . .... :,,~CiJ:.:>.einolysis by Peaks II, III, IV 
,_ fractions studied exhibited caseinolytic ac-
·-g i ty. This is shown in Figures 6-4, 6-5 and 
belo~, and caseinolytic activity is expressed 
t erms of enzyme concentration in mg/ml in Table 
·,..... 4 below • 
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gure 6-4: Caseinolysis by Peak II. 
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Conunent: There was a poor correlation between 
caseinolysis and protein concentration, and also 
betwe en fibrinolysis and caseinolysis in the 3 
experim~nts where combined results are available. 
Figure 6-7 shows these results graphically. · 
---~~~-· -·---- - - - -···- ·-- - --·· 4. ---~ .' - .. ·- --- ---· •• - ---~---
• 
0 
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0 
. ' 
,050 0 
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Figure 6-7: Relationship between pr·otein concen-
tration and caseinoly tic activity of 
Peaks I 
-• 
II 
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; III -0 
IV ·.-D 
·,30 
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-:Tahl~ 6-3: Caseinolysis in terms of protein con-
centration of Peaks I, II, III, IV. 
. ' 
Fibrinolytic activity is only available 
for Peak I. 
-. 
B .c 
) 
' 
D E F 
I 
/). Activity* Proteiq /). Activity/ Lysis D 
. -1 
mg/ml 1 mg 
-
..,.. 
protein units/£. E 
. I ' 
' ,. 6 -1) 0,42 0,023 1 18,3 21 , 0 I 87 \..t 
(Fig 6-2) 2,08 0,113 18,4 42,6 0,43 
· (Fig 6-3)_ 2,08 0,075 27,7 23,6 1 , 1 7 
1 ::· 0,98 0, 2 02 4,9 
(~·ig 6-4) 0,76 0,069 11 , u 
(Fig 6-4) 1, 25 C· , 101 12,4 
1, 10 0,083 13,3 
l. i 0,41 0,048 8,5 
1,01 0,070 14,4 
ff'i g 6-5) 1 , 71 0,097 17,6 
IV 0,95 0,109 8,7 
I r.t ' ... 6-6) · 0,085 0 I 086 , 9,9 
* ..Activity expressed as tangent of best slope on graph 
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6.4 (3) N-acetyl-L-tyrosine ethyl ester monohydrate (ATEE) 
This substrate is · used in an accepted technique 
for the assay of the chymotrypsins (Schwert ar.d 
Takenaka, 1955). ATEE is hydrolysed at the es-
ter linkage, causing a decrease of extiriction at 
237 nm. The reaction is formulated as follows: 
chymotrypsin 
N-acetyl-L-tyrosine + methanol 
T1:" .  e unit of enzyme is ~pec:ified as that amount of 
enzyme causing a decrease of extinction at 237 nm 
of 0,0075 per minute at 2s0c. 
Technique The technique for this assay was taken 
from the Miles-Seravac manual (Miles-Serav3c, 1972 
pp 14-15). It was planned to measure ATEE este-
rase activity of cholelysin and also the effect of 
the known inhibitor(s) of cholelysin (see Chapter 
VII)when incluJeu in the reaction mixture. This 
made it necessary to ~odify the standard test met-
hod, for this allowed only 0,2 ml for added test 
substances. 
The ATEE-esterase activity of cholelysin, as repor-
ted in section 6.4.1, was carried out in the stan-
dard way. However, for the experiments reported 
in 6.4.2 and in Chapter Seven (below) it was neces-
sary to modify the standard test to make possible 
the inclusion of larger volumes of test mate~ial 
(either cholelysin or inhibitor) in the technique. 
6.4.1 
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For these experiments, the following modification 
was made: 
ATEE Diluent ATE:S Volume Unit of 
rng/100 ml {ml) used for test activity 
{mg) {ml) 
Standard 25,2 3 0 , .757 0,2 0,0075/min 
Revised 37,6 2 0,752 1 , 2 0,01/min 
In .the revised method, the unit of activity was 
altered, because conditions were no longer standard, 
and 0,01/min was more convenient than 0,0075/min~ 
Cholelysin was found to have esterase activity against 
ATEE. Peaks I, II, III and IV were assayed in sepa-
ra~e experiments, which are shown in Figures 6-8 and 
6-9. 
j 
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Figure 6-8: Esterase activity of cholelysin against 
ATEE. Chymotrypsin control is shown 
in Figures 6-10 and 6-11. 
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I 60 I CHOLELYSIN PEAK II ·--•-- . . I .. PEAK II I ~~--11•1-,-e• 
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Figure 6-9: Esterase activity of cholelysin Peaks 
II and III against ATEE. Peak IV was 
inactive against ATEE. (Chymotrypsin 
control) . 
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The experimental results shown in Figures 6-8 and 
6~9 are set out below in Table 6-4. 
Table 6-4: Esterase activity, protein in mg/ml- 1 , 
and fibrinolytic activity of cholely-
sin Peaks I, II, III with chy-
motrypsin control . 
__ :..,..!: _____ -- _____ _...~--~ ~ ......... 
-~ 
. 
- .. -----1.--~· ~ 
----- -- -
. nitial Chymotrypsin Protein Chymotrypsin Lytic Chymotrypsin/ 
rate 
-1 units/mg OD/min units mg/ml protein units lytic ratio 
0, (,068 8,9 0,01 890 
0,0682 9, 1 0,01 910 9(,0 
0,0684 9, 1 0,05 182 31,5 5,B 
0,0903 12,04 0,235 51 11,7 4,4 
0, 0770 10,27 0,275 37 9,8 3,8 
i __ 
-
-----
6. 4 .2 
Note: Chymot..:yp3in control used a t 10 units/ml 
concentration. Chyrnotrypsin {i) shown in Figure 
6-9. 
It was of interest to discover if esterase and 
··- fibrinolytic activities paralleled each other. 
··Accordingly, sirnul taneous assay of these proteo-
. lytic activities was made on fractions of Peak r 
eluted off Whatrnan DE 32 in the usual way. The 
result is shown in Figures 6-10 and 6-11. 
• 1 
! 
I 
I 
I ' 
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Table 6-S: Comparison of the fibrinolytic and es-
terase activities of cholelysin Peak I. 
In this table: 
'Units/ml ATEE' are obtained from: 
Dilution factor X initial rate 
0,01 
'ATEE/lysis ratio' is obtained from: 
Units/ml ATEE 
lysis units 
Revised 
Fraction Dilution Initial rate Units/ml Lysis Lysis ATEE/lysis factor OD/minute ATEE mm diam units ratio 
5 1 0,0320 3,20 9 6,0 0,53 
10 1 0,0350 3,50 10 6,8 0,51 
15 ·1 0,0362 3,62 13 9,8 0,40 
20 1 0,0337 3,37 12 8,7 0,39 
25 1 0,0394 3,94 14 11 , 1 . 0,35 
30 1 0,0269 2,69 14 11, 1 0,24 
35 2 (0,2612) 52,24) 
s (0,1000) 50,00) 
10 (0,0478) 47,80) 
mean 50,01 25 42,9 1 , 17 
40 20 0,0259 51,7 29 10 I 1 0,74 
45 20 0,0299 59,8 29,S 74,6 0,80 
so 20 0,0273 54,6 30 79,2 0 69 
55 20 0,0271 54,2 29,!> 74,6 0,73 
60 20 0,0248 49,6 26,5 51,6 0,96 
65 20 0,0230 46,0 26 48,S 0,95 
70 10 0,0415 41,5 26 48,5 0,86 
75 10 0,0371 37,1 22 29,7 1,25 
80 5 0,0578 28,9 13 9,8 2,95 
85 s 0,0450 22,5 8 5,3 4,24 
90 5 0,0521 26,1 13 9,8 2,66 
95 5 0,0650 32,S 20 23,2 1,40 
100 5 0,0398 19,9 8 5,3 3,75 
Fraction 35 was estimated at three different di-
lutions to confirm the large increase in esterase 
activity found at this p o int. 
60 
4 
20 
• • 
• 
• 
• 
• 
• 
• 
• 
• 
,, 
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Table 6-5 is shown graphically in Figure 6-10 
below. 
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Figure 6-10: ATEE esterase and fibrinolytic acti-
vities of cholelysi~ Peak I estimated 
simultaneously. Whatman DE 32. 
Fractions reduced from 3,2 ml .to 0,65 ml, 
and every 5th fraction estimated. De-
tails as in Method A p66 for eluting of 
Peak I from Whatman DE 32. Optical den-
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From these results, it appeared that esterase and 
fibrinolytic activities were found together, but 
that there was a dissociation in the relative ac-
tivitie3 present; fractions 5 - 30 showed a dif-
· ferent ATEE/lysis ratio from fractions 40/100. 
This 
low. 
6 
40 · 
20 
point is shown graphically in Figure 6-11 be-
_._; __ -- k._c -~ - •.• 
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Figure 6-11: Esterase and fibrinolytic activities 
of experiment shown in Table 6-5 and 
Figure 6-1p, plotted against each other. 
Fractions 5 - 30: O O 
Fractions 35 - 100: • • 
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Comment: this interesting result suggests that 
there are two forms of cholelysin in Peak I, and 
that the more slowly eluting form has a higher 
esterase/fibrinolysis ratio. Furt.hermore, the 
two activities in this second form bear a semi-
.logarithmic relationship to each other, though 
the significance of this relationship has not been 
pursued further. 
6.5 (4) N-benzoyl-L-arginine ethyl ester hydrochloride (BAEE) 
, 
6.5.1 
This substrate was also of interest, as it is used· 
in an accepted method of assay for trypsin (Schwert 
and Takenaka, 1955). BAEE is hydrolysed at the 
~ster linkage, causing an increase of extinction 
at 253 nm. This reaction is formulated as follows: 
trypsin 
l 
BAEE + N-benzoyl-L-arginine + ethanol 
The unit of enzyme is specified as that amount cau-
sing an i!1crease of extinction at 253 nm of O, 003 
per minute at 25°c. The technique was taken from 
the Miles-Seravac manual (Miles-Seravac, 1972 pp 
48-49). Trypsin standard gave 101% of expected 
activity. Standard assays are shown in Figures 
6-12 and 6-13. 
Cholelysin was found to have esterase activity 
against BAEE. Peaks I, II, III and IV were as-
sayed in separate experi~ents. The results are 
given in Table 6-6, and are shown graphically in 
Figure 6-12. 
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Table 6-6: Esterase activity, protein in mg/ml- 1 , 
and fibrinolytic activity of cholely-
sin Peaks I, II, III and IV on BAEE, 
with trypsin control. 
!nitial 1·ryp,;in Protein Trypsin Lytic. Tryps in/lytic En~yme rate 
mg/ml-l 
unit ,:; /mg OO/t1.!.n units protein units ratio 
Trypsin 
(1) 0,035 11, 7 0,02 585 610 
' 
(iii ,0,038 j 12,7 0,02 635 
I Pe.ik ·I o,c.o 13,3 v,20 66,5 42,9 1,55 I II 0,008 2,7 0,10 27 11,8 2,29 1II 0 0 o,o4e 0 11,8 I IV 0 0 0,109 0 8,7 I - - -
-- -
- ------
. -·-- --··-------
.. 
Peak I used in this experiment had an unusually 
high protein content. The results of these ex-
. periments with various substrates are summarised 
in Table 6-7. 
Table 6-7: Summary of observations on. substrate ac-
tivities 0£ cholelysin studied here. 
Substrate Cholelysin Peaks 
I . II III IV G200 
Casein + + + + 
ATEE + + + 0 
BAEE + + 0 0 
Plasminogen 0 
Trypsinogen 0 
Chymotrypsinogen 0 
Peak 
Peak 
Peak 
Peak 
Peak 
Note: 
I/-t;.rypsin ratio 66,5/610 = 0,1 
II/trypsin ratio 27/610 = 0,04 
I/chymotrypsin ratio 182/900 = Q,2 
II/chymotrypsin ratio 51/900 = 0,06 
III/chymotrypsin ratio 37/900 = 0,04 
(a) Peak I/trypsin ratio is derived from the 
fourth column of results in Table 6-6 
'Trypsin units/mg protein'. 
(b) Peak I/chymotrypsin ratio is derived from 
the fourth column of results in Table 6-4, 
'Chymotrypsin units/mg protein'. 
I 
j 
,25 
! 
,15 
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J_ _________ 60 I 180 
Minutes of incubation 
CHOLELYSIN Peak I ...... 
Peak II 0--0 
TRYPSIN ...... 
300 
F~gure 6-12: BAEE esterase activity of cholelysin 
· peaks I and II, with trypsin control. 
~eaks ~II and IV were inactive. 
sin (i) shown. 
Tryp-
The experimental results from which Figure 6-12 was 
derived are set out in Table 6- 6 . 
• 
6.6 
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Discussion 
1 All four peaks of cholelysin are proteolytic. 
2 However, each peak shows apparently distinctive 
specific:ity for the two synthetic substrates. 
(i) Peak IV hydrolyses neither the tyrosine-
containing group of ATEE nor the arginine-
containing group of BAEE. Its caseinoly-
tic activity must thus be due to some 
specificity other than for these two 
commonly encountered amino acids. 
(ii) Peak III shows some tyrosine specificity, 
but no activity against the arginine pep-
tide bond. lt is therefore chymotrypsin-
like in this respect. 
(iii) Peaks I and II both show broader :,pecifi-
city, hydrolysing both the tyrosyl and · ar-
ginyl residues, though Peak II is less ac-
tive against the latter substrat~ and is 
possibly thus distinguiHhable from Peak I. 
(iv) Both Peaks I and II show a lower relative 
ester~se activity against the two synthe-
tic substrates than trypsin and chymo-
trypsin. HJwever, the protein content 
of the Peak I used in the BAEE experiment 
was usually high for the lytic activity 
show, and it is probable that a prepara-
tion with higher specific lytic activity 
might have equalled or surpassed chymo-
trypsin in terms of BAEE esterase activ·i-
ty. 
(v) The two forms of cholelysin demonstrated 
in section 6.4.2, with shar~ly diff~rent 
esterase/lytic ratios, we re of particular 
. interest. It is hoped to study this phe-
nomenon further. 
·. 
6.7 
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Sununary: 
Substrate specifidities for cholelysiri are presen-
ted. Trypsinogen, chymotrypsinogen, and plasmi-
nogen were studied, and alpha-casein, ATEE and 
·BAEE. All four Peaks showed different specifi-
citi~s against the synthetic substrates ATEE and 
BAEE. Peak I had two forms with differing ratios 
of ATEE and lytic activities when measured simul-
taneously. 
r 
..... 
'. 
' 
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CHAPTER SEVEN 
STUDIES ON THE INHIBITION OF CHOLELYSIN 
7.1 Introduction 
Proteases active against the substrates discussed in 
Chapter Five above have many naturally occurring in-
hibitors. It was of interest to study possible in-
hibitors of cholelysin, and these studies are repor-
ted in this chapter. 
7.2 S~bst ances studied for inhibitory effect were: 
(1) Human serum on cholelysin 
(2) Human serum on A'.r:'EE-esterase activity of 
cholelysin 
(3) Serum of rat, rabbit, guinea-pig and mouse on 
cholelys~n 
(4) Alpha-Z-macroglobulin 
(5) Soy bean trypsin inhibitor 
(6) Aprotonin ('trasylol') 
All results a~e shown in abridged form. 
are given in Appendix 7. 
7.3 Experimental design 
Full deta.:!..ls 
All experiments on inhibition which were done by mixing 
a potential inhibitor of cholelysin with a chol~lysin 
fraction were done as follows: 
Control of the same cholelysin fraction used in that 
specific experiment, dilute~ 1/1 with tris buffer 
pH 8,5 M 0,006. 
Test: Control+ inhibitory substance in equal volumes. 
Both read as mm diameter of zone of lysis after 21 hours 
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of incubation at 37°c. Results we re then transformed 
into units from the scale in Chap t er Three p 40. 
7.4 Human serum 
Human serum contains many potent i nhibitors of trig-
gered enzyme systems of the blood such as coagulation, 
fibrinolysis, complement, and kallikrein-kinin. Those 
relevant to fibrinolysis are lis ted in Chapter Two. 
It was of interest to discover i f cholelysin was also 
inhibited by one or more of them. 
7.4.1 Experimental design: Blood was taken from 10 healthy 
adults into glass test tubes and i ncubated in a water-
bath at 37°c for 60 minutes. The tubes were then cen-
trifuged at room temperature, and the sera were pipet-
ted out and stored at -40°c until used. Storage did 
0 not exceed 30 days. 'Heated serum' • was heated to 56 C 
for 30 minutes before testing. Through the courtesy of 
the Department of Chemical Pathology, Groote Schuur 
Hospital, a -1 antitrypsin was est i mated on all sera 
studied. 
7.4.2 Unheated serum. Testing for inhib ition was carried 
out by the method described in 7. 3 above. The per-
centage inhibition was calculated from the formula: 
Control (units) - test (units) X 100 control (units) 
Every test was run in duplicate, and the results in 
mm diameter o f zone of lysis were averaged before 
converting into units of lysis. The 50 % inhibitory 
point was estimated from a plot o f individual results 
for each serum on graph paper. Re sults are shown in 
Table 7-1 and Figures 7-1 and 7-2. 
•. t. 
'---~ 
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Table 7-1: Inhibitory effect of human serum on the 
lytic action of cholelysin. Control 
measured in 1/1 dilution in tris buffer 
M 0,006. Test serum introduced in place 
of tris buffer, and lytic effect measured. 
Full workings are shown in Appendix 7. 
-- - -- -~----"-~--- ~-----· . - - . ·~. -·- . -- --·· - --
_ _. .. _...,._. ,. -. - -
Serum sample 
Dilution 
Inhibition (%) of serum 
1 2 . 3 4 5 6 7 8 9 10 x s 
1/20 83 89 100 84 100 100 100 100 100 90 95, 1 6,59 
1/40 54 72 72 69 59 87 78 79 85 70 72,5 10,45 
1/80 37 45 57 70 25 48 51 33 0 33 46,9 15,47 
1/100 · 30 10 34 '10 30 41 41 25 48 9 27,8 14,14 
1/160 5 0 - 20 0 30 30 25 15 29 3 15,7 12,74 
1,320 0 0 0 0 15 3 15 9 15 0 5,9 6,94 
a1-antitrypsin 350 450 410 370 330 450 410 280 31 C 330 
50% 
(mg %) 
inhibition 1/45 1/70 1/85 1/90 1/50 1/7P 1/80 1/60 1/100 1/95 1/70 
- ·---- - - - --·-..- --·-
- - -- ... -- --· 
When the mean values of these 10 experiments w:~ r.e plot-
ted, they gave the result illustrated in Figure 7-1. 
The SD% inhibitory point was estimated from a plot of 
results from each serum on semi-logarithmic paper. 
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Figure 7-1: Inhibitory effect of human serum on lytic 
action of cholelysin. Mean of 10 experi-
ments plotted (from Table 7-1). 
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13J'h a~1-antitrypsin content of these sera did not have 
·.-. aningful relationship_ to the 50% inhibition point. 
-...i"'-1..· ~- is brought out in Figure 7-2, which plots these 
values against each other. 
! 
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,._..igure 7-2: . a-1-a11titr~'psin content of 10 sera plotted 
against the reciprocal of their point of 
50% inhibitiun of the lytic action of cho-
lelysin. 
~ ~ these results, it can be concluded that a potent 
"libitor or inhibitors of the lytic action of chole-
i ,s in ~xist(s ), which probably bears no relationship 
l~ their a-1-antitrypsin content. 
_J il a ted serum 
Serum heated to 56°c for 30 minutes was then tested for 
i. inhibitory effect on the lytic action of cholelysin. 
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Results of 3 tests are shown in Table 7-2. 
Table 7-2: 
Serum 
number 
Effect of heating human serum to 56°c for . 
· 30 minutes on its inhibitory potential 
against the fibrinolytic action of chole-
lysin. 
Ir1hibi tion ( % ) 
· 3 8 1.0 
Unheated Heated Unheated Heated Unheated Heated 
Dilution 
1/10 100 100 100 80 90 100 
1/40 72 72 79 70 70 82 
1/lU 57 30 33 38 33 72 
1/100 34 15 25 38 9 64. 
, 
1/160 20 5 15 29 3 9 
1/320 0 0 . 9 20 0 0 
Comment: From this experiment it was apparent that heat 
degradation of the inhibitor (s) of chole.i.ys1.n in seru!ll. had 
not occurred. In fact, it was possible that inhibition 
had been slightly increased in the case of sera 8 and 10. 
7.4.4 a-1-antitrypsin deficient serum 
It was of interest to compare the inhibitory effect of 
these deficient sera on the lytic potential of c?olely-
sin, with that of normal sera. Through the courtesy of 
Dr B Novis, Respiratory Clinic, Groote Schuur Hospital, 
sera were obtained from two patients with homozygous 
a-1-antitrypsin deficiency. , These sera contained 27 mg 
and 18 mg/100 ml respectively (Normal 250-450 mg%). 
Inhibition was tested in the usual way, and gave the re-
- 103 -
sults shown in Tables 7-3 and 7-4. 
Table 7-3: Inhibitory effect of serum congenitally 
deficient in a-1-antitrypsin. Mean value 
of 10 controls (from Table 7-1) included 
for comparison. 
Control: 16 15 14 Mear. 15 mm = -12,6 units/! 
Test Lysis Units Inhibition % Control dilution (mm) 
1/20 0 0 100 95, 1 
1/40 0 0 100 72,5 
1/80 0 0 100 46,9 
1/100 0 0 100 27,8 
1/160 f\ 5,3 58 15, :• 
-~ 1200 10 6,8 46 
'1/320 12 · 8,7 31 5,9 
1/640 14 11 ,.1 12 
Table 7-4: Inhibition of· a second serum congenitally 
deficient in a-1-antitrypsin (~0mozygous). 
a-1-antitrypsin content 18 mg%. Control 
on this occasion was new. 
Control: 15,15 16 Mean 15,3 = 13, 1 u/l 
Test . Lysis Units Inhibition Control dilution inhibi ti.on 
1/10 0 0 100 100 
1/20 1 1 7,7 42 · 38 
1/40 13 9,8 26 17 
1/100 14,5 11 , 8 10 0 
•. 
Comment: The experiment in Table 7-3 suggested a more 
powerfully inhibitory effect of a-1-antitrypsin defi-
% 
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cient serum. This was not born out by the second 
experiment. However, the result shown in Table 7-3 
led to a series of experiments to fractionate serum 
by electrophoresis, in an attempt to locate the inhi-
bitors present. 
7.4.5 Paper electrophoresis of normal human serum was car-
ried out to establish which zone or -zones were invol-
ved in the inhibition of cholelysin. Chymotrypsin 
was included for comparison. Paper was preferred to 
.gel techniques, because of the high serum load that · 
could be applied to paper, and for the ease with which 
it could be divided into strips for assay of fibrino-
lyt ic activity. 
Ex~:riment 
Whatman filter paper No I was used in strips 5 cm wide. 
0,2 ml of serum was applied 2 cm on the anode side, and 
run for 19 hours at ~~ o V and 4°c. The electrode buf-
fer was 0,83 M barbitone pH 8,6. 
Serum source: healthy adult male (No 8 of Table 7-1 1 
The procedure adopted was as follows: 
(1) two strips of paper were used 
. (i) contained 10 ul of serum diluted to 
0,2 ml with electrode buffer, for stai-
ning and identity of bands 
(ii) contained 200 ul serum for test. 
(2) the strips were dried at room temperature. · 
Staining of strip (i) was with 1% amidoschwarz 
in 10% acetid acid and 90% methanol (ii) unstai-
ned. 
(3) Strip (ii) was cut into longitudinal strips as 
is shown in Figure 7-3. 
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Figure 7-3: Partition of a paper strip for studies of 
inhi.bi tion . of cholelysin by portions of 
serum separated by electrophoresis. 
o = origin. 
After an electrophoretic run, the paper strip was dried 
at room temperature. Strips A and E were cut off and 
ntained. Strips Band D were cut longitudinally and 
transversely, and applied directly to the fibrin plate. 
B was further cut into 0,5 cm strips hefore application. 
Onto each strip was pipetted either 0,1 or 0,2 ml of 
cholelysin Peak I, and the fibrin plate was incu~ated 
overnight in the usual way. Paper strips were lifted 
off the fibrin plate, and underlying zones of lysis 
were measured, and transformed into units: results 
for strip B were multiplied by 2 before recording them. 
Strip C was applied in 0,5 cm strips, and chymotrypsin 
solution 8 0 mg/ l, 0,1 ml, was p i pe tte d on to each strip. 
The result was read directly in chymotrypsin mg/land 
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recorded. 
Figure 7-4 is a photograph of the paper strip used for 
location of globulin bands, and of stained strips A and 
E. 
Figure 7-5 shows the result of .this experiment. 
]) 
Figure 7-4: Staining and experimental controls prepared 
as described above. In experimental control, 
1 L 1 .= Strip D: ' 
'R' = Strip B 1 
in Figure 7-3 
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Figure 7-5: Serum inhibition of cholelysin 22,8 units/l 
and of chymotrypsin 80 mg/l. In this ex-
periment, 0,1 ml cholelysin applied to strip 
B (0,5 cm partitions) and 0,2 ml cholelysin 
to strip D (1,0 cm partitions). Strip C 
divided into 0,5 cm partitions, and 0,1 ml 
of chymotrypsin solution applied to. each par-
tition. Results in units of lysis (chole-
lysin) or mg/l (chymotrypsin). Results 
from strip Bin units were multiplied by 
2, before plotting on graph. 
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,~· ., .. ,.c.cmmp-. :···~, ,.n Figure 7- 5 • From Figure 7-4 it is appa-
P. = ·albumin 
- a.-slobulins 
~ inter a-globulins 
= $-globulins 
--...---'~±:i:.::.i.cn is maximal in the S- and inter a-globulin 
·a1 is absent in the a-globulins. This . provides 
~~""" ·. ~ .idence that inhibition is not due mainly to 
-ei. er a- 1-antitrypsin or to a.-2-macroglobulin. Chymo-
trypsin shows a different pattern of inhibition, in the 
. .$-..gJ.nhn in and a.-globulin (a-1-antichymotrypsin) areas . 
• 4 . 6 Platelet-rich and platelet-poor plasma possessed inhi-
bitory potential similar to that of serum deri~.-ed from 
the scUfie plasma. See Appendix 7. 
7.5 Ef ec~ of serum inhibitor of cholelysin on AT~~-es~erase 
activity 
.In this experiment, dilutions of normal human serum were 
........:._""_ · · " . t · . '-he incub::.tion mixture used in the modified 
AT.EE-~s"t.erase test for cholelysin esterase activity. 
Be~ n ..sc ' he re were two variables (serum and cholelysin) 
:t1:m 1 ~~· mental arrangements were somehwat complex; 
they e described in detail in Appendix 7. The re-
...s.ult~ ~re listed in Tables 7-5 and 7-6 and are plotted 
; ..!" · s 7-6 and 7-7. 
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Table 7-5: Fibrinolytic activity of cholelysin Peak I, 
and inhibitcry effect of human serum at va-
rious dilutions on it, assayed before use of 
this serum for the experiment detailed below 
in Table 7-6 and Appendix 7. Experimental 
design for assay of inhibitory effect of 
serum as set out in 7.3. 
Cholelysin fibrinolytic effect control: 
. 28 
Serum 
dilution 
20 
50 
100 
200 
500 
27,5 27 mm 
Lysis 
1 2 
5,5 6,0 
17,5 24,0 
24,5 24,5 
26,5 25,5 
27,0 28,0 
Mean 27 = 54,8 units 
Mean Units 
., 
5,75 4,0 
20,75 25,4 
24,5 40,4 
26,0 48,5 
27,5 58,0 
Inhibition% 
85 
54 
26 
1 1 
0 
Table 7-6: Inhibitory action of human serum on ATEE-
estFr a s e activity, and fibrinolytic acti-
vity, of cholelysin Peak I. See Appendix 
for details . 
Serum A'l'EE esterase . % inhibition % inhibition 
diluti on activity (uni ts) ATEE esterase fibrinolysis 
activity 
20 0 100 85 
40 2,7 93,1 
50 8,7 79,4 54 
80 18, 1 57,1 
100 22,4 47,9 26 
200 32,6 22,7 11 
400 37,5 11 , 1 
500 40,9 3 I 1 0 
40 
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Figure 7-6: Graph of serum inhibition of ATEE-esterase 
activity of cholelysin. 
Figure 7-7: Relationship of inhibition of ATEE esterase activity, 
and fibrinolysis to each other, at aimilar aerum di-
lution. 
•' 
- --··- - --------
7.6 Inhibitory effect of serum of _rat, rabbit, guineapig 
and mouse. It was decided, in conjunction with the 
South African Inventions Development Corporation, to 
study the anti-coagulant effect of cholelysin in an 
animal model. In view of the marked inhibitory effect 
of human serum on the fibrinolytic action of cholelysin, 
it was necessary to study the inhibitory effect of 
serum from possible laboratory animals. These studies 
are reported here. 
Experimental design followed the plan described in 7.3 
and 7.4.1 above. The results are described in Table 
7-7. Only unheated serum was studied. 
. • 7 
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~le 7'-7: Inhibitory effect of serum of rat, rabbit, 
~ ~·, - 'g 
guinea-pig and mouse against cholelysin. 
Full workings shown in Appendix 7. 
.. _1 /1 
1/2 
i ;, 
on 
100 
100 
89 
51 
··111130 O 
1/1 000 0 
Concl.1sion 
Rabbit Guinea-pig 
Inhibition % 
100 100 
100 100 
81 100 
45 56 
17 0 . 
0 0 
Mouse 
100 
100 
95 
36 
0 
0 
Human 
(Table 7-1) 
100 
1.00 
100 
100 
27,8 
0 
This brief series of experi~ents showed that ail 4 spe-
cies possessed serum inhibition against fibrinolysis by 
cholelysin, but that they were (in single tests) less 
..i.nhihitory than the average of 10 experiments ~ ith human 
serum. The cholelysin for most of ~hese experiments 
was supplied through the courtesy of the South African 
.. -~·J n '!i=>r,.tions Development Corporation and Dr T Haylett of 
" ouncil for Scientifi c and Industrial Research, 
Pretoria. 
Alpha- 2-macroglobulin 
Tl:n: .; ibitor of many circulating activated enzymes 
.i nterest, as it is known to bind plasmin. The 
...p.uism · -macroglobulin complex retains slow fibrinolytic 
ac · jv: t y (Harpel, 1977). A small quantity was obtained 
ou h the courtesy of Dr Potgieter, Department of 
~~
1
-uology, Natal Blood_ Transfusion Service, Durban, in 
+ orm of a 10% solution in tris buffer pH 8,0. It 
was uo t electrophoretically pure. 
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As expected, it was weakly fibrinolytic, and this ef-
fect had to be allowed for in calculating the inhibi-
tory effect of the macroglobulin on cholelysin Peak I. 
This was done by altering the standard formula for the 
ca1c·u1ation of inhibition. 
Control (units) - test (units) X 100 Control (units) 
tq: 
Control (units) - (test units - macroglobulin 
lytic activity x lOO)) 
Control (units) 
A 
B 
The sample supplied by Dr Potgieter had a lytic poten-
ti.aJ of 1 0 mm diameter zone of lysis = 6, 8 uni ts. Thus, 
equation (B) ab0ve was altered to: 
C01.-trol (units) - (te ::·t units - 6,8) X 100 Control (units) 
It was assumed that this lytic potential was still ex-
pressed, in experimenr.s iP which macroglobulin solution 
. 
was mixed wi.th cholelysin, and the mixture incubated on 
the standard fibrin plate. 
The followi~g fractions were tested: G200 - Peaks I, 
II, III and IV. 
Results are shown in Table 7-8. 
'. 
7.8 
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Table 7-8: Inhibitory effect of macroglobulin on 
cholelysin fractions. Equation (B) on 
page 111 was used, to derive 'Inhibition%'. 
Cholelysin Control 
fraction mean units 
G200 28 62 
Peak I 30,5 84,4 
Peak II 19,5 22,2 
Peak III 17,5 17, 1 
Peak IV 10 ,s 7,3 
Soy bean try:esin inhibitor 
Test 
mean units 
18,8 20,3 
-
26 48,5 
15,8 13,7 
15 12,6 
1 1 7,7 
(SBTI) 
Inhibition% 
78 
51 
69 
66 
88 
This broad SJectr um protease inhibitor is known to in-
hi~J .t plasmin, trypsin, and chymotrypsin. It was there-
fore tested for inhibitory activity against cholelysin 
fractions. The routine method was followed, but as it 
proved somewhat ineffective, a 24 hour period of incuba- · 
tion was added to th8 study. Thus, incubation of SBTI 
and cholelysin fraction in equal volumes at 20°c took 
place (a) for 20 minutes 
{b) for 24 hours. 
Results are shown. in brief below, with full details shown 
in Appendix 7. 
Table 7-9: Incubation of SBTI and cholelysin for 20' 
at 20°c. 
Cholelysin SBTI % 
fraction 0,0005 0,001 0,002 0,004 0,006 0,008 
G200 52 76 78 91 90 91 
Peak I 55 55 6.8 82 96 90 
Peak II 49 55 60 78 94 78 
Peak III ·77 80 81 100 100 100 
7.9 
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Table 7-10: Incubation of SBTI and cholelysin for 
24 hours at 20°c. 
F 
Cholelysin SBTI % 
fraction 0,002 0,004 0,006 0,008 
G200 84% 88 93 95 
Peak I 83 91 96 96 
Peak II 76 82 85 100 
Peak III 100 100 100 100 
Comment: Incubation for 20 minutes produced erratic re-
sults. However, incubation for 24 hours produced more 
marked, and more consistent results. Peak IV was 'out 
of stock' at the time that these experiments were car-
ried out. 
Ap~otonin ('Trasylol' ~ 
This is a polypeptide derived from bovine lung tissue. 
It is an inhibitor of many proteolytic enzymes inclu-
ding: 
trypsin 
chymotrypsin 
kallidinogenase 
plasmin 
plasminogen activator (Martindale, 1977). 
Ampoules containing 10 000 units (Bay2r) were available. 
... 
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Table 7-11-: Inhibitory effect of aprotonin 2 000 units 
on cholelysin fraction tested by pre-
incubation at 20°c for 60 minutes. 
·cholelysin Control Test Inhibition 
fraction mean units mean units 
G200 27 54,8 1 1 7,7 86 
Peak I 35 146,4 0 0 ioo 
Peak II 20 23,2 20,4 7,2 69 
Peak III 16 14,2 0 0 1 oo-
Peak IV 10 6,8 0 0 100 
The effect on Peak I, the major cholelysin fraction 
used _.;_;i this study, was of ?o.:., ticular interest. This 
par~icular preparation contained 0,10S m~/ml of protein 
as determined by Folin. M~~tindale (1977) gives the 
· following inhibitory effect of aprotonin on trypsin~ 
500 ng trypsin i .1hibited by 1 unit of aprotonin. Thus 
500 x 2 000 ng = 1,0 mg of trypsin would be inhibited 
by the 2 000 units of aprotonin used in this s~udy. 
In Tnble 7-11 it was shown that 2 000 units of aprotonin 
gave complete inhjnition to 0,1 ml of cholelysin Peak I 
with an activity of 146,4 u/l, or a chymotrypsin equi-
valent of 0,015 mg, setting up a upper limit to the 
quantity of aprotonin required for full inhibition of 
this Peak. However, fraction G200 and Peak II both 
showed some resistance to the inhibitory action of apro-
tonin under the same conditions. As shown, these frac-
tions had far lower lytic activity than the Peak I pre-
paration tested, suggesting that there is another cho-
lelysin with greater resistance than Peak I. As the 
Peaks are all derived (rom fraction G200, this result 
is logically acceptable. 
would be interesting. 
Further study of thi~ aspect 
% 
7.10 
.. 
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Discussion and summary 
(i) The human serum· inhibitor of cholelysin discus-
sed in this chapter has been shown to be po~:ent, 
with an average 50% inhibitory point at a dilu-
tion of 1/70 (average of 10 sera studied). 
(ii) This inhibitor is fully expressed in two sera 
from patients with homozygous deficiency of 
a-1-antitrypsin, and this point was confirmed 
_by electrophoretic fractionation of normal s~rum 
on Whatman filter paper, where the inhibition was 
shown to be in the inter-a, and B-globulin areas. 
(iii) Serum inhibitory for the fibrinolytic action of 
cholelysin was show~ t0 be inhibitory for the 
ATEE-esterase activity of the ~am~ preparation. 
(iv) a-2-macroglobulin, s ,~, bean trypsin inhibitor and 
aprotonin were all shown to be inhibitory of cho·-
lelysin. In the case of a-2-macroglobulin and 
aprotonin, there was some suggestion that various 
fractions of cholelysin might have difforential 
resistance to the inhibitory action studied. 
This was not followed further. 
, 
r 
. . .. 
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CHAPTER EIGHT 
BIOLOGICAL STUDIES 
·· -~ -... :......... =~Y of cholelysin as a fibrinolytic agent 
..J:ed ·±o r onsiderations of its use therapeutically. 
A .l..iinited set of investigations of the effect of 
t::hol~:'..ysin on routine coagula.tion tests was under-
ta..lcen. and an attempt was made to det8rmir.e the 
LD50 and the biological half life of cholelysin in 
.the T t • 
8.2 Routine · coagulation studies - Experimental design 
~~ · v llowing routine tests were done! with anct with-
out .cholelysin • 
. ~r-t-~~ ~hromboplastin time (PTT) 
.:.:. .:..(_,~ prothrom0in t i 1r.e (PT) 
Thrnmbin time (TT) 
."£.ilir. · -cg2n assay (Fib) 
Fibrin split products by latex particle agglutina-
..ti.on :technique {FSP) 
studies: collagen 
: · ~i..:" od 7 for references. 
ADP 
adrenaline 
~ -4:W.-1 ~ases, the test was done in 1/1 dilution with 
i toue buffer pH 7,4 as a control, and then with 
. ,c: ly~ ·n substituted for the barbitone buffer. 
'· 
-· -
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Some studies were repeated after 1 and 2 hours of in-
~ubation of cholelysin with substrate at 37°c. 
8.2.1 Routine coagulation studies 
Results are shown in Table 8-1. 
- -
Table 8-1: Effect of cholelysin 75 u/l in equal ad-
mixture with plasma, on the PTT, PT; TT 
and fibrinogen assay tests. Effects of 
60 and 120 minutes of pre-incubation at 
37°c are also shown. Clotting times in 
seconds. 
~--~-- - ---
-
-- __ ..._ 
_,___,_ 
-
I PTT PT TT Fibrinogen seconds seconds seconds mg/100 
Pre-
incubation (min) 0 I 60 I 120' 0' 60' 120' 0 I 60' 120' 0' 60 I 
Control 47 47 48 15 15 15 15 1 6 16 250 255 Cholelysin 38 u/l 44 44 45 15 14 14 ,5 16 16 16 255 
-- - -~ 
178 
-- -
- - -- ·- --
- T 
~ ... - _,... -,-._ 
The experiment reported ir1 Table 8-1 showed that cho-
lelysin had little effect on the PTT, PT and TT, all 
of which are plasma tests. However, there was an 
obvious fibrinogenolytic effect, which was investiga-
ted further. This is reported in Table 8-2. 
ml 
120 
245 
60 
118 
Table 8-2: Fibrinogenolytic effect of various concen-
trations and incubation times of cholelysin. 
Results in fibrinogen mg/100 ml. 
Cholelysin 
·concentration (u/l) 
Fibrinogen 
concentration 
(mg/100 ml) 
Period _of pre-
incubation 
(minutes) 
0 
60 
-60 
54 
41 
8 
45 30 15 
108 162 216 
Fibrinogen mg/ml 
102 
68 
168 
130 
220 
180 
0 
270 
270 
270 
Comment: This fibrinogenolytic effect was only demon-
strated in purified fibrinogen solution. Experiments 
using whole plasma showed no fibrinogenolytic effect, 
probably because of the strongly inhibitory ef l ect of 
plasma, reported in Chapter Seven. 
8.2.2 Platelet aggregation studies 
Routine aggregation studies were performed, using cho-
lelysin 75 u/l mixed in equal volumes with platelet 
rich plasma 600 000/ul. These studies are shown in 
Figures 8-1, 8-2, and 8-3. 
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Figure 8- 1: Left hand graph: routine platelet aggre-
gation with collagen 1 mg/ml. Upper graph : 
control. Lower graph: cholelysin . 
Right hand graph: routine ADP aggregation 
study with ADP 1 000 µmol/l final concen-
tration. Upper graph: cholelysin. 
Lower graph: control. 
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Figure 8-2: Routine platelet aggregation study with 
ADP 10 µmol/l final concentration. 
Upper graph: cholelysin. 
control. 
Lower graph: 
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Figure 8-3: Routine platelet aggregation studies with 
adrenalirie 100 and 10 µmol/l. Left hand 
graph: adrenaline 100 µmol/l final con-
centration. Upper graph: · cholelysin. 
Lower grapn: control. Right hand graph: 
adrenaline · 10 µmol/l final concentration. 
Upper graph: contro l . Lower graph: 
cholelys in. 
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comment: collagen and adrenaline aggregation of hu-
man plat elets were not influenced by cholelysin at 
the concentrations tested. However, there was proba-
bly an inhibitory effect on ADP-induced aggregation 
-
at 10 µrnol/l,. though not at 1 000 µmol/l . These ex-
periments did not indicate a major effect on platelet 
function, and were not followed furtper. 
8.3 LD50 - Experimental design 
Six Wistar rats weighing between 200 arid 250 g were 
chosen for this experiment. They were cannulated 
with a silicone cannula of external diameter 1 mm, in 
t~e jugular-vein. 
saline 200 u/ml. 
The cannula was filled with heparL1 
0,5 ml of blood was aspirated, and 
1, ~ ml of cholelysin solution was then injected over 
3 minutes. The cholelysin solution was in normal 
saline, 553 u/l, protein concentration 82 µg/ml. The 
cannula ~as withdrawn and the rats observed. None died 
over 14 days . · They were then killed. 
no significant lesions. 
Autopsy showed 
3.4 Biological half-life: experimental design 
Tl1e same model was chosen as in 8. 3. At the end of 
the cholelysin infusion, blood was aspirated from the 
cannula int~ heparin -saline 200 u/l, equal volumes of 
both. The mixture was centrifuged at 12 000 x G for 
0 
. 10 minutes at 4 C, and the plasma plated on a standard 
fibrin plate in the usual way. 
Table 8-3. 
Results are shown in 
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Table 8-3: Biological half~life of cholelysiri in the 
Test 
Wistar rat. 
in units/.e. 
Rat plasma with 
heparin 100 u/l 
Normal saline 
with heparin 200 u/ml 
Cholelysin (total units) 
2 minntes 
10 minutes 
25 minutes 
I 
Three rats tested. 
Rat No 
. 1 . 2 
0 0 
0 0 
0,553 0 ,.553 
10 ; 6 8,2 
0 0 
J 0 
8.5 Cholelysin as in vivo anticoagulant: rat model 
Results 
3 
er 
0 
' 0,553 
6,5 
0 
0 
The rat model is described in Method 22. The method was 
originally describe] by Chan (1967, 1958) and was used by 
him to study the anticoagulant effect of the snake venom 
ancrod ('arvin'). The basic method established a rate 
of thrombosis of the rat carotid artery following the chro-
nic implantation in it of a polyethylene catheter. An-
crod was then injected into a series of rats; they were 
given doses 2-4 hours after the arterial implantation, 8 
hours later, and agains at 24, 32, 48, and 56 hours after 
the comple tion of the operation. The results of these 
series of experiments ar2 shown in Table 8-3 . 
• 
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Table 8-4: Anticoagulant effect of ancrod in the rat 
(from Chan, 1970). 
No days No animals % occlusion 
postop 
p 
2-3 
4-5 
7 
Total 
Con-
trol 
19 
13 
6 
38 
Test Con-
trol 
Test 
19 
1 1 
6 
36 
63,2 36,8 >0,05 
76,9 36,4 >0,05 
100,0 50,0 <0,05 
73,6 38,9 <0,01 
% red 
thrombus 
Con- Test 
trol 
p 
47,4 16,8 · <o,os 
69,2 
100,0 
63,1 
9,1 40,01 
33,3. <0,05 
16,7 <0,001 
· Conunent: this series of experiments showed a clear ·cut 
a1.ticoagulant effect of ancrod under these conditions in 
the rat. It wa decided to select this method for its 
reJ~tive simplicity, ~o study the anticoagulant effect of 
cholelysin; an important consideration was the relative · · 
scarcity of cholelysin concentrate, as at the time only 
small scale purificat ion was being effected. Fortunately 
we were assjsted by the South African Inventions Develop-
ment Corporation, who kindly arranged with Dr T Haylett 
of the Council for Scientific and Industrial Research to 
manufacture larger quantities for us. He experienced 
some difficulties with ox bile (see Chapter Four) but was 
~ble to supply us with sufficient Peak I concentrate for 
a limited series of ~xperiments. 
8.5.1 Because of the short supply of Gholelysin, and also be-
cause of the limited time available each day for · expe-
rimentation, the method of Chan was modified as follows 
(Table 8-5). 
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Table 8-5: Comparison of the rat model of Chan and 
the model adopted for this study, to study 
the anticoagulant effect of cholelysin. 
Rat 
Weight 
Anaesthetic 
Anticoagulant 
Route of 
administration 
Chan 
Sprague-Dawley 
180-250 g 
Intraperitoneal 
pentobarbitone 
Ancrod 
Tail vein 
Time of admin~s- 2-4, 10-12, 21, 
tration (hours 32, 48, 56 
postop) 
I 
Duration of 
each injection 
Day of killing 
for study 
Single push 
0, 3, 5, 7 
This study 
Wistar 
200-250 g 
Ether 
Cholelysin 3 ml of 
- 500 u/l 
;= .. 1, 5 unit 
Jugular 
Immediate 
3 hours by slow pump 
o, 3, 5, 7 
Comment: it is evident that the· anticoagulant load on 
each animal would be far lower than was the c~se ·1ith an-
croa, for the following reasons: 
(1) Ancrod does not possess a natur ally occurring 
antibody . Cholelysin has a potent antibody 
or antibodies. 
(2) fil1;C~od was given in multiple injections, cho-
lelysin only in one injection. 
8.5.2 Results are shown in Tables 8-6 and 8-7 and Figure 8-4. 
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Table 8-6 : Anticoagulant effect of cholelysin in 
rat model. 
..-'· 
No of days No animals % Occlusion % Red thrombus 
postop Control Test Control Test Control Test 
. 
0 20 19 35 10 20 5 
3 18 20 67 20 50 :0 
5 16 14 69 57 63 29 
7 10 10 100 ·100 100 70 
For these experiments, significance is given in Table 
8-7. 
I 
Table 8-7: Levels of significance for experiments shown 
in Table 8-6 (results for ancrod f r om Table 
8-4 in brackets). 
% Occlusion 0,05 > p > 0,20 (< 0,01) 
% red thrombus < u,05 (< 0,001) 
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Figure 8-4: Anticoagulant effect of choielysin ih 
a rat model. - 20 Rats used for each 
point on the graph. 
0,05 > p > 0,20. 
This result gives 
8.6 
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Comment: In view of the marked inhibitory potential 
Jf rat plasma for the fibrinolytic action of cholely-
sin, it is perhaps surprising that any kind of posi-
tive result was obtained. But is was not a striking 
result. The starting point for further investigation 
of the anticoagulant effect ~f cholelysin should be an 
attempt to saturate the inhibitor in vivo and in vitro, 
before proceeding to biological studies of the type 
described in section 8.4. 
Summary 
The -effects of cholelysin on the partial thromboplas-
tin time, one stage prothrombin time, and thrombin time 
tests are described. Ther~ was a slight shortening of 
the partial thromboplastin time test. A fibrinogeno-
lytic effect was observed. After 60 minutes 0£ incu-
bation at 37°c cholelysin 60 u/l had destroyed the 
clottability of t5% of the fibrinogen tested. Plate-
let aggre gation studies were performed, and ch ,Jl ely sin 
appear~d to interfere with the aggreq~ting effect of 
ADP 1 0 µmol/ l. However, ADP 1 00 0 µmol/ .l, .adrenaline 
10 and 100 µmol/l, and Eollagen 1 mg were not in-
terfered with. 
The anticoagulant effect uf cholelysin was tested in an 
in viv o rat model originalJy used to assess the anti-
coagula nt effect of ancrod. The result approached, 
but did not reach, statistical significance, as 
0,05 > p > 0,20. 
9. 1 
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CHAPTER NINE 
POLYACRYLAMIDE GEL ELECTROPHORESIS 
Introduction 
Polyacrylamide gel electrophoresis (PAGE) is an 
invaluable method for the rapid and accurate se-
paration of proteins. The basic principle of 
the method is the formation of .a lattice of poly-
merised acrylamide, which may range in final per-
centage concentration from 2 to 50%. Molecules 
of a test substance may be separated electropho-
retically in thi~ gel through the operation of 
two major factors: 
(1) size of molecule in relation to size of 
pore in the lattice of polymerised acryla-
mide. With 2% gels, molecules of 800 000 
molecular weight may migrate freely; with 
40% gels, molecules as small as 20 000 mole-
cular weight are retarded. 
(2) charge on molecule in relation to potential 
difference applied. According to the condi-
tions chosen, it is possible to alter the ba-
sis of separation i e: a small molecule mi-
grating in a large pore gel can be separated 
on the basis of charge on the molecule alone. 
On the other hand, a large molecule migrating 
in a gel which restricts its movement is se-
parated on the basis of size. 
The charge difference between molecules may . be eli-
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minated by using sodium dodecyl sulphate (SDS). 
SDS has a hydrophobic chain with a sulphated hydro-
philic tip. The hydrophobic chain embeds in the 
test protein, leaving the sulphate anion exposed. 
This causes tbe entire molecule to assume a nega-
tive charge, which effectively eliminates the dif-
ferential charge effect from the process of sepa-
ration by PAGE. SDS may partly of ·wholly denature 
a protein. 
The choice of a single concentration of polyacryla-
mide will restrict separation Qf proteins to a small 
range of molecular weights. If a range of molecu-
lar weights is anticipated, . they may be separate<l 
simultaneously by the use of a linear gradient gel. 
In such a gel, a gradient cf polyacrylamides is 
; produced from 2 to 40% or .more. 
Oligomers and polymers in the protein under investi-
gation may be minimised or eliminated by the use of 
mercaptoethanol and urea. 
( i) mercaptC"etl·.anol reduces disulphide bonds. 
If the cest molecule is a polymer ~ith di~ 
sulphide bonding, the use ·of mercaptcethanol 
will reduce this to monomer. At the same 
time, if mercaptoethanol denatures the pro-
tein, this will give some indication of its 
chemical structure. 
(ii) Urea used in high concentration before or 
during electrophoresis eliminates oligomers 
which might be due to hydrogen bonding; 
this enables the minimum molecular weight of 
a protein to be determined. 
9.2 
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Experimental design 
Early work with ammonium sulphate precipitated 
bile suggested a molecular weight for cholelysin 
of - 23 OOO(Figure 5-6, where column chromato-
graphy on sephadex GSO ga~e a Kav of 0,3). Later 
work, reported in Chapters Six and Seven, sugges-
ted that more than one typ~ of cholelysin might 
exist. For this reason, a linear gradient gel 
was _selected, with a final range of polyacrylamide 
concentrations from 2,1 to 41% (see Methods for de-
tails) . 
Samples of test material we:i.:-e applied to the gel 
mix~d with either SDS, or SDS + mercapLoeth~nol. 
Electrophoresis was run at a constant current of 
1 2mA (-9V) per tube for 5 hours. 
Chymotrypsin was used as a reference marker for 
cholelysin. Ribonuclease, chymotrypsinogen and 
lactate dehydrogenase were used as reference mar-
kers for fibrin split products. 
This technique ~~s used for sever&l purposes: 
(1) To estimate the molecular weight of cholely-
sin, correlating fibrinolytic activity with 
stained band on the gel. This involved an 
assessment of the effect of SDS and mercapto-
ethanol on the fibrinolytic activity of chole-
lysin. 
(2) Separation of the split products of stabilised 
fibrin. Plasmin and cholelysin were compared 
Fibrinolysis was also inhibited by SBTI after 
varying periods of time, and the ' resultant 
split products analysed by PAGE. 
9.3 
Tube No 
1 
2 
· 3 
4 
5 
6 
7 
8 
9 
10 
1 i 
12 
I 
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Cholelysin Peak I on PAGE 
Two preparations of Peak I were used: 
(1) designated A1, with activity equivalent to 
270 µ/! (40 nun) 
(2) designated B1, with activity equivalent to 
199 µ/! (37 ,5 nun). 
100 ul of .each, in 1/1 dilution in glycerol, was 
applied to the polyacrylamide gel= 50 µl of.Pea~ I 
solution, giving a total applied to the gel for A1 
of 0,0135 units and for B1 of 0,00995 units. 
Chymotrypsin was used iP a concentration of 1 mg/ml, 
di]uted 1/1 with glyceroL and a to~al of o, ·1 ml ap-
plied= 0,05 mg. 
Table 9-1: E~periment to determine characteristics 
of cholelysin Peak I by PAGE. Chymo-
trypsin control. Under the cc!umn hea-
ding 'destination' - 'Frozen' means free-
zing in liquid nitrogen, 'Plated' means: 
1,5 nun thick sections of the gel were made 
and applied to a fibrin plate for incuba-
tion in the usual way (see Table 9-2). 
Destination ul applied Sample applied 
Stained 100 A1 + B1 + _ SDS + . glycerol 1 / 1 
Stained 100 B1 + mercaptoethanol + SDS + glycerol 1/1 
Stained 100 A1 + .sos+ glycerol 1 /1 
Stained 100 . · Chymotrypsin standard 
Plated 100 -. A1 + i31 +SOS + glycerol 1 /1 
Plated 100 B1 + mercaptoethanol + sos + glycerol 1 /1 
Plated 100 A1 + SDS + glycerol 1 / 1 
Plated 100 Chymotrypsin + glycerol 
Frozen 50 Chymotrypsin standard 
Frozen 100 A1 + SDS + glycerol 1 /1 
Frozen 50 A1 + SDS + glycerol 1 /1 
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Table 9-2: Results of fibrinolytic assay of chole-
lysin after PAGE. Chymotrypsin stan-
dard. 1! mm thick cuts of each gel ap-
plied to a fibrin plate ~hj_ch was incuba-
ted for 21 hours at 37°c. Every second 
Cut No 
2-4 !", 
42 
(43) 
44 
(45) 
46 
(47) 
48 
(49) 
50 
(51) 
52 
(53) 
54 
To ta~ 
unit:; 
Total units 
' , 
IM\ di am 
0 
20 
1'-01 
21 
(21) 
· 10 
0 
0 
0 
0 
0 
0 
0 
0 
applied to ,;e l 
I loss 
section was plated. Total volume of 
gel= 2 ml; 60 cuts were made= 0,033 ml 
per cut. Results calculate d as follows: 
(1) assume that each unplated gel had the 
activity of the section above it, except 
in the case of the last active cut. 
(2) volume per cut 0,033 ml= 0,000033 l. 
'Units per gel section' derived from 
units X 0,000033. Unplated sect i o r. s 
of gel, and extrapolated values, shown 
in ~rackets. 
(Al) (Bl) 
eel' 1 Gel 2 Gel 4 (C',ol e lysin) (Cholelysin) (Chymotrypsin) 
Units Units mg. -units/t per gel 11\111 diam units/t per gel iMI d i am mg/l per ge l section section t ection 
0 0 
23 0,000759 0 0 
(23) (0,000 759) 0 0 
26 0,000858) 0 0 
(26) (0, 000858) 0 0 
6,8 0,0002 24 21 26 0,000858 26 - 48,S 0,001601 
(21) (26) (0, 00"8 58) (26) (48,5) (0,001601) 
10 6,8 O,OO J 224 11 7,7 0,000254 
0 (11) (7,7) (0 ,000254 l 
0 10 6,8 0,0002 2~ 
0 (10) (6",8) (0,0002 24) 
0 10 6,8 0,000224 
0 - (10) (6 ,8) 0,000 224 
0 10 6,8 0 ,000224 
0,00346 0,00194 0,00483 
0,01350 
'. 0,00995 0,05000 (mg) 
74 81 90 
9.3.1 
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Results 
The stained gels are shown in Figure 9-1. 
2 
- Al 
- Al 
SDS 
-
Bl . Chymotryps_i_n __ 
Figure 9-1: PAGE of two preparations of cholelysin, 
designated A1 and B1. 
In the Figure tubes 1, 2, 3 and 4 refer to tubes of 
the same number in Table 9-1. Thus 
1 = A1 + B1 
2 = B1 
3 = A1 
4 = chymotrypsin 
The arrow pointsto the faintly staining cholelysin 
band. All cholelysin tubes contained SDS to a final 
concentration of 2 g/100 ~l. Tube 2 contained mer-
captoethanol 2 g/100 ml in addition to SDS. 
The fibrinolytic activity of gel sections from equiva-
lent tubes was measured as described under Table 9-1. 
The results are shown in Table 9-2 and - in Figure 9-2. 
60 
f::: 40 
·r-1 
tll~ 
>t'-.. 
r-1 tll 
Q) .µ 
r-1 ·r-1 
0 f::: 
.c: ~ 20 u 
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The results of the plated gel sections are shown 
graphically in Figure 9-2. 
10 20 . 30 40 50 60 
Gel section no 
• ~. Al 
B1 
T--l\l"--lV Chymotrypsin 
~ 
Figure 9-2: Fibrinolytic activity of two preparations 
of cholelysin Peak I and chymotrypsin stan-
dard obtained following PAGE. Alt~r~ate 
gel sections plated. Results from Table 
9-2. 
Comment on this e~periment: 
There was satisfactory resolution of protein bands by 
PAGE with SDS as is shown in Figure 9-1. Hqwcver, 
there was considerable loss of fibrinolytic activ_ity, 
greater in the specimen (B1) with mercaptoethanol, 
and greater yet in the chymotrypsin control. It was 
evident that the molecular weights of the two prepara-
tions of cholelysin examined were close to that of 
chymotrypsin (- 13 000). 
9.4 
9.4.1. 
9.4.2 
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-It was necessary to examine the effects of (1) SDS 
and (2) mercaptoethanol on the fibrinolytic activi-
ty of Peak I. 
Effects of SDS and mercaptoethanol on fibrinolytic 
activity of Peak I. 
3DS 
In an experiment to be shown in Chapter 11 , chole-
lysin Peak I+ SDS 2 g/100 ml was run through a sepha-
dex G50 column. The cholelys~n preparation had an 
activity of 38,7 mm= 232 u/l. 2 ml were loaded on 
·the column= 0,464 units. The effluent contained a 
total fibrinolytic activit:{ of 0 , 225 units= 48!t. re-
covery, within the range of 50-85% recovery from 
~ ; s~phadex G200 reported in . ~able 5-13. Thus, un~er 
these conditions SDS had slight or no inhibitory ef-
fect on the fibrinolytic action of Pe~k I. 
Mercaptoethanol 
Two experimer.ts ilere dor.e to investigate the effect 
of mercaptoethanol on cholelysin. In ~he first ex-
periment, cholelysin was diluted 1/20 with sample ap-
plication buffer containing mercaptoethanol 0,3 mg/100 
ml. The mixture was left at room temperature for 30 
minutes a~d 21 hours, and then plated on a fibrin 
plate in . the usual way. The results are shown in 
Table 9-3. 
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Table 9-3: Effect of mercaptoethanol on fibrinolytic 
activity of cholelysin. Cholelysin di-
luted 1/2C with sample application buffer 
contairiing mercaptoethanol 0,3 g/100 ml 
and ieft for varying periods of time at 
room temperature before incubating on the 
tandard fibrin plate._ Results in mm dia-
mete~ of zone of lysis and in units. In-
hibition calculated as set out in section 
7.4.2. 
Incuba tio.1 
0 
30 minutes 
20 hours 
Control: 20, 20, 20, 20: mean 20 nm - . 23,2 
units 
Lysis Units Inhibition i mm diam 
17,5 17, 1 26 
13,5 10,5 55 
0 100 
In view of this result, a more elaborate experiment 
was carried out to establish the inhibit0ry potential 
of mercaptoethanol on the fibrinolyti c activity of 
cholelysin . In a further experiment, the cholelysin-
mercaptoethanol mixture was dialysed against tris buf-
fer to test if the fibrinolytic activity of cholelysin 
had been irreversibly destroyed by mercaptoethanol. 
The resul"ts of these experiments a~e shown in Tables 
9-4 and 9-5. 
'. 
/ 
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Table 9-4: Inhibitory effect of various concentra-
tions of mercaptoethanol on the fibrino-
lytic activity of cholelysin. Cholely~ 
siri C1 diluted 1/20 with sample applica-
tion buffer containing various concentra-
tions of mercaptoethanol in g/100 ml. 
Mixture incubated on standard fibrin plate 
after O and ~O minuteB of incubation . . In~ 
hibition calculated as set out in section 
7.4.2. 
Mercapto-
ethanol 
Cmg/100 
0,3 
0,2 
0, 15 
0,1 
0,05 
0,01 
0,3 
0,2 
0, 15 
0,1 
0,05 
0,01 
% 
mi ) 
Control (mm diamter of zone of lysis: 19, 
18,5, 19, 1S,5: Mean 18,75 = 19,1 units/£. 
Incubation O minutes Inhibit.ion % 
1 2 mean units 
16 16 16 14,2 26 
16,5 16 16,25 14,7 23 
16,5 16,5 16,5 15, 1 21 
17,: 17,5 17,5 17, 1 10 
17,5 18,0 17,75 17,6 8 
18,0 18,0 18,0 18 , 2 5 
Incubation 30 minutes 
11 1 1 11 7,7 60 
12 12,5 12,5 9,0 53 
- 13 13 13 9,8 49 
16 15 1 5 , .3 13,4 30 
16 16 16 14;2 26 
18 18 18 18,2 5 
9.5 
9.5.1 
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Table 9-5: Effect of dialysis of mercaptoethanol-
cholelysin mixture on fibrinolytic acti-
vity of cholelysin. Cholelysin 34, 5 nun 
(140 u/l) diluted 1/20 in sample applica-
tion buffer containing mercaptoethanol 
0,3 g/100 ml and both dialysed for 48 
Specimen 
·. 
1 Control 
Test 
hours against tris . buffer M 
with one change of dialysis 
trol diluted 1/20 in sample 
0,006 pH 8,5 
fluid. Con-
application 
buffer containing no mercaptoethanol. 
Result in mm diameter of zone of lysis 
and in units/i.. 
Lysis mm diam Units/i. Illhibition % 
1 2 mean units 
11, 0 11 , 5 . 11 , 25 7,9 
0 0 0 100 
It was concluded that mercaptoethanol produced irre-
versible denaturation of cholelysin Peak I. 
Fibrinolysis 
Introduction 
Fibrinolysis was discussed in section 2.5. For ease 
of reference, this discussion is briefly recapitula-
ted here. 
Thrombin splits fibrinopeptides A and B off the intact 
Aa and BB chains of the fibrinogen molecule. The re-
sultant fibrin 'monome~ polymerises spontaneously, 
through weak H+ bonding, to form non-stabilised fibrin, 
. / 
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which is readily lysed by plasmin. 
Thrombin also activates Factor XIII (fibrin stabili-
sing factor). Factor XIIIa, potentiated by Ca++ 
(Thomson op cit, 1970) causes glutamyl-lysyl 
transpeptidation of the a and y chains of non-stabilised 
fibrin, forming a polymers and . y dimers. This proce-
dure is 95% complete after 60 minutes; increasing 
opacification of the clot accompanies the transpepti-
dation, and the resultant fibrin clot contains only 
stabilised fibrin. These processes are illustrated 
in Figures 9-3 and 9-4 • 
XIII 
Thrombin 
Fibrinogen 
non-stabilised fibrin+ fibrinopep-
tides A and B 
XIIIa + Ca++ 
stabilised fibrin 
Figure 9-3: Formation of non-stabilised and stabili-
sed fibrin under the influence of throrn-
in and Factor XIII. 
I 
9.5.2 
9.5.2.1 
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( Fibrinogen ) 
(Non-stabilised fibrin) Stabilised fibrin 
Fragment X 
Fragment D Fragment Y 
Fragment D Fragment E D dimer 
Fi~~re 9-4: Comparison ,f the split products of plas-
min digestion of fibrinogen and non-
stabilised f ~brin, and of stabilised fi-
brin. The major differerence is the 
1•resence of D dimer in the split products 
of stabilised fibrin. The sp~ .i. t products 
of non-stabilised fib~in differ from the 
split products of fibrinogen only in the 
absence of fibrinopeptides from the X, Y 
an<! E fr?.·Jments. 
Fibrinolysis by cholelysin and plasmin 
The technique adopted for the manufacture of fibrin 
plates for this study produced stabilised fibrin. 
These plates alone were used during investigation cf 
fibrinolysis by cholelysin and plasmin. 
Experimental design 
Polyacrylamide gel electrophoresis (PAGE with a 
linear gradient) was used, for resolution of the 
wide range of molecular weights of fibrin split pro-
ducts that was anticipated (Stead, 1981). 
9.5.2.2 
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Split products of fibrin digestion by cholelysin 
and plasmin after 24 hours incubation were prepa-
red as described in Method 18. In brief, soluble 
fibrin prod~cts were aspirated fron a standard fibrin 
plate and the fibrinolysin/fibrin reaction was quen-
ched with SBTI. The split products were then mixed 
with reducing agents in sample · application buffer to 
give a mixture with final concentration of: 
SDS 2 g/100 ml 
mercaptoethanol 2 g/100 ml 
urea 6 M. 
·The mixture was loaded on the gel to give a tot?! 
load of 10-20 ug of protei~ and run at 2 mA and - 9 V 
per tube for 5 hours. Lactate dehydrogenase, chymo-
i trypsinogen and ribonuclease were used as molecu~ar 
markers . Staining and destaining were carried out 
as described in Method 18. 
Results are shown in Figure 9-5. 
I 
9.5.2.3 
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P24 C24 L 
C 
R 
Figure 9-5: Split products of plasmin and cholelysin 
digestion of cross-linked fibrin at 24 
Discussion 
'P24' = Plasmin 'C24' = · 
cholelysin products. L = lactate 
dehydroge~ase; C = chymotrypsinogen; 
R = ·ribonuclease. 
F'rom this figure, it was evident that the split pro-
ducts of cholelysin and plasmi~ differed completely. 
Cholelysin appeared to have a wider range of substra-
tes than plasmin. Because cholelysin produced very 
rapid appearance of lysis on the fibrln plate; a 
clearing zone usually being visible within 3-5 minutes, 
it was desirable to study the kinetics of the cholely-
9.5.3 
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sin/fibrin reaction more closely. 
are described in Chapter Ten. 
Summary 
These kinetics 
Cholelysin with chymotrypsin control, and split pro-
ducts of fibrin digestion by cholelysin and plasmin 
were studied by PAGE. Cholelysin was studied with 
. SDS added, and with and without additional mercapto-
ethanol. Only a single band was obtained by PAGE, 
which stained poorly by standard techniques. The 
molecular weight appeared close to, but not identical 
with, that of chymotrypsin. Simultaneous assay of 
fibrinolytic potential of gel sections was done; 
this shoWt!d that lysis and stained bands coiricided 
~or cholelysin and chymotrypsin. 
Split products of plasmin and cholelysin digestion 
of cross-linked fibrin were entirely different. 
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CHAPTER TEN 
SPECTROPHOTOMETRIC STUDIES - ENZYME KINETICS 
10.1 Introduction 
10.2 
10.2.1 
The rapidity with which fibririolysi~ by cholelysin 
occurred on a fibrin plate led to a desire to stu-
dy the kinetics of this reaction. By takirig ad-
vantage of the adherence of the fibrin gel to surfa-
ces, and of the solubility of fibrin degradation 
products, a new method was devised to follow enzyme 
kinetics. This was termed the composite cuvette 
method for the analysis of enzyme kirietids. 
The composite cuvette method for analysis of enzyme 
kinetics. 
Principles 
(1) The substrate must be in gel or solid phase, 
and one or more degradation products must be 
soluble. 
(2) A clear cut difference on the scanning spec-
trophotometer must be shown between substrate, 
and the degradation products of the reaction. 
( 3) The substrate mus.t be able to occupy half of 
the light path inside the cuvette when held 
in the vertical position. 
(4) The enzyme solution is then poured in, and 
the reaction followed at the wavelength of 
maximum difference. 
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in the case of a fibrin substrate, the preparation 
of the composite cuvette takes advantage of the 
fact that a fibrinogen solution can be made to clot 
slowly if lcw concentrations of thrombin are added. 
Clotting fibrinogen solution, as prepared for the 
standard fibrin plate (Method 10, solution after 
Step 3) took 2 - 3 minutes to begin clotting, and 
~as thus entirely suitable. 
Experimental design 
(1) Spectrophotometric scanning 
(2) Preparation of composite cuvette 
(3) Study of enzyme kinetics 
10.2.2.1 Spectrophotometric scanning 
I 
For crosslinked fibrin, the cuvette was filled with 
clotting fibrinogen solution, and was then incubated 
for 2 hours at 37°c. For fibrin split products of 
cholelysin digestion (FSPC), the cuvette was filled 
with lysed fibri~ aspirated from a fibrin plate in-
cubated with sholelysin fo~ 24 hours. The reaction 
was quenched with SBTI (see Method 18). 
The spectrophotometric scans performed are listed in 
Table 10-1. 
Table 10-1: Composite cuvette. Spectrophotometric 
scans and reference standards. 
Scan Substance scanned Reference standard 
A Fibrin Air 
B FSPC Air 
C Fibrin FSPC 
D FSPC Fibrin 
- . 14 7 -
10.2.2.2 Re sults 
The first three scans are shown in Figures 10-1, 
10-2 and 10-3. Scan D gave no clear cut peak 
(not shown) . 
I 
200 400 600 
Wavelength in nm 
800 
Figure 10-1: Spectrophotometric scan of fibrin 
with air as refere nce standard, 
Scanning rate 100 nm/minute. Span 
0,5A == 0,50/l". Chart speed 
0,5"/minute. 
I 
I 
·, 
I 
- 148 -
' 2(10 400 
Wavelength in nm 
I 
600 
Figure 10~2: Spectrophotometric scan of FSPC with 
air as reference standard. Scanning 
rate 100 nm/minute. Span 0,5A = 
0,050/1". Chart speed 0,5"/minute .. 
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10 
50 M I M r I 
I ., 
I C 
I· .Q a 
ii... 
0 30 Cl) 
.c 
co 
+-' 
I C 
I Q.) (.) 
10 I · s-Q.) a.. 
200 700 
Wavelength (nm) 
_¥'igure 10-3: Spectrophotometric :;can of fibrin clot, 
using FSPC as the reference standard. 
Scanning rate 100 nm/minute. ·Span 
0, 5A ( 0, 0 5 0 / 1 11 ) • Chart speed O, 5 11 /min. 
Comment: The peak shown at 335 nm was due to fibrin. 
Thus, digestion of fibri~by cholelysin in the compo-
site cuvette resulted in a decrease of extinction at 
J 
335 nm. When FSPC w8re scanned, using fibrin as a 
reference standard, no sharp peak was found. 
10.2.3 
I 
I 
. I 
.. . 
L 
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Preparation of composite cuvette 
A quartz cuvette was half-filled with clotting 
fibrinogen solution prepared as for use on the 
standard fibrin plate. The cuvette ~as capped, 
laid on its side (with a side towards the light 
path within the spectrophotometer upwards) and 
incubated at 37°c for 2 hours. A fibrin clot . 
formed which wa~ firmly adherent to the cuvette. 
The cuvette was removed from the incubator, the 
cap taken off and cholelysin or plasmin solution. 
poured in. This was now a composite cuvette. 
The technique is illustrated in Figure 10-4. 
CLOTTING 
SOLUTION 
1 
CLOT FORMED 
.. ~ .: . .  . 
CHOLELYSIN Ii I )>~ i\ 
SOLUTION I I ..... ---. . ; ' 
I :;;, -:._:· .-;'.:, 
I ::.·.'.'; } •'.' FIBRIN 
I )\\ ~\ -----11 .. , ,, . I ;,'.·.", .-+., , --. 
I I;:·:: '. 
I ', ·' : :.··t.·: ;': 
:· .. ~ ,: ':" 
- .~. ~ \' 
335nm 
3 
Figure 10-4: Method of preparing a composite cu-
vette for study of the kinetics of 
the ~holelysin-fihrin reaction. The 
figure 335 nm refers to the wavelength 
at which the reaction was followed in 
the spectrophotometer. 
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10.2.3.1 Study of enzyme kinetics 
The composite cuvette was placed in a thermosta-
tically controlled spectrophotometer at 37°c, and 
the decrease of extinction at 335 nm followed on 
a recorder. 
10.2.3.2 Results are shown in Figures 10-5, 10~6 and 10-7. 
t 
lf) 
M 
M 
20 40 60 
minutes of incubation 
figure 10-5: Composite cuvette. Cholelysin-fibrin 
reaction. Stabilise d (crosslinke d) 
fibrin 2 mg/ml. Cholelysin 110 u/l. 
Two phases of relatively rapid decrease 
of extinction (A and C) are shown, se-
parated by pha se B where the ra te of 
change plate a us. 
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Comment: The graph of the cholelysin-fibrin reac-
tion shown in Figure 10-5 suggested that there was 
a two-phase attack on the fibrin molecule by cholely-
sin. This hypothesis was tested by subsampling from 
the composite cuvette (liquid phase) and carrying out 
PAGE on the samples. As a control, plasmin 0,2 
units/ml was used in the composite ~uvette ins~ead 
of cholelysin, and subsampled at the indicated times. 
10' 30 ' 
Cholelys1n 
Figures 10-6 and 
10-7: 
L 
C 
R Markers 
Comparison of the split products of 
cholelysin and plasrnin digestion of 
stabilised fibrin. Molecular mar-
kers (from above downwards) L = 
lactate dehydrogenase C = chymo-
trypsinogen R = ribonuclease. 
. / 
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Comment on Figure 10-6: This figure demonstrated 
the correctness of the hypothesis that cholelysin 
made a two-phase attack on the stabilised fibrin 
molecule. It is evident that only two products 
were present ut 2 minutes, and many more at 10 minutes. 
On the other hand, the plasmin digest contained many 
products at the outset, which increased in density 
but not in number up to the 30 minute point. 
Figures 10-5 and 10-6 are shown superimposed in 
Figure 10-8 • 
I 
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Figure 10-8: Superimposition of Figures 10-5 and 
10-6 to show time relationship of gene-
ration of split products by cholelysin 
from stabilised fibrin. 
10.2.4 
10.3 . 
I 
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Discussion 
This interesting result showed that the composite 
cuvette method was a valid technique for following 
the cholelysin-fibrin reaction. Beyond using the 
method for obtaining early split products of plas-
min digestion of stabilised fibriri, no attempt was 
made to study the plasmin/fibrin reaction further. 
However, advantage was taken of this method · to s±udy 
kinetics of the cholelysin/fibrin reaction. These 
experiments are described in 10.3. 
Kinetics 
Both substrate and enzyme were used in different 
concentrations in the cocposite cuvette met~od~ in 
an attempt to establish a Lineweaver-Burk relation-
ship (Lehninger, 1975). Unfortunately, the results 
of varying the concentration of substrate ~ere anoma-
lous, and require further study. They wil~ not be 
reported here. 
Varying the con ~entr~rion of ·the cholelysin solution 
produced a clearcut change in the velocity of the 
reaction in the second phase (phase C in Figure 10-5). 
This is shown in Figure 10-9. 
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Dilutions of cholelysin 
as ind.:j..cated 
10 
Figure 10-9: 
20 30 40 50 
Minutes of incubatio~ 
Superimpo~ition of four graphs of va-
riations in V with concentration of 
cholelysin. Substrate: stabilised 
fibrin 2 mg/ml. Enzyme: Cholelysin 
1/2 = 140 u/l, 1/3 = 93 u/l, 1/4 = 70 u/l, 
1/5 = 56 u/l. This Figure is analysed 
overleaf. 
/ 
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Cormnent on Figure 10-9: this Figure was analysed 
for relationship between velocity of reaction in 
first and second phases (Phases A and C) and reia-
tive enzyme concentration. A clearcut relation-
ship was found for phase C; the results are shown 
in Table 10-2, and graphically in Figure 10-10. 
Table 10-2: Analysis of kinetics of fibrinolysis 
Conr.entration 
of cholelysin 
1/2 
1/3 
1/4 
1/5 
by cholelysin in terms of relative con-
centration of enzyme vs V. The stee-
pest portion of the second phase of each 
curve was selected, and Tan 8 estimated. 
e Tan e (V) Ta~ e (~) 
66,5 2,30 0,435 
53 1,33 0,752 
44 0,97 1,031 
38 0,78 1 , '.l 82 
10.4 
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.J 
I 
1 , 0 
1/V 
0,5 
I • 
I I. 
I 
I 
I 
0 1 2 3 4 5 
1/concentration 
Figure 10-10: 1Jouble reciprocal relationship be-
tween enzyme concentration and ve-
locity ~f fibrinolysis in the second 
phase of the colelysin-fibrin reac-
tion. 
Conclusions and summary 
The composite cuvette method was developed for the 
study of enzyme kinetics at a sol/gel interface. 
This method was appli~d to the cholelysin/stabilised 
fibrin reaction, which was found to be biphas~c. 
The degr adation products of the two phases of the 
reaction were analysed by PAGE, and it was shown 
that cholelysin made a two-phase attack on the mole-
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cule. The kinetics of the enzyme/substrate reac-
tion were analysed by the composite cuvette method 
in terms of variation in enzyme concentration. A 
~inear relationship was found between the reciprocal 
of enzyme concentration and the reciprocal of V 
jsecond phase). 
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CHAPTER ELEVEN 
MOLECULAR WEIGHTS 
11.1 Introduction 
11 • 2 
The molecular weights of cholelysin and of fibrin 
split products of digestion by cholelysin and by 
plasmin are reported in this chapter. To cut down 
unnecessary detail, 
shown in Appendix 11; 
are shown here. 
workings are 
only the principal results 
The molecular weight of cholelysin was estimated by 
column chromatography (Petersen and Sober, 1962; 
Laurent and Killander, 1964). Experiments were 
done at widely varying intervals of time, on several 
preparations of cholelysin, and with and without so-
dium dodecyl sulphate (SDS). Experiments with SDS 
added are reported separately. Molecular weights 
were estimated from a graph supplied by the makers 
of 'Sephadex' . 
11.2.1 Column chromatography without SDS 
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Table 11-1 : Molecular weights 
without SDS~ for cholelysin fractions. 
, 
Molecular 
Preparation Vt of column Sephadex K weight av (estimated) 
Ammonium 
su.~phate 224 G50 0,3 23 000 
precipitate 
Peak I 46,5 G75 0,5 1 1 000 
Peak II 46,5 G75 0,45 13 000 
Peak III 46,5 G75 0,58 8 000 
Peak IV (i) 46,5 G75 0,62 7 500 
(ii) 46,5 G75 0,005 50 000 
Rechromato-
graphy of 
Peak I. 
Two experi- 224 G75 0,25 28 0 : lJ 
ments 224 G75 0,28 27 000 
11.2.2 Column chromatography with SDS 
SOS was added to ~he cholelysin preparation before th
e 
experiment to linal concentration of 2 g/100 ml, and 
incubated together at room temperature fer 30 ~~nutes
 
befor e the experiment was performed. All samples we
re 
batchwise Peak I. Chymotrypsin was used as a contro
l. 
The results are shown in Table 11-2. 
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Table 11-2: Molecular weights of batchwise Peak I 
with sos 2 g/100 ml. Chymotrypsin 
control. 
Molecular 
Preparation Vt of column Sephadex K weight av (estimated) 
Batchwise 124 G75 0,4 14 31)0 Peak I 
Peak I 140,5 G75 0,39 14 500 
-
Peak :t 140,5 G75 0,63 7 000 
Chymotrypsin 140,5 G75 0,40 13 OOO(known ) 
11.2.3 Polyacrylamide gel electrophoresis of cholelysin with 
SDS 0r with SOS and merca1,toe thanol, both 2 g/100 ml 
final concentration. This experimen t was shown in 
Figure 9-1 ( stained gels) ;: ·:1d in Table 9-2 · and Fi·gure 
/ 
9-2 (fibrinolytic activity of parallel experiments, 
with gel cut in~o sections and applied to a standard 
fibrin plate). Cholelysin stains poorly, but a line 
can be discerned in Figure 9-1, and this is ccnfirmed 
in the parallel experiment reported in Table 9-2 and 
Fi rJure 9-2. From these experiments, it was apparent 
that the molecula~ weiqht of the preparations of cho-
lelysin studied was of the same order as chymotrypsin 
<- 13 000). 
11.2.4 Paper electrophoresis of batchwise Peak I was attemp-
ted, but definite stained bands could not be elucidated. 
11.2.5 Discussion 
These results cluster into three groups of molecular 
weights, with two values outside them. These are: 
7 000 
14 000 
28 000 
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The discrepant results are 
{1) 23 000, from a single experiment reported in 
Chapt~r Five, Figure 5-6. This experiment 
was performed on ammonium sulphate precipita·· 
ted bile, with elution by tris/NaCl, and gave 
K = 0,3 on sephadex G50. These conditions av 
were never repeated. 
(2) 50 000, from a single experiment using Peak IV. 
This experiment gave two ~idely separated val~es 
for K , viz, 7 000 and 50 000. Thi~ was also av 
a single experiment. 
Vith or without these discrepant results, the possi-
bility is rais8d that cholelysin in monomeric form 
h~~ a molecular weig~t of - 7 000, with polymers of 
- 14 000 {- 21 000) and - 28 000. The experiments 
with SDS, reported in section 11.2.2, are noteworthy, 
as they were done wi+h particular care in view of the 
wide variations in mulecular weight found in the expe-
riments reported in 11.2.1. Even so, two values were 
found in the presence of adequate amoun~s of SDS. 
The higher molecular weights (- 28 000) found on re-
chromatography of Peak I could have been due to poly-
merisation of the molecule when in high purity and 
concentration. 
The molecular weights of the four Peaks without . SDS 
were only estimated once, and rechromatographed Peak I 
twice, before the decision was made to concentrate on 
Peak I for further experimentation. No attempt was 
made to correlate molecular -weights with substrate 
activities. It is possible that certain molecular 
weights are ·associated with particular substrate acti-
vities; for example, high molecular weight (- 50 000) 
Peak IV. 
11 • 3 
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Molecular weights of fibrin split products 
These experiments were shown in Chapters Nine and Ten. 
The PAGE technique used (linear gradient) gave high 
resolution, ~ith a fixed end point for each band in 
relations to the gradient. This end point was inde-
pendent of voltage and of prolongation of the proce-
dure beyond the standard time. Thus, relative mobi-
lity need be determined only in relation to the length 
of th~ gel at the end of processing (Stead, 1981). _ 
Samples of split products were obtained from the com-
posite cuvette at various times, and fibrinolysis was 
quenched by SBTI (see Method 8). Results are shown 
in Figures 11-1, 11-2, 11-3, and 11-4. 
2 1 101 30' 
Cholelysin 
Figure 11-1: 
Figure 11-2: 
FSPC 
. FSPP · 
L = 
Ch = 
R = 
10' 30' 
Plasmin 
lactate dehydrogenase 
chymotrypsinogen 
ribonuclease 
PAGE of cholelysin split products of 
r ... rs 
fibrin digestion at the times indicated. 
Plasmin split products shown in Figure 11-2. 
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Figure 11-1 is a repea~ of Figure 10-6. 
Figure 11-3 is a repeat of Figure 9-5, and i~ one 
of a series from which relative mobilities and mo-
lecular weights were calculated, while Figure 11-4 
shows the progr ess of FSPC over 24 hours. 
tJ 
P24 C24 
L 
Ch 
R 
rkers 
P24 = FSPP at 24 hours 
C24 = FSPC at 24 hours 
See text for further details 
1 3 Comparl·son of FSPC and FSPP afte r Figure 1 - : 
24 hours of incubation on the standa rd 
fibrin plate. 
cus s ed below. 
Ident i fied band s are di s -
P1 = D dimer (y") fragment 
P2 = B" fragment 
n~ = ~ " fr~amen t 
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~ . 
30' 50· 
Cholelysin 
2 hr 24 hr c 
R 
Figure 11-4: Progress of FSPC at the indicated 
periods of incubati0n with chymotrypsino-
gen and ribonuclease markers. Lactate 
' 
dehydrogenase ·was unavailable when this 
expe riment was performed. This photo-
graph is include d for interest. 
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11.3.1 The relative mobility of marker proteins was esti-
mated as discussed in section 11.3 above, and plot-
ted on a graph. This graph is shown in Figure 11-5. 
Relative mobility of protein bands marked in Figure 
11-3 was then estimated, and the approximate molecular 
weights derived from the same graph. See also Table 
11-3. 
0,3 
Di mer 78 000 
76 000 
/ . 
0,4 
45 000 
000 
36 OOv 
0,5 0,6 
15 000 
-----·•-----1---
0, 7 0,8 
Relative mobility 
"ff "'f' molecular markers 
• • · degradation products 
Figure 11-5: Major products of the deg~adation of sta-
bilise d fibrin by plasmiri and cholelysin. 
Molecular markers: 13 700 ribonuclease 
25 700 chymotrypsinoge n 
36 000 lactate dehydro-
genase 
See Appendix 11 for detailed working. 
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The molecular weights of the identified bands of FSPP 
and PSFC, as derived from their relative mobilities, 
are shown in Table 11-3. 
Table 11-3: Molecular weights of bands P1, P2, P3 of 
FSPP, and of C1, C2, C3, and C4 of FSPC 
as shown . in Figures 11~1 and 11-3. The 
suggested iden~ity of the FSPP bands is · 
also shown. 
FSPP FSPC 
Band Molecular Suggested Band Molecular 
weight identity weight 
I> 1 78 000 D-dimer (81 000) C1 25 000 
P2 45 000 B II (44 500) C2 15 000 
P.3 14 200 a" (-15 000) C3 76 000 
C4 43 000 
11.3.2 Discussion 
Pizzo, Taylor, Schwartz, Hi11 and McKee (op cit, 1973) 
found that three major fragments of stabilised fibrin 
remained after prolonged digestion with plasmin. These 
are listed in the column 'Suggested identity' of Table 
11-3 above. Our findings, using the linear gradient 
gel technique of Stead (op cit, 1981~ agreed reasona-
bly with those of Pizzo, Taylor, Schwartz, Hill and 
McKee. 
However, the products of cholelysin digestion of sta-
bilised fibrin were entirely different. 
( 1) The first two products '·were C1 25 000 and C2 
15 000. 
(2) C1 had disappeared by 30 minutes. 
,: 
11 • 4 
(3) 
- 169 -
A large number of new split products had ap-
peared by 10 minutes. Two of these showed 
a marked increase in density by 24 hours, and 
· were labelled C3 and C4. C3 afpears to be 
two products of closely similar molecular 
weight. 
Thus, it is concluded that cholelysin makes a two phase 
attack on the stabilised fibrin molecule, and also shows 
a wider substrate specificity than plasmin. 
Sununary 
The molecular weights of · choJ.3lysin and of the split 
prod~cts of the digestion of stabilised fibrin by cho-
lelysin and plasmin were analysed. 
. , 
. 
(1) By column chromatography, cholelysir. was found to 
have two molecular weights in the presence of 
SDS. One of these was probably a dimer of the 
other. A third molecular weight, probably a 
tetramer, ~as found in duplicate estimate of a 
rechromatographed sample of Peak I. Finally, 
two possibly discrepant estimates we:i..e =om:.d, 
which were not studied further because of chan-
ges of policy. The significance of these two 
discrepant estimates remains uncertain. 
Cholelysin was found to have poor staining qua-
lities, which hindered identification of the en-
zyme by PAGE or paper electrophoresis. However, 
in one experiment where a clear line was discer-
nible in the gels containing cholelysin, the 
identity of the band was established by simul-
taneous assay of gels for fibrinolysis, with a 
chymotrypsin control. 
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(2) Using the linear gradient PAGE technique, in 
the presence of molecular markers, the 24 hour 
split products of plasmin digestion of stabi-
lised fibrin (FSPP) were found to agree close-
ly with those in published work. Cholelysin 
split products were analysed -for molecular weight.· 
All molecular weights found were different from 
those: of FSPP. · Two bands were present after 
two minutes of digestion by cholelysin. - One 
of these bands had disappeared by 30 minutes; 
the other band remained and grew steadily larger 
over24 hours. Numerous other bands were ob-
served -from 10 minutes onwards, confirming the 
two phase nature of ~he cholelysin/stabilised 
fibrin reaction as first observed 0y the ccm-
1 posite cuvette techni~ue. 
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CHAPTER TWELVE 
.SUMMARY 
12.1 Summary 
12.2 The nature of cholelysin 
12.3 Possible future work 
The study describes a new proteas~ with some unusual pro-
perties, that has been found in the bile of 11 mammalia; .. 
specie3 studied, including man. · rt is a fibrinolysin, 
with an activity per milligram exceeding th2t of chymo-
trypsin; and it is also fibrinogenolytic. It has been 
given the tentative name of cholelysin to emphasise its 
fibrinolytic potential. However, it has a range of spe-
cifities against ot~er substrates, including ~-casein, 
and the synthetic esters of tyrosine (ATEE) an1 arginine 
(BAEE). It does not activate the zymogens plasminogen, 
chymotrypsinogen and trypsinogen. 
CHAPTER 
FOUR 
Ox-bile was used for almost all work reported 
in this study, because the bile of this species 
was available in large volumes from the Munici-
pal Abattoir, Cape Town. From the point of 
view of this study, everything in bile was redundant ex-
cept the protein carrying Jibrinolytic potential, and much 
time and effort was expended to devise an effective system 
for the purification. and concentration of this fibrinoly-
sin (cholelysin). 
CHAPTER 
FIVE 
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The final procedure contained the following 
steps: ~ 
desalting with sephadex ASO or AG 1-X-8 
precipit~tion with ammonium sulphate 
dialysis 
column chromatography on sephadex G200 
batchwise elution from. Whatman DE 32 
dialysis 
flash freezing in liquid nitrogen 
freeze drying 
This produced a white powder, free of bilirubin, of which 
10-50% by weight had fibrinolytid potential. 
CHAPTER 
THREE 
I 
Quality control throughout was done by means of 
a standardised fibrin (llate assay. Cholelysin 
was found to follow the semi-logarithmic dose 
response c~rve typical of most fibrinolysins 
tested by this method. Chymotrypsin had a closely simila
r 
dose-response curve, and this enabled cholelysin activL:y 
to be read in units/l equivalent to the a ~tivity of chymo-
trypsin in mg/l. 
CHAPTER 
SIX 
An earlier method of purification used NaCl gra-
dient elution of c~olelysin from Whatman DE 32. 
This produced a series (usually 4) of peaks of 
activity. When these were studied on various 
substrates, the interesting finding emerged that all four 
peaks were caseinolytic, though each peak showed apparentl
y 
distinctive specificity for the two synthetic substrates. 
In particular, Peak IV hydrolysed neither ATEE nor BAEE, · 
and Peak III was also inactive against BAEE though showing
 
some ATEE esterase activity. Peaks I and II showed broad
 
similarities with minor differences. 
In a separate study, the ATEE esterase activity of Peak I 
was compared with its fibrinolytic activity . 'T'Ym form
s 
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of cholelysin were found with sharply differing esterase/ 
lyti~ ratios; the second form showed a semi-logarithmic 
relationship between these two activities. 
CHAPTER 
SEVEN 
Extensive studies were made of the inhibition 
of cholelysin, · using ·human serum and the serum 
of rat, rabbit and guinea-pig, platelet-rich 
and platelet-poor plasma; a 2-macroglobulin, 
soy bean trypsin inhibitor, and aprotonin. 
Human serum was strongly inhibitory; the 50% inhibition 
point was reached at an average dilution of 1/70 in 10 sera 
studied.. Heating the serum to 56°c for 30 minutes did not 
diminish ~he inhibitory potenti~l. The serum of two pa-
tients with homozygous a1-antitrypsin deficiency was 
strongly inhibitory as well. 
It was surprising th"t a broad spectrum inhibitor such as 
a1-antitrypsin played no part in the serum inhibit;.on 0f 
cholelysin, and b ecause of this paper ele~trophoresis of 
normal human serum was done to discover which area(s) were 
inhibitory. Chymotrypsin was run as a control. This ex-
periment showed no inh:bitic~ amongst a-globulins, with 
strong inhibition in the inter-a-antitrypsin and S-globulin 
zones. The pattern of inhib~tion differed sharply from 
that demonstrated by chymotrypsin. 
Rat, rabbit and guinea-pig sera were also inhibitory, but 
not as potently as human serum. Platelet-rich and platelet-
poor human plasma were equally inhibitory. Simultaneous 
assay of serum inhibition of cholelysin ATEE-esterase and 
fibrinolytic activities was done; this did not show a dis-
sociation of activities, or .a semi-logarithmic relationship, 
as had been found when these activities were ' studied ~ithout 
serum inhibition. The point of 50% inhibition of ATEE-
esterase activity of cholelysin by human serum was found at 
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a dilution of 1/90 in a single experiment. 
·a 2-macroglobulin, SBTI, and aprotonin, we~e studied for their 
inhibitory capacity. All were inhibitory, but to a variable 
degree among Peaks I, II, III, and IV of cholelysin. a 2-
macroglobulin showed least inhibition of Peak I and most of 
Peak IV; SBTI produced erratic ~esults when pre-incubate1 
with chol~lysin for 20 minutes, but consistent results when 
incubated for 24 hours at room temperature, when it ·showed 
a near-100% inhibition of Peaks I, II and III at a concen-
tration of 6 mg/100 ml. Aprotonin re?istance also diffe-
red among the peaks, Peak II being most resistant. 
CHAPTER 
EIGHT 
I 
Biological studies were underta~en to discover if 
cholelysin had signif:, :ant anticoagulant poten-
tial. In prelimiriary experiments, cholelysin had 
no effect 0n the partial thromboplastin time with 
kaolin, the prothrombin time, the thrombiri time, and the fi-
brL~ogen assay. However, incubation of cholelysin and pu-
rified fibrinogen showed a marked fibrinos~nolytic effect. 
Platelet aggregation with adrenaline, ADP and collagen was 
stud.le_d in the presence of cholelysin·. A moderate inhibi-
-- - -
tion of aggregation by ADP 10 µmol/l was demonstrated, 
but none to aggregation by ADP 1 000 µmol/l. Aggre-
gation by collagen and adrenaline was unaffected. 
A minimum lethal dose in the Wistar rat could not be deter-
mined, while the biological half-life of injected cholelysin 
was shown to be of the order of 5 minutes. 
A limited study of the anticoagulant effect of chole"Lysin 
was done in a rat model originally described for ancrod 
( 'arvin'). The quantities of purified Peak I require.a ex-
ceeded the modest manufacturing capacity of the programme 
at that time, and this experiment was possible only with 
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the kind c o-operation of the Sout h African Inventions 
Development Corporation and the Council for Scientific 
and :ndust rial Research. A statistically significant 
number of rats was s t ud'ied, but with dose schedules of 
only about 10 % of the average duration of those achie-
ved with a ncrod. The result approached, but did not 
reach, sta tistical significance. 
CHAPTER 
NINE 
Fibrinolysis by cholelysin was studied by a 
polyacrylamide gel system (PAGE) embodying 
a linear gradient. Fibrin split products 
at 24 hours were compared for cholelysin and 
plasrnin, a nd were found to be totally different. The 
inhibitory effects of SDS and meI <:!aptoet hc1nol on chole-
lysin were studied during the PAGE work. 
I 
CHAPTER 
TEN 
For further study of the dynamics of the cho-
lelysin/fibrin reaction, a new test was de-
vised, termed the composite cuvette method for 
the study of enzyme kinetics. In this method, 
the light path of t~e cuvette was half occupied by fibrin 
clot, the other half by cholelysin or plasmin solution. 
The react i on was followed in a temperature-con~rolleJ 
spectrophotometer, at a wavelength (335 nm) previous]y 
shown to d istinguish fibrin from a reference standard of 
fibrin spl it products in a scanning spectrophotometer. 
A biphasic reaction was found; the biphasic nature of this 
reaction was proved by subsampling from the composite cuvet-
te and sub jecting the sample to PAGE, when only two products 
were found after 2 minutes of fibrin digestion, and multiple 
products a t 10 minutes and later. Plasmin digestion of 
fibrin, o n the other hand, showe d a constant number of pro-
ducts from the commencement. 
CHAPTER 
ELEVEN 
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Molecular weights of fibrin split by cholelysin 
and plasmin were studied through the standard 
method of protein markers, and estimating rela-
tive mobility of known and unknown bands. This 
showed that the major bands of plasmin digestion after 24 
hours compared very closely with published work, while cho-
lelysin split produdts were all different. 
Finally, the molecular weight of cholelysin was estimated 
· in three ways (column chromatography without SDS, (2) 
column chromatography with SDS (3) PAGE. At least three 
molecular weights · of cholely~in were found by method (1), 
probably a dimer and tetramer of the basic molecular weight 
of - 7 000. Two discrepant results were only estimate~ 
once. By method · (2), molecular weight of 7000 and 13 000 
were found, despite the presence of SDS. By method (3) a 
molecular weight of about 13 000 was fourid; the protein 
band stained poorly on PAGE, · but the result was confirmed 
by simultaneous assay of a gel for fibririolytic activity 
with a chymotrypsiri control. 
12.2 The nature of cholelysiri 
Cholelysin . is a . protein .which acts as an anion at pH 7,4. 
It has a basic molecular weight of 7 000, with .a probable 
dimer at - 13 000 and a tetramer at - 28 000. It is un-
related to trypsin, chymotrypsinor plasmin. It is pre-
sent in variable amount iri bile, and probably does not ex-
ceed 10% of total bile protein. The fibrinolytic poten-
tial of o~ bile vari~s quite markedly from batch to batch, 
without reference to . total protein or bilirubin concentra-
tions. 
The origin of cholelysiri is uncertain; it is unlikely to 
be of dietary origin, as it was found in the bile of car-
nivores (cat, dog) herbivores (ox, sheep) and omnivores 
(man, pig). It is a previously undescribed protease, and 
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its signific"ance in the biliary tree is uncertain. It 
may be there to act as a fibrinolysin, along the lines 
of the systems of fibririolysis described in all other small 
tube systems in the body (though all previously described 
systems involve an activator of fibrinolysis by plasmin, 
and not a primary fibrinolysin). Alternatively, it is 
excreted in bile for physiological reasons having nothing 
to do with ·fibrinolysis. 
12.3 Future work 
This study has opened up many areas for future work. 
that _ appear to be of . . importance are: 
Those 
(1) Why is there a potent inhibitor? Does this imply 
the intermittent presence of cholelysin in the blood 
stream? If so, i~ cholelysin present in the plasm~ 
of animals or man with obstructive jaundice? This 
could be tested by use of a specific antibody in an 
animal model, or in man with obstructive jaundice. 
\2) Could cholelysiri play a major role in thrombolysis? 
The ready availability of ox bile, and the develop-
ment of relatively large scale techniques for the 
isolation of cholelysin, make it possible to study 
this field more intensively in the future. Both 
forms of thrombolysis currently available are unsatis-
factory; urokinase is non-antigenic but very expen-
sivei and steptokiriase is a potent antigen as well as 
being very expensive. Cholelysin could be more ef-
fective than either, but the inhibitor would have to be 
overcome. This .could be done in vitro, and by chro-
nic infusion of cholelysin in vivo until a lasting 
effect appeared. The rat model of Chapter Eight, 
repeated urider these conditions, might give a sta-
tistically signifidant_ result. 
- :(3) Biochemidally there is much of interest to follow up. 
The molecular weights need further intensive study; 
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in particular, the careful column chromatography 
with SDS producing two different molecular weights 
needs repetition. The relationship between the 
two peaks obtained on batchwise elutiun needs ex-
ploring; is the second peak a heterogenous collec-
tion of molecular weights? How do the substrate 
activities of the two (batchwise) peaks compare? 
The semi-logarithmic relationship between ATEE-
esterase and fibrinolytic activ_ities for batchwise 
Peak I needs further exploration. What is the 
nature of the serum inhibition of cholelysin? Is 
it a know inhibitor, if so which? What type of in-
hibition is it? Why does cholelysin stain poorly · 
\~it~ standard PAGE techniques? Can this be remedieG 
·by the use of other stains? A new technique incor-
p·.ra ting fibrin into PAGE, (Wilson, Becker, Hoal and 
Dowdle, 1980) might bypass the need for alternative 
staining techniques. 
The dynamics . of the cholelysin-fibrin reaction need 
further studying. What linkage is attacked by cho-
lelysin, givirig the reacti6n a biphasic nature? 
Can the reaction products be related to known degra-
dation products? Differential staining of FSPC for 
eg carbohydrate might give further clues. Why does 
variation of substrate concentration in the composite 
cuvette give anomalous results? Hew do other fi-
brinolysins behave under similar condition (eg tryp-
sin, chymotrypsin, plasmin). 
It is apparent that there is no shortage of possible 
lines of research on this interesting protease. 
'. 
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METHODS 
FIBRINOLYSIS BY BILE 
1 ACETONE precipitation .of whole b i le. 
0 Acetone and raw ox bile pre-coole d to O C •. Acetone 
added to bile 40% V/V. Precipit ate formed immediate-
ly. Centrifuged at o?c and 12 000 rpm (20 000 XG) 
for 1 O minutes. Precipitate red issolwed .. in tris buf-
fer pH 8,5 M 0,006. 
2 ATEE (N-acetyl-L-tyrosine ethyl e ster monohydrate) 
esterase activity . (Miles~Seravac Manual, 1972 p 14). 
Principle: ATEE is hydrolysed a t the ester linkage 
causing a decrease of .extinction at 237 nm. Unit: 
That amount of .enzyme causing a decrease of extinc-
o tion at 237 nm of .0,0075 per minutes at 25 C. 
The assay is carried out as follows: 
Reagents: M 0,067 potassium phosphate ·buffer pH 1;0 
M 0,001 HCI 
Substrate: M 0,00934 ATEE in buf fer 
(25,2 mg ATEE is dis s olved in buffer at 
70°c. The solution is cooled rapidly and 
the volume adjusted to 100 ml with buffer) 
Enzyme: A solution containing 
10 - 20 NF units/ml M 0 ,001 HCI 
Procedure: Into 10 mm quartz cells place the following 
at 25°c 
Test Control 
Substrate 3,0 ml 3,0 ml 
M 0,001 HCI 0,2 ml 
Enzyme at zero time 0,2 ml 
Record the decrease of extinction at 237 nm 
for five minutes 
NF U/mg 
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Calculate the activity as follows: 
A E 237 nm/minx 5 = .,,---=-::,-:,-,=---=--=-·-----0,0075 x 0,2 x mg enzyme/ml enzyme solution used 
Determine the suitao~ity of the substrate for 
this assay by carrying out a reference assay 
using a NF chymotrypsin standard. 
Note: In terms of µmol units using N-benzoyl-L-
tyrosine ethylester (BTEE) as substrate, crys-
talline a-chymotrypsin has an activity approxi--
mately 45 U/mg. 
ATEE: revised method. 
~he standard test made provi~ion for only 0,2 ml of test 
material, which was insufficient for testi!1g cholelysin, 
and cholelysin + serum inhibii:Lon. Accordingly. the stan-; . 
dard method was revised to allow for a larger volume of 
test material, as follows: 
ATF.E Diluent ATEE V-:,lume Unit of 
mg/100 ml (ml) used fo.c test activity (mg) (ml) 
Standard 25,2 3 0,757 0,2 0,0075 
Revised 37,6 2 0,752 1 , 2 0,01 
The unit of activity was increased to 0,01, as conditions 
were no longer standard, and this was a more convenient 
figure. 
3 BAEE (N-benzoyl-L-arginine ethyl ester hydrochloride) 
esterase activity (Miles-Seravac manual, 1972 p 48). 
Principle: BAEE is hydrolysed at the ester linkage, 
causing an increase of extinctinn at 253 nm. Unit: 
that amount of enzyme caus~ng an increase of extinction 
at 253 nm of 0,003 per minute at 25°c. 
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The assay is carried out as follows: 
Reagents: M 0,067 potassium phosphate buffer pH 7,6 
M 0,001 HCI 
Substrate: M 0,00025 BAEE in buffer (8,6 mg/100 ml) 
Enzyme: A solution containing approximately 40 NF 
units/ml in M 0,001 HCI 
. 
Procedure: Into 10 mm quartz cells place the following 
: J 
NF units/mg 
at 25°c: 
Substrate 
M 0,001 HCI 
Enzyme at zero time 
Test 
3,0 ml 
O. 2 ml 
Control 
3 IO ml 
0 I 2 ml 
Record the increase of extinction at 253 nm 
for five minutes. 
Calculate the act~vity as follows: 
= ~ E 253 nm/minx 5 
0, 003 x mg enzyme/ml enzyme sc,lution 
Determine the suitability of the substrate 
for this assay by carrying out a reference 
assay using a NF trypsin standard. 
The potential activity of tryps Lnoger.• is de-
termined by activating with trypsin at pH 8,4 
0 
and at 5 C for approximately 24 hours and 
then measuring the trypsin activity as descri-
bed. 
For acetyl trypsin the enzyme should be dis-
solved in M 0,067 potassium phosphate buffer 
pH 7,6. 
.... 
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4 BIURET 
A) Reagents: 
1) Biuret reagent: 
Weigh off: 
Potassium Sodium Tartrate 
Potassium Iodide (KI) 
Copper Sulphate (CuS04 5H2o) 
Sodium Hydroxide (NaoH) 
3,410 gm 
0,830 gm 
2;345 gm 
4,000 gm 
Dissolve and make up to 500 ml with distilled 
water. 
(This reagent is commercially available as 
"Merckotest Total Prote .i.n kit" - Tauber and 
Corssen, Cape Town) 
·2) Standard: 
Human albumin, 80 mg/l in distillea water. 
B) Method: 
Using 10 x 75 mm glass test tubes, proceed as follows: . 
Bank Std Test 
.Biuret reagent 1,05 ml 1,05 ml 1,05 ml 
Distilled water 0,02 ml 
Versatol 0,02 ml 
Assay Serum 0,02 ml 
Mix well and leave at room temperature for 30 minutes 
or at· 37°c for 15 minutes Zero with blank at 545 nm 
and read (Two blanks should be prepared if a double 
beam instrument is used). 
Calculation 
Reading of Test 
Reading of Standard x 
concentration of standard 
1 = gm/100 ml Total 
protein 
------·- - --
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· 5 CASEINOLYSIS (Johnson, Kline and Alkjaersig, 1969) 
Principle: casein is hydrolysed with the release of ty-
rosine. When plasmin is used as test enzyme, the unit is 
described 
(1) as that quantity of plasmin that releases 0,1 micro-
equivalent of tyrosine/minute from a specified casein . 
preparation, or 
(2) as that quantity of plasmin that, after 20 minutes of 
incubation with casein, causes an increase of extinc-
tion of 0,300 at 275 nm. 
~n the second definition, the reaction is stopped by the 
addition of perchloric acid after 20 minutes. 
Reagents: Tris 7,265 . g) 
MF.?thod: 
NaCl 5126 g) pH 7,5 at 1 000 ml · 
Perchloric acid 0,5 M 42,8 ml of 70% + water 
to 1 000 ml. 
a Casein 1,4 gin 100 ml of Tris NaCl buffer 
Standard plasmin/plasminogen 10 u/ml. 
Dilute plasmin or test plasma - 1/10 with tris 
NaCl buffer. Place 1,0, 0,8, 0,6, 0,4, 0,2 in 
a series of test tubes. Add buffer to 2,5 ml 
total. 
Add 2,5 ml a casein. 
Mix by inver$ion. 
Incubate 37,5°c. 
At 2 minutes and 32 minutes blow 2 ml aliquots 
into 3,0 ml of 0,5 M perchloric acid. 
Mix by shaking. 
Stand at room temperature -for 30 minutes. 
Centrifuge at 2 000 XG for 15 minutes. 
Remove supernatant through Pasteur pipette with 
cottonwool round tip. Read at 275 nm using 2 
minute sample as the blank. 
~ . -------~-~--
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6 CHLOROFORM/METHANOL PARTITION (Bligh and Dyer, 1959) 
· Principle: In this method lipids are partitioned between 
these two solvents. 
Materials: Chloroform, methanol. 
Method: 100 ml of bile homogenised in a Waring blender 
with 100 ml chloroform and 200 ml methanol for 2 minutes. 
A further 100 ml chloroform th8n added, -and, after another 
30 seconds of blending, 100 ml of distilled water. Blend 
final mixture for another 30 seconds, and pour off into a 
glass cylinder. Fibrinolytic activity concentrates at 
the chloroform/methanol interface, along with black tarry · 
material. Results are given in Appendix 5. 
7 COAGULATION 
Partial thromboplastin tL~e with kaolin (Proctor and Rapa-
port, 1961). One stage prothrombin time (Poller and Thom-
son, 1969) . 
Thrombin time: 'l'he c1u::t i11g time of control plasma with 
thrombin was aajusted by appropriate dilution of thrombin 
with barbitone buffer pH 7,4 until the control time was 
- 15 s. The clotting time of test plasma was then mease-
re'l, using th~ s~me concentration of thrombin. A prolonga-
tion of> 2 s was regarded as significant. 
Fibrinogen assay (Vermylen, De Vreker and Verstraete, 1963). 
Fibrin split products (Merskey Johnson Kleiner and Wohl, 
1967). 
Platelet aggregation studies: 
collagen (Packham, Warrior, Glynn, Senyi and Mustard, 
1967) 
ADP and adrenaline (Macmillari, · 196~). 
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8 COMPOSITE CUVETTE (see Chapter Ten) 
Principle: 
For this test, a gel-phase substrate and soluble degrada-
tion products are required. These two are scanned against 
each other in a scanning spectropho tometer, and the wave-
length of maximum difference selected for subsequent mea-
surement. The gel-phase substrate is caused half to fill 
the cuvette in the light path; the enzyme used is intro-
duced into the cuvette, and digestion of substrate commen-
ces. The reaction is followed at the selected wavelength, 
observing either a decrease of extinction (substrate scan-
ned, degradation products as refere nce standard) or an 
increase (degradation products sc anned, substrate as re-
ference standard). Kinetics can be directly followed, 
and degradation products obtained from the outset of the 
reaction. 
Reagents: 
MP.thod: 
Clotting fibrinogen solution as prepared for 
the standard fibrin plate (see Method 10). 
Standard quartz cuvette . 
Cholelysin Peak I in tr is buffer pH 8,5 
M 0,006 
Split products of fibrinogen by cholelysin 
digestion (FSPC) obtained from standard fi-
brin plate after 21 h ours of digestion of 
fibrin. 
(1) Establishment of point of maximum wave-
length difference between fibrin and FSPC. 
Clotting fibrinogen solution poured into 
a cuvette and inc ubated at 37°c for 2 
hours. After that time, the fibrin clot 
and FSPC each sca nned against air, and then 
against each other . The point of maxi-
mum difference i n absorption selected for 
further study. This was found to be at 
335 nm with fibr i n scanned, and FSPC as 
reference standar d. 
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(2) Preparation of composite cuvette. 
Clottirig fibrinogen solution poured into 
a quartz cuvette in sufficient quantity 
ot half fill it. The cuvette was then 
capped and laid on its side, with a side 
towards the light path upwards, and incu- . 
bated in this position at 37°c ·for 2 hours. 
After this pe~iod of incubation the fibrin 
clot formed was firmly adherent to the cu-
vette, which was then removed from the in-
cubator and placed in a thermostatically 
' 
0 controlled spectrophotometer at 37 C. 
(3) Kinetics of fibrinolysis by cholelysin were 
studied by pouring standard cholelysin s)lu-
tion, Peak I, tris buffer pH 8,5, into the 
vacant ~alf of the cuvette and following 
the reaction on a recorder for decrease of 
extinction at 335 nm. Aliquots could be 
subsamp~~d from the liquid (cholelysin) 
half of the composite cuvette at any time, 
and subsequently analysed by polyacrylamide 
gel electrophoresis (PAGE) (see 19 PAGE). 
9 EUGLOBULIN LYSIS TIME (Chakrabarti, Bielawice, Evans and 
Fearnley, 1968) 
Principle: plasminogen! plasminogen activator and most of the fibrinogen of plasma are precipitate~ by dilution with distilled water in the presence of co2 • The precipitate is reconstituted, clotted with thrombin, and incubated ·at 37°c 
until fibrinolysis occurs. 
Materials: Sodium citrate 3,8 g/100 ml 
CO2 
Method: 
Bovine thrombin 
Blood is collected without venous stasis by 
clean venepuncture and immediateiy mixed with 
10 FIBRIN PLATE 
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3,8% sodium citrate solution in a test tube 
standing in ice and water, the proportion of 
blood to anticoagulant being 4:1. The plas-. 
ma is separated in a refrigerated centrifuge 
at 3 000 rpm for 10 minutes. One ml plasma 
is added to 10,0 ml distilled water in a coni-
cal flask of 50 ml capacity standing in a bea-
ker of ice and water. Carbon dioxide is blown 
over the surface of the mixture for three minu-
tes by means of a Pasteur pipette connected by 
rubber tubing and valve to the delivery cyiin-
der. During this procedure, the flask is 
gently rotated to ensure full exposure of the 
mixture to the gas. 
The mixture is then transferred to a centri-
fuge to be c2ntrifuged at 4°c at 2 000 rpm 
for six minutes. The supernatant is discar-
ded and the inner surface of the tube dried 
with. no 1 WLatman filter paper. The euglo-
bulin precipitate is resuspended in 2,0 ml of 
saline phosphate buffer. The sus?ension is 
equally divided into two test tubes 5 in x; in 
and is clotted with 5 units (0,1 ml) thrombin 
in saline. The whole procedure is done in an 
ice water bath. After five minutes the tu~es 
are transferred to a water bath at 37°c and the 
time taken by the clot to dissolve completely 
is read as the lysis time. 
(1) Astrup (Astrup and Mullertz, 1952) 
(2) This study 
(3) Heated (T~omson, 1970) 
(1) Astrup 
Materials: Bovine fibrinogen prepared by ammonium 
Method: 
,, 
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sulphate precipitation from oxalated · 
bovine plasma. This preparation con-
tained 80-90% clottable protein in a 
0,6 g/100 ml solution. 
Thrombin - commercial 100 units/ml in 
NaCl 0,9% solution . 
Petri dishes - glass sterilised 
Buffer: sodium diethyl barbiturate 
M 0,067 pH 7,8 
Fibrinogen solution: 1 or 2 . mg/ml 
(usually 2 mg/ml). 
In each Petri dish 9,0 ml of diluted fi-
brinogen solution (pH: 7, 8 µ = 0, 15, f i- · 
brinogen concentration: 0,2 or 0,1%) is 
measure 1 from a buret. The Petri dishes 
are placed on a horizontal glass plate and 
clotted by means of 0,20 ml thrombin so-
lution. With a 0,1 ml pipet graduated in 
0,001 ml, exactly 0,030 ml of enzyme solu-
tion is placed as a small dro? on the sur-
face of the fibrin plate. Usually three 
single determinations are carried out on 
each plate. The area of digested fibrin 
is a quantitative measure of the enzym~ ac-
tivity; This is measured as follows: 
After incubation for 1&-20 hr at 37°c 
the product of two perpendicular diameters 
is recorded (in square millimeters) and 
the mean value of the three determinations 
are calculated. When especially accurate 
estimations are required, zones which are 
. 
not quite circular have to be disregarded. 
The areas are converted into concentrations 
by interpolation on a reference curve. 
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Note: An attempt was made to prepare bovine fibrino-
gen by this technique, using fresh oxalated 
bovine plasma from the Cape Town Municipal 
Abattoir. For reasons that could not be es-
tablished, these plates proved highly unstable, 
often showing spontineous -lysis within 24 hours -
of incubation at 37°c. Their use was there-
fore abandoned, and the method described be-
low was adopted instead. 
(2) This study 
Materials: Commercial human fibrinogen (Kabi) 90% 
clottable Calcium thrornbin solution: 
J . 
Method: 
Cacl 2 .2H2o 1,25 Min NaCl 0 ,9% solution, 
containing bo,· •.ne thrombin (Parke-Davis) 
1 unit/ml. 
Tri.s buffer M O, 2 pH 7, 8 
Petri dishes: plastic presterilised, 
disposable 10 cm diameter 
Plasmin (human): 0,1 un i t/ml in glycerol 
50% in tris buffer pH 8,5 M 0,006. 
(for making 10 plates) 
1 Make a fibrinogen Kabi solution 
0,2 g/100 ml by weighing out 0,52 g Kabi 
fibrinogen, and dissolve in 100 ml tris 
buffer. 
2 Pipette 10 ~l into each petri dish 
3 Add 0,2 ml thrombin solution to each 
petri dish 
4 Mix irn...~ediately by swirling 20 times 
evenly and gently 
5 Stand open at room temp~rature fer 2 
hours 
6 Incubate at 37°c for 2 hours 
Notes: 
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7 Store at 4°c until 30 minutes before 
use 
8 Stable for at least 4 days, usually 
5 days 
(i) Method 7 (Composite cuvette) refers to 
a 'clotting fibrinog~n solution'. _ This 
is the solution obtained after step 3 
above, which can _be handled further for · 
2 minutes befor~ clotting begins. 
(ii) The relatively high electrolyte concen-
tration of these plates meant some loss 
of sensitivity. However, they were very 
stable and reliable, and these qualitj~s 
were preferred to the highest degree of 
sensi~ivity. 
Test for fibrinolytic activity 
1 Plate out 0,02 ml of test solution or plas-
min standard on a standard fibrin plate. 
2 Incubate for 21 hours at 3~ 0 c in a wat~r-
saturated container. 
3 Read lysis diameter by ruler in two diame-
ters at right angles to each other; report 
in mm average diameter of zone of lysis. 
For very accurate estim~tions, discard all 
results not circular. 
4 Plasmin standard gave 12 + mm zone .of lysis 
under these conditons. 
{3) Heated fibrin plate 
Materials identical with (2), except that autoclaved 
glass Pet~i dishes (10 cm in diameter with perfectly 
flat bottom) were used. 
Method: Standard fibrin plate heated to so 0 c for 
for 45 minutes before use. This resulted 
in only slight loss of sensitivity. 
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11 FOLIN-LOWRY method of protein assay {Lowry, Rosebrough, 
Farr and Randall, 
1951) 
. ; 
Materials: 'Reagent C' - 50 ml of Na2co3 2 g/100 ml in NaOH 0,1 N + 1 ml Of Cuso4 0,5 g/100 ml in . 
potassium tartrate 1 g/100 ml. 
Method: 
I 
'Reagent E' - Folin-Ciocalteu reag8nt diluted 
with distilled water to 1 N. 
To 1 ml of test material add 5 ml of Reagent 
C. Stand at room temperature for 10 minutes. 
Add 0,5 ml of Reagent E. Shake vigorously 
with each additiGn. 
Between! and 2! hours after addition of Rea- · 
gent E, read exti1 .. .::tion at 7 50 nm. Crystal-
line ovalbumin preparation used as standard. 
12 FLASH FREEZING 
Materials: Dialysed cholelysin solution 
Liquid nitrogen 
Method: Specimens of cholelysin in solution were plun-
ged into liquid nitrogen in volumes of 10-20 
ml. Freezing was almost instantaneous. 
Thereafter, these specimens were freeze dried. 
13 FREEZE DRYING 
Materials: Flash frozen preparations of cholelysin. 
Freeze drying was carried out in a Virtis 
laboratory freeze dryer. Thereafter, speci-
mens were sealed in their plastic containers, 
0 and kept at 4 C. 
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14 INHIBITION 
(1) Direct mixing of test material with cholelysin 
( Chapter Seven) 
(2) Eluting of test material off filter paper following 
paper electrophoresis (Chapter Seven, Section 7.4.5). 
(1) Direct mixing of test material with cholelysin . 
. Control: the same cholelysin fraction used in 
that specific experiment, diluted 1/1 with tris 
buffer pH 8,5 M 0,006. 
Test: Control+ inhibitory substance in equal 
volumes, incubated together at room temperature 
for 20 minutes before test J.ng for f ibrinolysis. 
Both Control and test applied in 0,02 ml quanti-
~/ ties to a standard fibrin plate and incubated in 
the usual way. Results read as mm diameter of 
zone of lysis, and transformed into uuits of fi-
brinolytic activity, using the table of chymotryp-
sin equivalents in Chapter Three (Table 3-9). 
Calculation of inhibition % was done as follows: 
Control (units) - test (units) X 100 Control (units) F0rrnula. (A) 
Special instances: 
(i) a2 ·-macroglobulin possessed inherent fibrino-
lytic activity, which had to be allowed for. 
Formula (A) above was altered to allow for 
this: 
Control (units) - (test units - macroglobulin 
1 tic activity in units) X 100 Control (units) 
Formula (B) 
. . . . . . . 
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(ii) Soy bean trypsin inhibitor (SBTI). 
Incubation of cholelysin + STBI was carried 
out 
(~) 
(b) 
for 20 minutes 
for 24 hours 
Both mixtures were tested for fibrinolytic po-
tential on the standard fibrin plate. 
(iii) Aprotonin ('traylol') 
Ampoules containing 20 000 units/ml (Bayer) 
were available. Equal volumes of .aprotonin 
solution and cholelysin were mixed together, . 
giving a final concentration of aprotonin of 
10 000 units/ml. 
(2) Eluting of test material off filter paper following 
. paper electrophore~~s. 
Because the experimental details are highly relevant 
to the results, th ~s e Yperiment (with results) is describea in detail in Chapter Seven, section 7.4.5. Lower volumes of cholelysin solution were used than 
with standard fibrin plate assays, to ensure that 
the enzyme percolated through the filter paper, and did not reach the fibrin plate by spilling over the 
edges of the paper. Calculations of inhibition were performed by using_ Formula . (A), above. 
The method for assessing inhibition was as follows: 
(a) Test - Strips of paper containing fractions of 
serum after electrophoresis were laid on a fi-
brin plate, and 0,005 ml of chymotrypsin or cho-
lelysin solution applied directly to the strip . . 
(b) Control - Strips of identical filter paper, un-
used; were laid on a fibrin plate, and 0,005 ml 
of cholelysin solution applied directly to the 
strip. 
The paper strip was lifted off the fibrin plate before 
reading the result. 
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15 MOLECULAR WEIGHTS 
(1) by Kav 
(2) by PAGE 
(Laurent and Killander, 1964) 
(Weber and Osborn, 1969; Stead, 1981) 
(1) (a) Estimation of molecular weights from molecular 
exclusion data. 
I 
The theory of Laurent and Killander was applied 
to certain gel exclusion data to provide an es- . 
timate of relative molecular weights. The 
Laurent-Killander treatment is based on a para-
meter (K ) which represents the eluted volume av 
of a solute (Ve) relative to the void volume of 
the column (Vo) and total Cl'lumn volume (Vt). 
This is in effect .:-quivalent to the 'Rf' . en-
countered in other forms of chromatosraphy, 
and is calculated as follows: 
Ve - Vo 
Vt - Vo 
Laurent and Killander describe a relationship 
between .K and the Stokes' radius of spherical av 
molecules: 
/- In K = a (B + rs) av 
where rs= Stokes' radius of ·spherical molecule 
a= Constant made up from concentration 
of macromolecule rods constitution 
the supporting network 
a= Constant made up from the radius of 
the macromolecule rods 
Since for most proteins Bis small compared to 
rs, a plot of!= In Kav against rs will be 
linear. The · slope of the plot should be de-
pendent on gel concentration. Experimental 
confirmation of the linearity of the plot and 
the dependence of slope on gel concentration is 
found in the unpublished data of Sims, Bussey 
and Folkes (571 using agarose gel. 
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Since for a perfectly spherical molecule, 
MW = 4/31rr 3 p, where r = molecular radius 
p = density of molecule, 
then r o::_ 3/ MW, 
and since r is closely related to the Stokes' 
radius rs, 
rs a: 3/ MW, and .,;=- In K a: 3/ MW av 
Thus the linear relationship also holds between 
I- In Kav and V MW. -This provides a useful 
means of relating the elution properties of~ 
solute to its approximate molecular weight. 
GeT exclusion columns are normally calibrate,J 
by running standards of known molecular weight. 
However, in ~his study use was made of a graph 
provided by the manufacturers of sephadex, from 
which values of K could be directlv converted av 
-into molecu lar weights for sephadex GSO, G75, 
and G100. 
(b} Estimation of void volume (Vo} ~nd total vol'..lllle 
(Vt} of gel column. 
A dyed dextran preparation known as Blue Dex-
tran 2 000 _(Pharmacia, Uppsala, Sweden} was 
used for determination of void volume. The 
preparation consists of random polymers cove-
ring a wide range of molecular weights~ acer-
tain proportion of which are fully excluded by 
the column. These are used to estimate the 
elution volume of a totally-excluded solute. 
Five milligrams of ~Blue Dextran, dissolved in 
phosphate buffer for several hours, was applied 
to the column in 0,1 ml volume. The concen-
tration of dextran in the effluent was estima-
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ted spectrophotometrically at 260 mµ. 
; The total column volume was calculated f:rom 
the dimensions of the column. 
(2) The separation of proteins by PAGE in the presence of . 
I 
SDS is dependent on the molecular weights of their 
polypeptide chains (Weber· and Osborn, 1969). Using 
the . buffer system of O'Farrell (1975), a gradi~nt of 
-
polyacrylamide from 2 tot 41% was established, and 
proteins run as described in Method 18. Proteins 
reached .a position in the gel proportional to their 
molecular weight, when estimated by their mobility re-lative to the total length of the gel. The total 
length of the gel was measured, an<i the length tra-
velled from the top of th~ gel by each protein band 
under study, was calculated as the simple ratio: 
1 t . b'l't _ distance travelled by band re a ive mo 1 1 Y - total length of gel 
Using proteins of known molecular weight as markers 
in separate tubes in the same experiment, a graph 
was constructed from which the molecular weights of 
unknown proteins could be directly estimated (Stead, 
. 1981). 
16 SODIUM CHLORIDE GRADIENT and batchwise elution carried 
out by the methods of Petersen and Sober (1962). 
17 NEUTRAL SUGAR (Dubois, Gilles, Hamilton, Rebers and 
Smith , 1 9 5 6 ) 
Materials: redistilled phenol 
concentrated H2so4 
~-
Method: 
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To 1 ml of column effluent was added 0,5 ml 
of 5% (w/v) redistilled phenol and 2,5 ml of 
concentrated H2so4 . Cont~nts of the tubes 
were thoroughly mixed and. allowed to stand 
for 10 minutes. They were shaken and placed 
in a water bath at 25 ~ -30° for 10 - 20 minu-· 
tes. Thereupon the extinction was read im-
mediately in the Spectronic 20 spectro-
colorimeter at 490 mµ. 
18 PAGE (polyacrylamide gel electrophoresis) (O'Farrell, . 1975) 
Materii;ils: 
I 
Running tris buffer: Tris HCl M 1,5, pH 8,8 
and 0,4% SDS; ~lectrode buffer: Tris M ,025, 
glycine M 0,192, 0,1 SDS; 65~ acrylamide 
stock: 64,2% ac!.ylamide and 0,8% bisacryla-
mide in distilled water; 2,7% acrylamide: 
dilutLon of 65% stock in distilled water; 
sample application buffer: 0,1% SDS, Tris 
M ,002, 0.1% mercaptoethanol; reduction buf-
fer: 4% SDS, EDTA M 0,1, Tris HCl M 0,04, 
pH 8,8, 2% mercaptoethanol. 
For analysis of fibrin split products, final 
concentrations of reducing substances were: 
SDS 2 g/100 ml, mercaptoethanol 2 g/100 ml and 
urea M 6. 
Samples were prepared as follows: 
cholelysin - the most concentrated available 
preparation was applied to the gel to a total 
load of 0,010 - 0,020 mg of proteiri. 
fibrin split products -
(1) The lysed fibrin solution was aspirated 
from the standard fibrin plate after 24 
hours of incubation at 37°c with either 
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'plasmin or cholelysin, and applied to 
the gel as above. 
(2) Aliquots were aspirated from the liquid 
(fibrinolysin) side of the composite cu-
vette (see Method 7 above) at the stated 
times - usually 2, 10, 30 and 180 minutes 
and applied as above- to PAGE. Either 
plasmin or cholely~in split products were 
studied in this way. 
Fibrinolysis was quenched by the addition of an 
equal aliquot of soy bean trypsin inhibitor 
0,2 g/100 ml. 
Chol~l ysin solution usually 60+ u/l 
Plasmin solution usually 0,2 u/ml 
Molecular markers used were ribonuclease, 
chymotrypsinogen and lactate dehydrogenase. 
The solutirn·.s ,,·er e mixed in the following man-
r.er to make 1 volume of running gel: 0, 25 
volume of running gel buffer; 0,75 volume of 
acrylamide stock (65% or 2,7%?; 0,0033 volume 
of 10% ammonium persulphate. The mixtures 
were degassed, 0,0005 volume of TEMED was added, 
and 8,4 ml of the 2% mixture was added to the 
mixing chamber of the gradient former. This 
volume was half the filled volume of the seven 
electrophoresis tubes in each run, multiplied 
by a factor 1,176 to allow for the fact that 
gradient formation (theoretically from 2% to 
48,75%) was stopped after removal of 0,85 
volume. This ensured efficient mixing through-
out formation of the gradient, and gave a final 
concentration range of 2,1 to 41%. An 8-
channel peristaltic pump was used for gradient 
formation; seven channels removed the mixture 
. / 
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to the electrophoresis tubes, while the 
8th channel pu~ped the heavy (48,75%) so-
lution into the mixing chamber at half the 
total rate at which it was removed to the 
tubes. 
The gradient was pumped through a capillary 
tube to the bottom of the electrophoresis 
tube, and the initial low concentration was 
displaced upwards by the increasing density 
of the mixture. The upper gel surface was 
covered by a layer of distilled water and 
the mixture allowed to polymerise overnight. 
Samples (prepared as described below) were 
applied in sample a pplication buffer: gly-
cerol (1 :1) or reduction buffer: glyceroJ 
(1:1), and electrophoresis was run at a cun- · 
stant current of 2 mA ( 9V) per tube for 5 
hours. 
Gels were stained in 0,1% Coomassie Blue in 
50% TCA for 20 minutes, and destained in 7% 
acetiL! acid. 
Relative mobilities were determined (Stead, 
1969, 1981) and molecular weights read from 
the graph provided by the molecular markers. 
19 PAPER ELECTROPHORESIS 
Principle: separation of plasma proteins on basis of 
charge. Used when relatively large-scale separation of 
plasma proteins is required. 
Materials: Whatman No 1 filter paper 5 cm wide 
Barbitone buffer M 0,083 pH 8,6 
Serum 
Arnidoschwarz stain 
' ·----- .. ---------·---- .... ------~- __ .... -·-'- - --- -·-..: ~ 
Method: 
/ 
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Glacial acetic acid 
Methanol 
Bromphenol crystals 
Serum applied to separate- strips 
(1) 0,010 ml (staining) 
(2) 0,200 ml (test) 
Electrophoresis carried out at 4°c, with 
barbitone buffer, at 140 volts, 4-6 mA, run 
for 19 hours. Staining with amidoschwarz 1% 
in glacial acetic acid 10% and methanol 90%. 
Full experimental details given in the main 
text, Chapter Seven section 7.4.5. 
20 PRECIPITATION with drugs capable of causing cholestatic 
jaundice in man (Clarke, Martiz and Denborough, 1972). 
Principle: Chlorpromazine and other tranquillizers cause 
precipitation of the protein and glycoprotein components 
of bile in vitro; this results from inter1ction betwcer. 
tha carboxyl groups of the protein and glycoprotein moieties, 
and the positively charged amine groups on the drug mole-
cu:i..es. 
Materials: rhe authors listed chlorpr0mazine, promazine, 
trifluperazine, amitryptilene and iprindole. 
The first four of these drugs were ob~ained 
from the manufacturers in pure form. They 
were mixed with 'Fraction G200' cholelysin 
to . final ccncentrations that had been found 
by the authors to . cause maximal precipitation 
of proteins and glycoproteins, as the follo-
wing Table shows: 
• 
I 
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Drug 
Chlorpromazine 
Pro-.naz ine 
Trifluperazine 
Amitryptiline 
:,; 
Molecular 
weight 
318,9 
320,9 
480,4 
313, 9· 
Final concentrations 
(mM) 
Proteins Glycoproteins 
10 30 
5 30 
3 10 
10 ineffective 
Following incubation of mixture fer 30 minutes 
at room temperature, the specimens w~re centri-
fuged at 12 000 X G for 20 minutes. Superna- · 
tants were pipetted off, and the precipitates 
.redisso~ved in tris buffer M 0,006 pH 8,5, to 
the original volume. 
Aliquots of cholelysin preparction diluted with 
buffer, and of rE~lssolved 
tested for fibrinolysis. 
in Appendix 5. 
precipitate, were 
Results are repored 
21 PRECIPITATION WITH POLYETHYLENE GLYCOL 
Materials: 
Method: 
polyethylene glycol in tris buffer pH 8,5 
cholelysin 'fraction G200'. 
Aliquots of polyethylene glycol and cholely-
sin solution were mixed in varying final con-
centrations of polyethylene glycol and incu-
bated for 30 minutes at room temperature. 
The mixtures were then centrifuged at 12 000 X 
G for 20 minutes, and supernatants pipetted off. 
Precipitates were redissolved in tris buffer 
pH 8,5 M 0,006 to the original volume, and 
both supernatants and redissolved precipitates 
tested for fibrinolysis. Results are shown in 
Appendix 5 . 
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22 RAT MODEL (Chan, 1969, 1970) 
Principle: Formation of clot in relation to a poly-
ethyle~e tube chronically implanted in the carotid ar-
tery of the rat. 
Treatment with cholelysi.n used in an attempt to diminish 
the rate of clot formation. 
Materials: 
Basi•; 
method: 
Wistar rats 200-250 g 
Ether 
Polyethylene tubing external diameter 0,965 rcun 
(PE so, Clay-Adams) 
Heparin 
Cholelysin Peak I 
Rats were a.1aesthetised with ether. The 
neck was shaved and the left carotid artery 
isolated through a midlirie incision· down the 
front of tllP. neck. A 10-15 mm segment of the 
a~tery was temporarily occluded between two 
"bulldog" clamps and a small txannverse cut 
made into the wall of the occluded segment. 
1l'he opened segment was then flushed clean of 
blood with heparin-saline (100 u/ml). Under 
a dissecting microscope, a 3-4 mm length of 
p~lyethylene tubing with an outer diameter of 
0,965 mm and an internal diameter of 0,58 !rut\ 
(PE SO, Clay Adams) was inserted into the lu-
men of proximal portion of the artery. The 
inserted tube was filled with heparin-saline 
and advancee into th~ lumen of the distal por-
tion of the artery, across the cut in the ves-
sel wall and then secured on both sides of the 
arterial opening by cotton ties. When the 
occluding arterial clamps were released, normal 
blood flow was immediately established and nor-
-----~-~-----
- -- - - ~- ---- - ---- --------~----
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mal pulsations of the artery before and be-
yond the polyetnylene tube was observed. The 
time taken from the occlusion of the artery to 
release of the cramps after insertion of the 
tube, varied from 6-10 minutes. The wound was 
then closed and the animal had an uneventful re-
covery from anaes~hetic, and remained healthy 
in the postoperative period. 
Study of the progress of thrombus formation was 
by sacrifice of the animals at various inter-
vals after the operation. The operated rats 
were put under anaesthetic, anticoagulated with 
100 u of heparin intravenously, _the wound re-
opened and the artery inspected carefully in situ. 
Patency of the blood vessel was assessed by the 
presence or absence of pulsatile flow and state 
of filling of the distal portion. ·Any throm..: 
bus · visible through the vessel wall was noted. 
The artery was then removed in toto in its 
course in the neck and immedi2 ·;:-.ely opened 
longitudinally. The type of thrombus present 
was recorded. 
Cholelysin anticoagulant test: 
The jugular vein was cannuiated with PE 50 
Clay~Adams polyethylene tube filled with 
heparin saline 100 unit/ml. Infusion of cho-
lelysin solution 364-482 units/£ was commenced, 
at a rate of 1 ml/hour with a slow infusion 
pump. Control animals were infused with 
. 
sodium chloride 0, -45 g/100 ml in glucose 
5 -g/100 ml, at the rate of 1 ml/hour. After 
the infusion had commenced, the basic method 
as outlined above was proceeded with. At the 
; 
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end of the arterial implantation, the anaes-
thetic was continued for a further - 2 hours 
while the infusion of cholelysin or glucose/ 
saline continued to total 3 ml. After that 
period of time, the anaesthetic and the infu-
sion were discontinued, an¢i the animal allowed 
to recover. It was killed either immediately 
{'2 hour' value) or at the stated periods, when 
the neck was opened and the state of the caro-
tid artery recorded. 
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acetic · acid+ 
acetone+ 
MATERIALS . 
ATEE - Mi.les Seravac Cape Town 
acrylamide - Merck 
ADP - Sigma Corp St Louis USA 
A. G.l.X8 200-400 mes11 chloride form - l3ior'ad Laboratories 
albumen (human) - Western Province Blood Trarist'usion Service Cape Town 
I( -casein - Worthington Biochc!!lical Corporation New York USA 
'( -chymotryp3in - Miles .Serava.c Cape Town 
41<2-macroglobulin - Natal Blood Transfusion Service Durban Natal 
amitryptil~ne powder -Frosst MSD Halfway House Transvaal 
amidoschwarz -Merck 
amn::.on-iU!Il. sulpbate + 
. + 
ammonium. persulphate 
aprotonin - Eayor Ge~any 
l3A'ET.! - Miles Seravac ~ap1 Town 
bile -Human· Dept Surgery Groote Schuur Hospital Cape Town 
ox,pi6 ,gcat, sheep: MunicL,_al Abattoir Cape Town 
other! Research Laboratories ,Medical School, University of Cape Town 
bilirubin - Tauber & Corsaen Cape To~n 
bisacryla.n.ide - Merck 
blue dextran 2000 - 'Pharmacia Uppsala Sweden 
brcmphenol crystals - ~erck 
calcium chloride+ 
rhymotrypsinogen - :Miles Seravac Cape Town 
~hlorpL~mazine powde:r:- - ¥.aybaker Port Elizabeth 
collagen - Sig;na Corp St Louis USA 
Coomassia brilliant blue R250 - l'lierck 
copper s•.1lph=ite+ 
~ dialysis tubing - Arthur H. Thoffias 
·, EDTA - :titerck 
epinephrine - Dispensing chemist stock 
ether+ 
· fibrinogen (humen) - Kabi Stockholm 
Folin-Ciocalteu phenol reagent Merck 
glyci:,e - Merck 
glycerol.+ 
heparin- · DADE Laboratories 
hydrochloric acidT 
NOTE: + after a chemical= Analar grade 
-- -
' ., 
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lactate dehydrogenase- Miles Seravac 
liquid nitrogen - A:frox 
mercaptoetnanol - Merck 
ovalbumin - Miles Seravac Cape Town 
petri dishes - . polyethylene and gless - Labore.tory & Scientific Cape Town 
porchloric acid+ . 
phenol+ 
plasmin ) .American National Red Cross Washington DC USA plasminogen) 
})latelin + activator - G:eneraL Diagnostic:3 New Jers-ey USA 
polyethylene glycol - Bri ~ish Drug Houses 
polyethylene tubing PE 50 - Clay Adams USA 
potassium sodium tart~ate+ 
potassium 
potass:j..um 
potassium 
potassium 
tartrate + 
iodide+ 
phosphate+ 
+ oxal!:l.te 
promazine powder - Wyet'1 Ll'llioratorles Isando Transv:i.al 
ribonucle ase - Miles Seravac Cape Town 
sepbadex G5C G75 GlOO G200 A50 - J':1arruacia Upr,sala Sweden 
-sodium carbonate+ 
sodium. chloride+ 
sodium citrate+ 
sodium diethyl. barbi tura~e + 
sodium dodecyl sulphatr_, ·- Serva Feinbioehemica Heidelberg West Germany 
sodium hydroxide+ 
sodiU1.1 glycocholatc - Difeo Laboratory 
. + 
sodium phosphate 
sodium taurocholate 
soybean trypsin inhibitor - Miles Seravac Cape '.i'own 
sucrose P.NAse free- Miles Seravac Cape Town 
sulfuric acid+ 
TEMED (N N N I N' tetramethylcnediamine) - Merck 
thrombin · Hyl <1nds L~boratcry 
tricalcium phosphate+ 
trifluperazine powder - Smith Klin French Laboratories Isando Transvaal 
... tris ·. !_ tris (hydroxy methyl bminomethane - Tauber & Corssen 
trypsi:i ) I' . - 0 C T trypsinogen) 1111.es .:Jeravac ape ovm 
vereatol - General Diagnostics New Jerse~ 
urea - Merck 
Whatman DE 32 - Hicbna".l & Kleber 
Whatman :filter paper- Hickman & Kleber 
Wistar rats-UCT Medical School Animal House 
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•. ~ Tabl.e 3-3A PLASMIN AJ3SAY 
Stability of fibrin plate after various periods of atcrage at 4°c. Stsndard plasmin used throughout, O,l. U/ml. All results in mm diameter of zone of lysis. 
Day 
Year 0 l 2 3 4 14 mean 13 me·an 12 mean 14 meen 12 me an l.970 15 13 14 · 15 l.2 l.4 14,3 13 13,0 12 12,7 14 14,3 12 12,0 
l.3 13 12 13 12 1972 1.2 14 14 1.3 13 
.1.5 13,3 -14 13, 7 15 13, 7 12 12,7 12 }-2,3 
14 14 ·12 13 14 l.974 l!, 15 12 12 12 l3 13 13 14 13 14 13,5 13 13,8 12, 3 13 13,0 14 13,3 
'. 
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;,; 
Table 3-5A 
Dose-response curve of chvleJ.ysin. Five pre parati ona of Peak I studi0d in doubling dilutibns . Results in mm diameter of zone of lysis. 
PreEaration Nol 
Dilution Repetitive assays · .Mean X SEM 
l/l 36 39 36 37 38 37,2 l,3 0,58 
1/2 32 34 33 34 32 33 l,O 1,0 
- .1/4 27 .30 30 29 28 28,8 l,3 0,58 l/8 25 22 24 24 23 23, 6 1,1 0,51 1/16 20 21 19 18 18 19,2 1,3 0,58 
Preparation No 2 
l/l 36 36 33 35 1,7 1,0 l/2 32 31 31 31,3 
l/4 26 27 26 ?.6,3 
1/8 21 21 21 21 
l/16 18 16 l.6 16,7 · 1, 2 0,7 l'rc pare.ti on ro 3 
1/:l 30 ·28 27 29 28,5 . 1,3 0~5 1/2 21 22 21 24 22 1,4 0,7 l/4 17 16 16 16 l.6, 3 
1/8 10 9 8 9 
JreEaration no 4 
1/1 27 25 25 2·'t 25, 25 1,2 o,6 
l/2 20 18 17 21 19 1.' 8 0,9 1/4 15 14 14 13 14 o,8 0,4 1/8 10 9 9 9,3 
~aration no 5 
1/1 . 22 19 21 20 . 20,5 1,3 o,6 
1/2 15 15 15 l.5 
1/4 J 10 9 i2 10 1,4 0,7 l/8 6 6 6 5 5, 75 
- -- - ... -- ·-- ..., ____ 
- - - - - - ---- -
.. 
·-· -
• 
-I 
• ,;111 
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Precipitation with various agents 
Acetone. The addition of aceto:1e at o0 c in various concentrat.iona 
to cholelysin led to precipitation of fibrinolytic activity. When 
equal quantities were mixed, the resultant precipitate contained all 
fibrinolytic activity when redissolved, but lost all activity 
within 30 minutes. The method was not pursued furthec. 
-Chloroform/methanol partition. Ttts method (see Methods) led to 
the partition of a tarry black liquid at tre interface between 
tre two solvents. Fibrinolytic activity was present in this 
black liquid, and could be recovered by redissolving in tris 
bufrer. It could be subjected to exclusion chro~atography, 
but was found to lose activi ty thereafter (in two experiments). 
The succes~ful development of a.."!Illonium sulphate precipitation 
cau~ed this method to be abandoned. 
Polyethylene glycol precipitation. (PEG) 
Expe : ·.LmentaJ.. design: 10ml of cholelysin solution, in . tris buffer 
M 0,006 pH 8,5. precipitat~ d by polye+.hylene glycol solutions 10ml 
of varying strength to final concentrations as shown. The mixture 
was stood for 30 minutes at room temperature, and then centrifuged 
at 4°c, 12 000 X G, for 20 iY:J inutes. Precipitate~ were redissolved 
in tris buffer to ·0,5ml, au.d both supernatant and precipitate were 
tested for fibrinolytic activity in the usual way. 
Results: 
PEG% Control Supernatants Precipitates 
1 2 units/1 l 2 units/1 
2 · 27, 28, 26 . 26,5 49 16,5 16,5 15,0 
29,28 
Mean 28 
= 62 uL1 
5 26 26 48,5 16,5 16, 5 15,0 
10 25,5 27 49 16 16, 5 14,5 
15 25 24,5 41 17 17 16,0 
20 25,5 24,5 42, 9 18,5 17, 5 18,2 
25 25 25,5 43, 5 19 19,5 20, 9 
30 24 24 37, 9 20;5 21 25,l 
35 24 23, 5 36, 2 22 22 29,7 
Comment: this poor separation was t,epe ated several times, and 
this technique was then abandoned. 
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· ... ~ 1..w thiazine s 
..In ew of the repr;rt by Clarke Mari tz and Den borough (1972) 
chlorpromazine and other tranquillizers cause a precipitation 
_ ~ _-.tl'te protein and glycoprotein components of bile in vitro, -
• ar t hese drugs in clinical use were studied for their effect on 
~lysin in vitro. These were: chlorpromazine 
promazine 
trifluperazine 
ami tryptilene 
.u. cases, the local agehts kindly procured the pure compound in-po,tder form, and this was dissolved in tris buffer to the 
concentrations found to. be optimal for precipitation by the 
author s. These optimal concentrati~ns were: 
chlorpromazine 
'l)TC)mazine 
trif1.uperazine 
ami tryptilene 
protein 
10 
5 
3 
10 
glycoprotein 
30 
30 
10 
0 
T.estE using these drugs in the concentrations given faile, to precipitate cholel ysin to more than a ve r y sl.lght degree ( f 10%) 
and the experiments were then abandoned. 
·· . . 
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Table 6-lA 
Attempt to activata trypsinogen, chym9trypsinogen and plasminogen with cholelysin, tr:. psin, chymotrypsin and plasmin, respectively. Results in mm diameter of zone of lysis. Cholelysin on 
substrate. 
None 
Trypsingeon 
Chymo-
trypsinogen 
Plasmino,gen 
Trypsin on 
su-hstr3.te 
None 
Try-psii >g&,1 
ChymotrYPsrn 
en subst-:..--.. te 
None 
Chymo-
trypsinogen 
Plasmin on 
substrc1te 
none 
Flasminogen 
Repetitiva assays 
11 12 14 12 
10 
11 
15 
14 
26 
14 
2l 
12 
2J. 
11 
12 
12 
15 
21 
16 
23 
13 
21 
12 
10 
13 
16 
24 
15 
23 
12 
21 
12 
12 
12 
16 
24 
13 
22 
12 
•. 
12 
13 
10 
13 
23 
14 
22 
12 
Mean 
12,2 
ll,6 
· 11,0 
1.3 . 
14,8 
23, 6 
14,4 
22,2 
12,2 
'21, (/ 
I~ - 221-
Appendix 7 
Table 7-lA 
Inhibitory efI·ect of human serum on lytic action of cholelysin. Control measured in 1/1 dilution in tris buffer M 0,006. Test serum introduced in place of tris buffer, and lytic effect measured. Inhibition calculate·d from the fonnula: 
~l tests in .duplicate. 
Serum 
No 
Control 
1 · 
2 
3. 
% Inhibition= Control (units) - test (units) X 100 Control (units) 
Dilution Lytic activity(uu.n) Mean· 
1/1 
l/20 
1/40 
l/8o 
l/100 
1/J.60 
j,,/320 
22, 
7 
15 
17 . 
19 
21 
22 
l/20 6 
l/40 12 
1/80 17 
l/100 21 
22, 
l/l60 ~ not done 
l/320 ~ 
l/20 0 
l/40 10 
l/80 
l/100 20 
l/160 20 
l/320 22 
l./20 7 
l/40 14 
1/Bo 13 
l/l.60 21 
l/320 22 
21, 
8 
l.6 
19 
19 
22 
22 
(2) 
l.l. 
l. 7 
21 
0 
13 
15 
17 
20 
22 
8 
11 
11 
23 
23 
22 21.,75 
7,5 
15, 5 
l.8 
19 
21,5 
22 
4 
ll,5 
17 
21 
0 
11,5 
15 
18,5 
20 
22 
7,5 
12,5 
12 
22 
2.2, 5 
•. 
Unite 
~ 
5,0 
13,4 
18,2 
20,5 
27,6 
29, 7 
3,2 
8,2 
16,0 
26,3 
0 
8,2 
12,6 
19,3 
23, 2 
29,7 
5,0 
9,1 
8,7 
29, 7 
31,7 
Inhibition% 
83 
54 
37 
30 
5 
0 
89 
72 
45 
10 
100 
72 
57 
34 
20 
0 
83 
69 
70 
0 
0 
,--_ 22 2 -
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Appendix 7 
Serum Dilution Lytic acti vi ty(mm) Mean Units Inhibition% 
No 
5 l/20 0 0 0 0 100 
l/40 13 16 14,5 11,8 59 
1/80 19 20 19,5 21,8 25 
.:(/ .. ;J/100 19 19 19 20,5 30 
l/160 19 19 20,5 30 
l/320 20 21 20,5 24,7 15 
-. 
6 l/20 0 o. 0 0 100 
l/40 5 ·5 5 3,7 87 
l/Bo 16 17 16,5 15,1 48 
l/100 17 18 17,5 .17,1 41 
l/160 18 20 19 20,5 30 
l/320 2:2 21 21,5 · 27,6 5 
7 l/20 0 0 0 0 100 
l/40 10 9 9,5 6,4 78 
l/80 17 15 16 14,2 51 
- / 
· 1/100 19 16 17·,5 17,1 41. 
l/160 19 20 19,5 21,8 25 
l/320 20 21 20,5 24,7 15 
Ne \' ? cor.-':rol 
l/1 21,2~,22,19,21,21,20,21.,21,21 Mean 20, 9 Uni ts 25,7 
8 l/20 0 0 0 0 100 
l/40 8 8 8 5,3 79 
l/Bo 18 17 17,5 17,l 33 
:·· .l/100 18 19 18,5 19,3 2c:; 
l/160 18 21 19,5 21,a 15 
l/320 19 21 20 23. 2 . 9 
9 l/20 0 0 0 0 100 
1/40 4 7 5,5 3,9 85 
l/80 10 12 11,0 7,7 70 
l/100 15 .16 15,5 13,4 48 
l/160 18 18 18 18,2 29 
l/320 20 19 19,5 21,8 15 
~ .., control 21,21,21,22 Mean 21,) Units 27,2 
10 l/20 6 0 3 2,8 90 
l/40 12 11 11,5 8,2 70 
.l/80 18 18 18 18,2 33 
1/100 20 21 20,5 24,7 9 
l/160 21 21 21 26,3 3 
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Tab.le 7-2A 
Inhibitory e:fi'ect of human serum heated to 56°0 for 30 minutes on fibrinolytic effect of cholelysin. Experimental design and calculations as in Tab.le 7-lA. Sera are from Table 7-lA, and are :1umbered from that Table. 
Serum Dilution Lytic acti vi ty(mm) Meen Units Inhibition% No 
Coni;rol 1/l. 22,22,21,22 2l., 75 ~ 
3 1/20 0 0 0 0 100 
· )/40 12 ll ll,5 8,2 72 1/80 18 20 19 20,5 30 1/100 20 2l. 20,5 24,7 15 1/160 2l 22 21,5 27,6 5 Control 1/1 21,22,22,19,21,21,20,21,21,21 Mean 20,9 Units 25, 7 9 . 1/20 ·7 8 7,5 5,0 80 1/40 13 9 ll 7,7 70 . :./80 17 17 17 16,0 38 / 1/100 17 l'{ 17 16,0 38 1/160 17 19 18 18,2 29 1/320 19 19 19 20,5 20 . Control 1/1 21, 21, 22", 21 ~l,3 21,2 
10 ·1120 v 0 0 0 100 l/40 8 7 7,5 5,0 82 1/80 10 10 10 7,7 72 1/100 12 14 13 9,8 64 1/160 20 21 20,5 24, 7 9 
'. 
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Inhibitory effects of platelet rich plasma (PRP), platelet poor plasma (PPP) 
E.Ild of serum derived from the same plasma, on the fibrinolytic action 
of cholelysin. 
Experimental design: blood was taken into -sodium citrate solution 3,lg/lOOml 
in the proporti on of 9 parts of blood to 1 part of sodium citrate solution. 
This was centrifuged at 900 X G for 3 minutes. The platelet rich supernatant 
was harvested, and the blood remaining was centrifuged at 12 000 X G for 
20 minutes to give PPP. An ru.iquot of fresh blood from the same donor 
was placed separately into a glass test tube and incubated in a waterbath 
at 37°0 for 2 hours, after which it was centrifuged and the serum removed. 
The PRP had a platelet count of 500 X 109/1. 
Inhibition was then tested as ·set out in sections 7.3, 7.4.1 and 7.4.2 in 
the main text.- Results are shown below, in mm diam zone of lysis and units. 
Dilution 
sample 
Control 
1/10 
1/20 
1/40 
1/100 
1/J.O 
1/20 
1/40 
1/100 
1/10 
1/20 
1/40 
1/100 
of Serum me an uni ts Inhibition 
14 15 14 
0 0 
10 10 
13 13 
13 13,5 
PRP 
0 0 
10 10 
13 13 
14 14 
PPP 
0 0 
10 9 
14 14 
15 14 
14,3 
0 
10 
13 
13,3 
0 
10 
13 
14 
(serum) 
11,5 
0 100 
6,8 41 
9,8 15 
10,5 9 
0 100 
6,8 41 
9,8 15 
11,1 0 
0 0 100 
9,5 6,4 44 
14 11,1 0 
14,5 11,8 0 
Inhitition Inhibition (PRP) (PPP) 
100 100 
41 44 
15 0 
0 0 
U
"\ 
N
 
N
 ' 
r-. 
T
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In
h
ibitory ef1
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t 
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an 
se
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·J 
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of' 
cholelysin. 
w
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). 
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se
ru
m
 
v
olum
e (µl) 
+
 
cholelysin 
In
 the 
te
s
t, 
v
ol.incubation m
ixture 
m
a.de 
up to
 1,2m
l 
w
ith tris buffer. 
C
holelysin v
olum
e
_
 
w
as 0,2m
l. 
Thus 
u
n
its 
of 
a
c
tivity/m
l 
w
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: 
%
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h
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c
alculated 
a
s
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 T
able 7-lA
. 
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re
vised A
TEE-eatera.ae 
a
s
s
ay 
v
olum
e (µl) 
=
 
v
ol.incubation 
m
ixture. 
1
,0
 X
 
In
itia
l 
r
ate 
=
 I.R
. 
X
 500 
0
,2
 
"
"
1 
INCUBATION M
IXTURE 
ATEE ESTERASE ACTIVITY 
Se
'ru
m
 
d
ilu
tio
n
 
v
olum
e 
(µl) 
l 
20 
50 
100 
500 ~ 
500 
500 
500 
100 
100 
100 
100 
100 
100 
20 
·20 
50 
50 
20 
20 
20 
20 
200 
200 
200 
200 
200 
200 
200 
200 
50 
~o 
11)0 
100 
200 
200 
50 
50 
200 
200 
100 
100 
200 
200 
C
holelysin 
v
olum
e (µl) 
R
atio 
cholelysin 
se
ru
m
 
Incubation 
V
olum
e 
tim
e 
a
t 
22° im
,c
ubation 
(m
inutes) 
m
ixture 
200 
200 
2~0 
(CHOLELYSIN CONTROLS) 
200 
·
 100 
-
100 
200 
In
itia
l 
U
uits 
~ In
h
ibition 
r
a
te
 
a
c
tiv
ity
 
0,0832 
0,0816 
0,0441 
0 0 
per m
l 
41,60 
40,80 
M
ean 
(X 2) 44,10 
~4?~Z 
(SERUM CONTROLS) 
200 
200 
200 
.
.
 0
.
 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
500 
500 
500 
400 
400 
·
.200 
200 
100 
100 
Bo 
80 
50 
50 
40 
4-0 
20 
20 
5 I 
9 I 
2 I 
2
' 
6• 
2
' 
6 I 
5' 
1
0
' 
2
' 
5' 
3 ' 
10
1 
2
' 
2 ,,
 
2 •
·
·
 
5' 
.200 
400 
400 
400 
250 
250 
300 
300 
4
-00 
400 
250 
250 
400 
400 
300 
300 
400 
400 
0 0 0,0810 
0,0840 
0,0802 
0,0771 
0,0728 
0,0675 
0,0628 
0,0451 
0,0444 
0,0351 
0,0368 
0,0168 
0,018
.L 
0,0058 
0,0048 
0,0003 
0,0002 
40,50 
42,00 
M
ean 
40,10 
40,9 
3
,l 
38, 55 
36,40 
37,5 
ll,l 
33, 75 
31,40 
32,6 
22,7 
22,55 
22,20 
22,4 
46,9 
17, 75 
18,38 
1
8
,1
 
5
7
,l 
8, 4 2 
9,05 
8,7 
79,4 
2,90 
2,40 
2
,7
 
93,6 
0,15 
0,10 
0,1 
100,0 
Com
m
ent: 
V
arious periods 
of incubation from
~
·
.
 to
 1
0
' 
~
ade 
n
o
 difference 
to
 I.R
. 
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Table 7-7A .... .-~ .. } 
Inhibitory ef:rect of serum of rat, rabbit, guinea pig and ~uouse on ox Ci'lolelysin, Peak: I. Experimental design identical to that set out in sections 7.3, 7.4.1 and 7.4.2 of main text above. 
Dilution 
Control J3 
RAT:~· 1/1 o 
1/2 0 
1/4 15 
1/10 27 
1/1r,o 36 
RABBIT · 
· l/1 0 
1/2 0 I 
1/4 21 
1/10 28 
1/100 29 
1/1000 3J 
Control 
GUINEA PIG 
l/1 
l/2 
1/4 
l/10 
l/100 
MOUSE 
1/1 
l/2 
l/4 
l/10 
1/100 
32 
0 
0 
0 
22,5 
30 
0 
0 
5 
24 
30 
Lytic activity 
(mm diameter) 
33,5 32 
0 
0 
15 
26 
30 
0 
0 
17 
28,5 
31 
32 
28 
0 
0 
0 
21 
31 
·O 
0 
3 
26 
28 
0 
0 
15 
28 
35 
0 
0 
20,5 
27,5 
34 
32 
27 
0 
0 
0 
23 
27 
0 
0 
. 3 
26 
29 
Uni"'ts 
(u/l) 
-.. 32, 8 · 112 
15 
27 
3j,7 
19,5 
28 
31,3 
32, 7 
29 
22,2 
29,3 
3,7 
25,3 
29 
•. 
0 
0 
12,6 
54,8 
122 
0 
0 
21,8 
62 
93 
108 
68,7 
0 
0 
0 
30 
71,3 
0 
0 
3,l 
44 
68,7 
Inhibition% 
100 
100 
89 
51 
0 
100 
100 
81 
45 
17 
0 
100 
100 
100 
56 
0 
100 
100 
95 
36 
0 
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Table 7-8A 
Inhibit_ory effect of o<.2-ruacroglobu+in solution on cholelysin preparations. 
Experimental. detail as set out in sections 7.3, 7.4.1 and 7.4.2 in 
main "text. :Because macro globulin showed inherent · fibrinolysis, this 
had to be allowed for, and the formula for calculating inhibition% 
was modified as follows: 
Inhibition% = Control(units) - (teat (units) - macrcglobulin X lOC lysia (units)) 
control (units) 
As the d.. 2-macroglobulin solution showed an inherent fibrinolytic p::tential. 
of 6,8 units/~, the equation read: 
All test 
Control 
Inhi"oition% = 
results reported 
Control(units) - f t est(units) - 6,8) X 100 con.;ro (um.ts) 
in mm diameter 'Jf zone of lysis Units ~ 2-macroglobu1.in: 9, 10, 11., S Mean 1.0 -6;8""" 
Pre1:;aration Inh;i.bition~ 
G200 - Control. 28 28 Mean 28 62 
Test 19 19 18 20 1.8 18,8 
~0~3 78 
Peak I Control 30 31 · 30,5 84-,4 
Test 26 27 25 26 26 26 48,5 51 
P~ak II Control 18 21 1g,5 22,2 
Test 17 15 16 16 15 15,8 13, 7 . 69 
Peak III Control l "/ 18 l 7,5 17,1 
Test 16 15 15 14 15 15 12, 6 66 
Peak IV Control 10 11 10,5 7,3 
. Test 11. 10 11 12 11. 7,7 88 
--- - ~ -- ~ 
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Table 7-9A. 
Inhibitory effect of soy bean trypsin inhibitor (SETI) en cholelysin. 
· - :Incubation for 60 minutes at 20°c, • .otherwise conditions as stated in sections· 7.3. and 7.4.1 md 7.4.2 in main text. SETI in g/lOOml. {a) SETI 0,0005% 
Cholelysin 
fraction l 
G200 29 
Peak I 29 
Peak II 19 
Peak III 22 
{b) SBTI O, 001% 
G 200 
Control 
2 mean units 
30 29,5 74,5 
29 29 70,l 
18 18,5 19,3 
22 22 29,7 
74,5 
1 
24 
23 
13 
10 
Test 
~ 
23 
22 
13 
10 
mean 
23, 5 
. 22, 5 
13 
10 
Peak I (Same controls) 70,1 
17 
22 
12 
19 
23 
12 
18 
22,5 
1~ Peak II 
Perul III 
I 
{ c) SBTI O, 002"~ 
G200 30 
Peak I 30 
Peak II 18 
Peak III 18 
{d) SETI 0,0<: 4% 
G200 29 
Peak I 28 
Peak II 17 
Peak III 16 
{e) SBTI 0,006% 
29,5 
30 
18 
16 
30 
29 
18 
16 
G200 29 29 
Peak I 28 28 
Peak II 25 24 
Peak III 16 16 
(f) SBTI 0,008% 
G200 29 
Peak I 28 
Peak II l7 
Peak III 16 
29 
28,5 
17 
16 
19,3 
29,7 9 9 9 
29,8 78 18 17 18 16 18 17,4 
30 79, 2 19 20 22 21 21 20,6 
18 18,2 10 10 ll 1110 10,4 
17 16 5 · 2 4 5 4_,o 
29,5 
28_,5 
17,5 
16 
7~-, 5 
65 
17,1 
14,2 
10 10 9 10· 10 
17 14 16 14 14 
5 6 5 5 5 
0 0 0 0 0 
9,8 
14,8 
5,2 
0 
29 70,l 10 9 10 12 8 9,8 
28 62 O 2 3 2 3 2 
24,5 39,7 o, 3 2 3 O 1,6 
16 14,2 0 0 0 0 0 0 
29 
28,3 
17 
16 
70,1 1111 8 9 7 
64,5 1~ 10 9 9 9 
16 5 5 4 5 5 
14,2 0 0 0 0 0 
9,2 
9·,4 
4, 8 . 
0 
units 
35,7 
31,7 
9,8 
6,8 
lts,2 
31,7 
8,6 
6,0 
16,8 
25 
7' -...~ 
3,0 
6,7 
12,2 
3, ts 
0 
InhU.i ti on5 
52 
55 -
49 
77 
76 
55 
55 
80 
78 
68 
60 I 
81 
91 
82 
78 
100 
6,7 90 
2,5 96 
2,4 94 
0 100 
6,2 
6,4 
3,6 
0 
91 
90 
· 78 
100 
,·-
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Table 7-lOA 
;;· 
Inhibitory e fr·e ct of ~oy bean trypsin inhibitor (SBTI) on cholelysin. 
Incubation with cholelysin fractions for 24 hours, othecv.ise conditions 
as stated in sections 7.3, 7.4.1 and 7.4.2 of main text. SBTI in g/lOOml.. 
(a) SBTI 0,002% 
Cholelysin CONTROL TEST 
fraction l 2 mean units mean units Inhibition}, 
G200 29,5 30 29,8 78 15 13 16 1_6 15 15 12,5 84 
Peak I 30 30 30 79,2 14 17 15 16 14 15,2 13,8 83 
Peak II 18 18 18 18,2 6 8 5 6 6,3 · 4,3 76 
Peak III 18 16 17 16 4 0 0 0 l 0 100 
(b) SBTI 0,004% 
G200 . 23 30 29,5 74, 5 13 12 12 12,3 9,0 88 
Peak I 28 29 ~18, 5 66 9 8 10 9 6,0 91 
Peak II :,_7 18 17,5 17,1 3 4 3 3,3 3,0 82 
Peak III 16 16 16 14,.2· 0 0 0 0 0 100 
(c) SBTI 0,006% 
G200 29 29 29 70,l 10 6 7 7,7 5,1 93 
Peak I 28 28 28 6' · ,:. 2 3 2 2,7 2,8 96 
Peak II 17 18 17, 5 17,l 2 2 2 2,0 2,5 85 
Peak III 16 16 16 14,2 0 0 0 0 0 100 · 
(d) SETI 0,008% 
G200 29 29 29 70,l 4 4 4 4 3,3 95 
Peak I 28 28,5 28,3 64,3 0 2 4 2 2,5 96 ~ .• 
Peak II 17 17 17 16 0 0 0 0 0 100 
Peak III 16 l.6 16 14,2 0 0 0 0 0 100 
I 
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Table 7-lV~ 
Inhibitory ef:rect of aprotonir~ (Bayer) on cholelysin. Ixperimenta were 
done w_ith prior incubation at ( a) 20°c for 60 minutes 
(b) 37°c for 60 minu~es 
In both cases, o, 2 ml o:f commercial 'Trasylol' (Bayer) containing 2000 uni ts 
of cprotonin ~as added to 0,2ml of cholelysin soluti~n. The mixture was 
plated out in the usual way after incubation. Aprotonin itself failed 
to lyse a fibrin plate. Results in mm diameter of zone of lysis, 
conve~ted into units/1. Inhibition calculated as dsscribed in section 
7.4.2 in main text~ 
(a) Rooin temperature (20°c). 
Cholelysin mea."l units :'est mean uni -cs Inhibi ": ior:i, 
fraction 1 2 
\1200 27 27 27 54,8 1111111111 ll 7,7 86 
Peak I 
-37 33 35 146,4 0 0 0 . o 0 0 0 100 
Peak II 19 21 20 23, 2 10 11 10 10 11 10,4 7.2 69 
Peak III 16 16 .16 14,2 0 0 0 0 0 0 (I 100 
Peak IV 10 10 10 6,8 0 0 0 0 0 0 0 100 
(b) at 37°c 
G200 26 26 26 48,5 14 11· ) 14 15 14,5 11,8 76 
:Peak I 26 28 27 54,8 a 9 8 8 8,5 5':.; 90 
:Peak II 18 18 18 18,2 12 13 13 12,5 12,7 9,~ 4S 
Peak III 20 20 20 . 2.3, 2 0 0 0 0 0 0 100 
Peak IV 5 5 5 3,7 0 0 0 0 0 0 100 
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Appendix 11 
FilCUre ll-5A 
The relative mobiJ.i ty of the various ba."'lds studied was estimated 
from measurement of several gels. In each case, thd position 
of the bcllld studied was estimated as a simple ratio of 
movement of band (mm) 
total length of gel (mm) 
There was variability in this result until the tecrmique waa 
established. Results on which Figura 11-5 is based were as 
follows: 
Markers: 
/ 
Lactate dehydrogenase -
Chymotrypsinogen 
Ri bonucle ase ) 
Plasmin . spl~t products-
l 'l ( D-dime r ) 
P2 ( " ) 
P3 ( 11 ) 
Cholelysin split products 
0,528 
0,621 
0,820 
o, 280 
0,458 
01797 
03 0,302 
C4 
Cl 
02 
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0,624 
0,785 
n 
4 
4 
4 
4 
4 
4 
5 
5 
5 
s 
o, 21 
0,17 
0,024 
o, 01_7 
O,Ol4 
0,024 
SIDiI 
0,011 
0,009 
0,012 
0,009 
0,007 
0,012 
0;017 0,008 
0,020 0~609 
0,020 
0,033 
0,009 
C,015 
